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ABSTRACT

Protein aggregation occurs when proteins adopt non-native conformations,
exposing hydrophobic surfaces due to misfolding. The exposed regions of two or more
proteins associate to form amorphous deposits or highly ordered, stable fibrillar
structures called amyloid aggregates. Within the cell, a robust network of proteins
safeguard against protein misfolding and aggregation. This network is referred to as the
proteostasis network and includes molecular chaperone proteins, co-chaperone
proteins, and the ubiquitin proteasome system. Molecular chaperone proteins function in
various cellular processes including intracellular transport, oligomeric assembly, and
efficient protein folding. Moreover, molecular chaperones are required for folding
denatured, misfolded, and de novo proteins into their native conformation. It is thought
that neurodegenerative diseases may be the result of a derailed proteostasis network in
response to aging, mutations, and environmental stress, among other factors that
contribute to protein aggregation.
The neurodegenerative diseases Alzheimer’s disease, Huntington’s disease, and
Parkinson’s disease are characterized by protein misfolding and accumulation into
aggregates composed of amyloid fibrils. In each of these protein misfolding diseases,
the roles of chaperone proteins are complex and not well understood. Given that these
diseases share a common theme of protein misfolding and aggregation, researchers
have questioned whether molecular chaperone proteins are involved in disease
pathology, which has led to investigations into the possible use of chaperone-based
strategies as treatment options. It is thought that protein aggregation in
neurodegenerative diseases results from disturbances in pathways that regulate protein
quality control. This thesis investigates the role of ATP-dependent chaperone proteins in

disaggregating and resolubilizing protein aggregates, including model aggregates,
amyloids of Sup35 in yeast and hyperphosphorylated tau in human cells. Here, we
investigated the biochemical properties of the Hsp100/Clp chaperone protein family,
which couples ATP binding and hydrolysis to unfold and reactivate aggregated and
misfolded polypeptides. We studied the role of molecular chaperone proteins in the
progression of protein aggregation in a model of Alzheimer’s disease and developed
novel chaperone tools for targeting amyloid proteins for protein clearance. Furthermore,
we investigated the mechanism of substrate recognition and amyloid disassembly by
Hsp104 in a yeast [PSI+] prion model of amyloid assembly. Moreover, we identified a
novel function of the chaperone protein ClpX in protein disaggregation in vitro and in
vivo. We observed that ClpX can bind and reactivate native and engineered protein
aggregates in the absence of ATP. Lastly, in an Alzheimer’s disease model of
hyperphosphorylated tau, we monitored changes in chaperone protein levels in
response to inhibition of protein phosphatases. Research from this dissertation will
contribute to further understanding Alzheimer’s disease pathogenesis, and, more
broadly, the breakdown of protein homeostasis in neurodegenerative disease, and roles
for chaperone proteins in managing proteotoxic aggregates in possible future therapies.
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PREFACE

This doctoral dissertation has been prepared in Manuscript Format under the
guidelines of the University of Rhode Island Graduate School. Manuscript I is titled “In
Vitro Approaches for Studying Amyloids and Neurotoxicity” and is formatted as a book
chapter. Manuscript I is published in the textbook Methods in Pharmacology and
Neurotoxicology, © Springer Science+Business Media, New York, 2018. Manuscript II is
titled “Site-specific mutations in the Hsp104 N-domain impair [PSI+] prion curing in
Saccharomyces cerevisiae” and is formatted as a research article intended for
submission to Prion. Manuscript III is formatted as a research article and is titled “The
protein chaperone ClpX targets native and non-native aggregated substrates for
remodeling, disassembly and degradation with ClpP.” Manuscript III was published in
Frontiers in Molecular Biosciences in 2017. Lastly, Manuscript IV is titled “ATPdependent chaperone protein expression in an Alzheimer’s disease model of tau
hyperphosphorylation” and is formatted as a research article intended for submission to
Neurotoxicology.
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1. Introduction to Protein Conformational Disorders and Neurodegeneration
Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD),
and transmissible spongiform encephalopathies such as Creutzfeldt-Jakob disease are a
group of progressive, fatal neurodegenerative diseases that share the common
pathological feature of protein aggregation and amyloid deposits [1]. Amyloid deposits
are composed of protein aggregates that result from proteins that adopt an aberrant,
non-native conformation through a misfolding event [2]. Neurodegenerative diseases
that share the common feature of protein misfolding are also referred to as protein
conformational disorders [3].
Neurodegenerative diseases have a devastating impact on family members,
caregivers, and society. Most diseases involve processes that impact the quality of life of
an individual, from classic involuntary muscle movements witnessed in both PD and HD,
to cognitive decline that occurs in individuals with AD. Neurodegenerative diseases also
have a major impact on the economy and caregivers. In the case of AD, in 2015,
American caregivers are estimated to have contributed over 18.2 billion hours of unpaid
assistance to people with Alzheimer’s dementia and other dementias, which amounts to
approximately $230.1 billion in unpaid care [4]. Incidence rates of these age-related
neurodegenerative diseases are expected to rise as the population ages. As of 2017, the
Alzheimer’s Association reports that an estimated 5.5 million people in the United States
have Alzheimer’s disease and by 2050, this number may increase to 16 million [4].
Understanding the biochemical, molecular, and cellular pathways and mechanisms
involved in Alzheimer’s disease pathology and progression is important for developing
more efficient disease-modifying therapeutic strategies. This chapter will discuss in vitro
technologies commonly used to isolate, visualize, and characterize amyloidogenic
protein aggregates and in vivo methods of identifying protein aggregates in the brains of
2

patients with Alzheimer’s disease. We will also provide examples of agents that have
been shown to promote aggregation, and discuss different approaches that may inhibit
or stall amyloid formation.
2. Proteostasis, Protein Misfolding and Aggregation
2.1 Protein Quality Control
Protein function is dependent on proper folding of a protein into a native,
thermodynamically stable and biologically active conformation, with a three-dimensional
structure. To ensure that proteins fold correctly there is a protein quality control network
in cells, which consists of a group of molecular chaperone proteins and proteases.
Stress and subsequent damage to functional, folded proteins may be caused by
environmental changes (for example, shifts in temperature or hydration), free radicals,
heavy metals, or tissue injury. These stresses can also modify the expression levels of
components of the protein quality control machinery within the cell to manage the
disruption to protein homeostasis [5,6] [7]. Thermotolerance studies in cells have led to
the identification of many proteins that are highly expressed during exposure to heat
stress. Therefore, these proteins were given the name “heat shock proteins”. In
eukaryotes, the heat shock response, which includes the increased expression of heat
shock proteins in response to physiological stressors, is stimulated by activation of heat
shock transcription factor (HSF-1) and transcription of chaperone genes, such as genes
encoding chaperone proteins Hsp70 and Hsp40 [8-10]
Heat shock proteins are highly conserved and ubiquitous proteins that represent
a component of the cellular protein quality control network. Heat shock proteins, or
molecular chaperone proteins, are essential for managing protein folding and
maintaining protein homeostasis in both normal conditions and conditions of
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physiological cell stress [11]. Misfolded proteins pose a threat to cell viability by
interfering with protein-protein interactions, protein-membrane interactions, promoting
aberrant protein interactions and inducing aggregation. Protein misfolding also increases
the demands on the protein quality control network, which is thought to lead to further
misfolding and aggregation events [12,13]. During aging, the cell’s ability to mount a
heat shock response in response to stress conditions decreases [14] . Expression of
ATP-dependent chaperone proteins, such as Hsp90 and Hsp70, declines with age and
this decrease in expression levels is even greater in Alzheimer’s disease and
Huntington’s disease [15].
Another component of the quality control network within the cell is the 26S
proteasome, a large protein degradation machine that promotes the clearance of
misfolded proteins and proteins with an ubiquitin tag. In some cases, misfolded and
dysfunctional proteins are tagged with multiple ubiquitin domains by ubiquitin ligases and
directed to the 26S proteasome for degradation. Protein degradation may also play a
role in age-associated neurodegenerative diseases, including AD and PD, where protein
aggregates have been shown to contain high levels of ubiquitin, which may contribute to
neurodegeneration and neuronal cell death [16] . Research suggests that proteasome
activity declines and may be impaired in the aging brain [17,18]. Together, the molecular
chaperones and the 26S proteasome maintain steady-state levels of healthy proteins
within the cell, creating a balance of active and degraded proteins, which becomes more
fragile as the proteostasis network weakens or is overburdened.
2.2 Protein aggregation and amyloids
When proteostasis is disrupted due to protein folding inefficiency or instability,
proteins become insoluble and aggregate. Several neurodegenerative diseases contain
a highly specialized and thermodynamically stable aggregate, called an amyloid.
4

Amyloid deposits are composed of bundled fibrillar aggregates rich in stacked betasheets that are oriented perpendicular to the long axis of the amyloid fiber [19,20]. A
network of hydrogen bonding interactions within and between beta sheets stabilize the
highly ordered beta-rich structure of amyloids [21]. Amyloid fibrils have common betarich structures, fibril morphologies, and chemical properties. Generally, the mature
amyloid fibril is approximately 100 Angstroms in diameter, twisted, and unbranched [22].
Amyloids are insoluble and resistant to detergents and many other chemicals known to
disrupt protein folding and proteolysis [23,24]. A unifying feature of amyloids is their
distinctive cross-beta pattern observed in X-ray diffraction studies. The amyloid fibril
structure is characterized by stacked beta-sheets that have an approximate intersheet
distance of 11 Angtstroms and interstrand distances of 4.8 Angstroms [22] .
It is thought that amyloids arise from a nucleation-dependent polymerization
event called fibrillization (Figure 1). By contrast, intermediates in the amyloid assembly
pathway, such as pre-amyloid oligomers, are soluble in solution and have diverse sets of
conformational states [25]. How proteins progress through conformational stages of the
amyloid assembly pathway(s) from oligomers to protofibrils and finally, to amyloid fibrils,
is not well understood, but novel methods using molecular probes and optical
spectroscopy may provide important information about these intermediate oligomeric
species [26]. Although the precise molecular events of amyloid assembly are not known,
in vitro experiments suggest that small oligomers assemble and polymerize to form an
intermediate protofilament, which further aggregates to become a mature fibril [25]. The
fibrillar aggregates accumulate into a deposit called an amyloid plaque, which is thought
to be irreversible. In vivo preformed amyloids can act as “seeds” to promote mature
amyloid formation in mouse models of amyloid assembly [27]. Although it is unknown
how amyloids propagate, a prion-like mechanism has been suggested, where a
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misfolded protein (i.e., an amyloid) induces conformational changes in folded protein by
templated conformational conversion [28] . In this model, the amyloid acts as a seed or
template to spread the beta-rich structure to other proteins, promoting fibrillization and
thus seeding aggregation.
The pathogenesis of several neurodegenerative diseases is linked to the
formation of amyloids that accumulate within specific tissue regions. In AD, amyloid beta
plaques are formed from the misprocessing and overproduction of the amyloid precursor
protein (APP), and plaques are typically found extracellular to neurons in the frontal
cortex and hippocampus of patients (Figure 1B). A second hallmark of AD pathology is
known as the tau tangle. Tau tangles, or neurofibrillary tangles (NFTs) are intracellular
aggregates formed by the polymerization of paired helical filaments (Figure 1B) [29-31]
[32]. In PD, misfolded, aggregated alpha-synuclein (α-synuclein) has been shown to be
the major constituent of both Lewy bodies and Lewy neurite pathology in the brains of
patients with PD patients [33]. HD is predominantly genetic, and involves duplications in
the Huntingtin gene (Htt). Individuals with htt mutations develop aggregates of Htt in
amyloid-containing inclusion bodies, which are typically found in the striatum, cortex, and
the spinal cord [34]. Although these neurodegenerative diseases share the common
feature of amyloids deposits, they also exhibit differences. The neuronal cell populations
that are lost in each of the diseases varies, the disease symptoms are heterogeneous,
and the pathological proteins that misfold into amyloid in each disease share few
similarities in sequence and structure. In addition, amyloid load is poorly correlated to
cognitive decline in neurodegenerative diseases and accumulating research points to
prefibrillar oligomers as the toxic species responsible for neurodegeneration and
behavioral symptoms [35].

6

Besides age-related neurodegenerative diseases, transmissible spongiform
encephalopathies, also referred to as prion disorders, provide further examples of
pathological

alterations

in

protein

conformation

that

are

associated

with

neurodegeneration and lead to death in humans [1]. In these disorders, a soluble prion
protein (PrP) adopts a new conformation, or protein fold. This new conformer of the prion
protein is an amyloid and it has self-templating and infectious properties. In the prion
conformation, the protein can then bind to another native protein and cause it to adopt
the aberrant, alternative conformation. In this way, the abnormal conformer can selftemplate and propagate the disease-associated protein conformation [36]. Diseases that
fall within the TSE category include scrapie in sheep, bovine spongiform encephalopathy
(“mad cow” disease), chronic wasting disease in deer and elk, and Creutzfeldt-Jakob
disease in humans [37] [38].
3. Detecting Amyloids and Monitoring Fibrillization
3.1 Monitoring the Kinetics of Amyloid Formation in vitro and Quantifying Aggregation
It is hypothesized that the mechanism of amyloid assembly is a nucleationdependent fibrillization characterized by a rate-limiting, slow lag phase required to form a
critical nucleus followed by the polymerization of fibrils at an exponential rate [39,40]. For
a nucleus to form (termed “nucleation”), a set of high-energy oligomeric intermediates
must be stabilized by a molecular event, such as a protein conformational change. The
factors that drive nucleation and the structures of the high-energy conformational states
that compose the nucleus are not well understood [41]. Although amyloids are stable
structures in general, the fibrils can break into smaller fragments that may seed
additional amyloids. Multiple detection and quantification methods for amyloids rely on
the optical qualities of amyloids and the kinetics of amyloidogenesis. Congo Red and
Thioflavin T (ThT) are small molecules that bind selectively to amyloids, inducing
7

changes in optical features such as fluorescence quantum efficiency [26]. Light
scattering or fluorescence assays are used to monitor the kinetics of amyloid fibril
assembly over time [38]. Traditional methods for screening amyloid aggregates include
biophysical, optical, and microscopic techniques that visualize small molecule binding to
amyloids, such as Congo red (CR) and ThioflavinT (ThT) dye binding [42]. The most
commonly used techniques for reporting and quantifying amyloids, in addition to novel
methods for identifying different conformational states of amyloids, are explained below.
3.2 Detection of Amyloids by Molecular Probes and Fluorescence Spectroscopy
Fluorescence spectroscopy is used to identify and characterize protein
conformations of amyloids in vitro under both steady state and kinetic conditions,
allowing researchers to investigate amyloid assembly and visualize amyloid fibrils. The
most commonly used fluorescent dyes that bind selectively to amyloid are Congo Red
[43] and ThioflavinT [44]. ThT is a benzothiazole-based fluorescent dye that specifically
binds to the surface of cross-β sheets of amyloid fibrils[45]. Vassar and Culling
demonstrated that ThT showed highly specific binding to amyloid deposits in tissue
sections and this binding was associated with an enhanced fluorescence signal from
ThT [23]. When ThT binds amyloid fibril in vitro or in situ, it shows enhanced
fluorescence that can be monitored by fluorescent spectroscopy [46]. In vitro binding of
amyloid fibrils to ThT was first described by Naiki and coworkers[44]. When ThT was
added to samples containing up to 2.0 µg/mL of amyloid fibrils, researchers observed an
intense fluorescence at an excitation maximum of 450 nm and an emission maximum of
482 nm [44]. The molecular probe ThT has also been used to monitor amyloid fibril
assembly in real-time [47,48].
There are limitations and caveats to quantifying amyloid fibrils based on ThT
fluorescence assays. The selectivity of ThT binding to amyloid fibrils is unclear. ThT
8

fluorescence emission can be affected by different amyloid fibril morphologies and pH; at
a basic pH, the ThT molecule becomes hydroxylated [22]. ThT can also bind to other
fibrils besides amyloids, such as keratin and elastin [49] . Moreover, research shows that
ThT can bind to nucleic acids of DNA and this binding is associated with enhanced ThT
fluorescence;[50] however, reducing the pH lowers the affinity of ThT for nucleic acids
[51]. The presence of polyphenols such as curcumin, quercetin, and resveratrol in
samples containing fibrillar amyloid-beta interferes with ThT fluorescence readings in
both in situ ThT assays and single time-point ThT assays [52]. Considering that factors
such as ionic strength, pH, fibril morphology, and concentration of both ThT and protein
fibril can modify the fluorescence emission of ThT, it may be more useful to combine
other methods of measuring amyloid fibril kinetics with ThT fluorescence assays [53].
Congo Red is a crimson-hued, lipophilic diazo dye that selectively binds with high
specificity to amyloid fibrils in vitro, in situ, and ex vivo [46]. . The Congo Red
birefringence assay can be used to identify amyloid fibrils. Using a polarized light
microscope, the presence of amyloid can be investigated by determining if the sample
stained with Congo Red shows apple-green birefringence under crossed polarizers; if no
birefringence is observed, then it can be concluded that no amyloid is present [46]. The
characteristic apple-green birefringence can be difficult to detect and other problems
with this technique include high levels of background staining and challenges to
reproducibility [53,46]. Research supports that Congo red does not bind to different
amyloid fibrillar deposits by the same mechanism and may have relatively low sensitivity
[54-56]
A spectroscopic assay that examined Congo Red dye binding to fibrillar betapleated sheet insulin, a representative amyloid, showed that the absorbance spectrum of
Congo Red changes upon binding to amyloid [43]. Klunk and coworkers further
9

developed and extended the Congo Red-insulin fibril spectroscopic assay to quantify
amyloid fibrils by examining amyloid-beta aggregation with Congo Red. Briefly, the
absorbance of amyloid samples stained Congo Red and amyloid samples alone must be
measured at the wavelengths 403 nm and 541 nm before performing necessary
calculations to quantify the aggregated amyloid beta concentration in the samples [57].
When Congo Red binds to amyloid fibrils, it exhibits a red shift in absorbance maxima
from 490 nm to 540 nm [58]. Congo red dye binding to amyloid fibrils causes Congo red
to change in color from orange-red to rose and because of this, a spectral shift in the
absorbance

spectrum

of

Congo

Red

can

be

measured

using

a

UV-Vis

spectrophotometer [59].
Congo Red and Thioflavin T dyes do not bind to pre-amyloid conformations in the
amyloid assembly pathway. The development and use of fluorescent dyes 1anilinonapthalene-8-sulfonate (ANS), 4-4-bis-1-phenylamine-8-napthalene sulfonate
(Bis_ANS), and 4-(dicyanovinyl)-julolidine (DCVJ) allows for identification and monitoring
of early amyloid protein conformations [60]. Bis-ANS has been shown to bind to
prefibrillar protein conformations associated with the early stages of the amyloid
assembly pathway. When Bis-ANS binds to the hydrophobic residues on the surface of
proteins and is excited at 360 nm, it emits a 530 nm wavelength [48]. DCVJ was shown
to bind selectively to prefibrillar oligomers, making it a useful tool for studying the early
stages of amyloid assembly [60].
Moreover, A drawback of Congo Red and Thioflavin T dyes is that they cannot
be used in vivo. The development of BoDipy-Oligomer (BD-Oligo) by the research group
of Teoh et al. may have bridged this gap in the field. BD-Oligo is a fluorescent probe
selective for oligomeric intermediates in amyloid formation [61]. BoDipy-Oligomer can
cross the blood brain barrier and can label disease-associated oligomers in real-time
10

without using radiation, making it an attractive candidate for clinical screens of
presymptomatic patients of AD [61] [62]. A novel stain that has recently begun to be
employed for the detection of Aβ plaques is Amylo-Glo. While this has recently been
shown to bind to Aβ plaques in 11 month APP/PS1 transgenic mice, the specificity of the
marker for Aβ as opposed to other aggregated proteins has not been predetermined
[63]. Unlike Congo Red and Thioflavin T, Amylo-glo has a blue UV excitable stain,
making it ideal for co-labeling and staining studies, it is also much brighter than these
traditional dyes and appears more sensitive [64].
3.3 Seeding and Amplification Assays
3.3.1. Protein Misfolding Cyclic Amplification
Protein Misfolding Cyclic Amplification (PMCA) is a technique that was
developed in 2001 for the detection and amplification of prion proteins [65]. The first
phase of PMCA involves utilizing a trace amount of infectious prion purified from either
brain homogenates or cell lysates to induce the conversion of the normal protein into the
misfolded infectious aggregate. In the second phase, the sample is sonicated, which
fragments the aggregate and therefore frees up the template to polymerize again.
Therefore, by PMCA the fibril concentration increases exponentially [66]. A concern of
the PMCA reaction and technique is its ability to detect low levels of prion protein in a
sample, as well as the efficiency of the reaction. PMCA may vary depending on
experimental conditions, such as the reaction components and sonication. A
modification of the experimental design to include Teflon beads (PMCAb) increased the
efficiency of the PMCA reaction and the sensitivity of prion detection [67].
Quantitative ‘qPMCA’ was developed to quantify the prion concentration in a
sample since the amount of cycles of PMCA needed to detect the prion is directly related
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to the amount present in the original sample [68,69]. Briefly, the procedure involves the
purification of prion from the original lysate, followed by PMCA reactions containing
multiple dilutions of prion. Then the number of rounds of PMCA required to produce a
detectable signal are determined by Western blot analysis. From this, a curve is
generated of prion concentration versus PMCA detection round. Extrapolating from this
curve would provide the original prion levels in the sample [68,69]. Although developed
for prions associated with TSEs, PCMA has recently been applied to the detection of Aβ
oligomers in cerebrospinal fluid of patients with AD [70].
3.4 Inducing Amyloid Formation and Seeding
3.4.1 Quaking Induced Conversion Assay and the Amyloid Seeding Assay (ASA)
The amyloid seeding assay (ASA) is a method in which rapid amyloid formation
or seeding occurs when amyloid fibrils are added to a fresh pool of soluble proteins. The
ASA is useful tool to screen for agents that may be aggregation inhibitors, and for
detecting prions in biological samples. The formation of these aggregates can be
observed by monitoring Thioflavin T (ThT) binding to amyloid fibers over time [71].
Similar to PMCA, the Quaking Induced Conversion Assay (QuIC) was developed
to address technical difficulties associated with PMCA. In QuIC automated orbital
shaking is utilized instead of sonication, which is used in PMCA. Both the ASA and QuIC
assays are limited in their ability to accurately quantify protein aggregates and are
considered less reliable than the new real-time quaking induced conversion assay (RTQuICK) [72]. RT-QuICK utilizes some components of the QuIC assay, such as
intermittent shaking but also incorporates ThT to monitor the formation of fibrils, as seen
in ASA’s [73].Furthermore, prion and fibril concentration is accurately determined by
using RT-QuICK if it is coupled with end-point dilution analysis. In this method,
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homogenates are serially diluted. Then the samples are analyzed by RT-Quick for each
dilution, and then ThT fluorescence levels are measured to establish a baseline. The
advantage of utilizing RT-QuICK is that it is a rapid, sensitive, cost-effective assay as
compared to alternative techniques [72].
3.4.2 Monitoring Amyloids in vivo
The ability to develop in vivo detection and monitoring methods for amyloid
assembly remains difficult for most of the amyloidogenic diseases, especially in HD and
PD. In HD, researchers have had success utilizing positron emission topography (PET)
to monitor disease progression in individuals diagnosed with the disease relative to
healthy individuals. However, in both PD and HD there is still no tracer that can both
bind to aggregates and be simultaneously monitored by PET scans. In contrast, there
have been more successful developments of radioligands selective for beta-amyloid and
paired helical filament tau protein that enable in vivo monitoring and visualization of ADrelated amyloid plaque and neurofibrillary tau protein aggregate accumulation.
The PET imaging agents that are selective for fibrillar amyloid-beta plaques
include 11-C-labeled Pittsburgh compound B and florbetapir-F18 [74]. The first PET
imaging probe developed that could bind to amyloid beta aggregates was Pittsburgh
Compound B (PiB-C11) [75]. PiB-C11 effectively binds to amyloid plaques in brain
regions of people with Alzheimer’s disease that correlate with the same brain regions
showing amyloid accumulation from post-mortem histopathological analysis of brain
tissue [76]. However, PiB-C11 has a short half-life of approximately 20 minutes, which
limits its efficiency [77]. The first FDA-approved PET tracer for clinical imaging of
amyloid-beta deposits is florbetapir-F18 (AmyvidTM) [76]. The PET ligand florbetapir-F18
(18F-AV-45) binds to amyloid beta plaques with similar specificity and regional uptake as
PiB-C11 and has a half-life of approximately 110 minutes [77]. Recent studies have
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shown that florbetapir-F18 is both sensitive and specific to the detection of Aβ and can
be used to clinically distinguish individuals [78]. Moreover, in vitro analysis of the of
florbetapir-F18 binding in human postmortem brain tissue sections confirmed that the
labeling intensity of florbetapir-F18 correlates with amyloid plaque density and the PET
tracer did not bind to neurofibrillary tangles [74].
Research findings from postmortem brain analyses show that neurofibrillary
tangles correlate with cognitive decline and neuronal death whereas amyloid plaques do
not strongly correlate with dementia severity [79,80]. Therefore, there development of
PET tracers that bind to paired helical filaments, which are composed of pathologically
hyperphosphorylated tau, could be used to diagnose and monitor treatment outcomes in
vivo [81]. The PET ligand
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F-AV-1451 binds selectively and with high affinity to

hyperphosphorylated tau in paired helical filaments [82,83]. A study that investigated 18FAV-1451 binding in healthy elderly people found that uptake and retention of AV-1451
correlated with age and amyloid plaque accumulation [84]. AV-451 uptake in the medial
temporal lobe was also found to be significantly associated with cognitive decline and
impaired episodic memory [84]. The development of amyloid beta and tau PET-imaging
probes provide a new tool for measuring pathological amyloid beta and neurofibrillary
tangle deposits in vivo, which could be useful in the clinic for diagnosis of Alzheimer’s
disease.
4.0 Cytotoxicity assays
Amyloid assembly intermediates are widely considered to be more toxic species
in the amyloidogenesis pathway, rather than the mature amyloid fiber present in
plaques, yet there is still ambiguity about whether protofibrils, oligomer species, or a
combination of both causes toxicity. Research shows that oligomers from the selfassembly of amyloid beta peptide are 10-fold more toxic to neuronal cell cultures than
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fibrillar amyloid-beta (1-42) peptide. Amyloid-beta peptide (1-42) is toxic to cells at
micromolar concentrations whereas oligomeric species are toxic at nanomolar
concentrations [85]. Reliable cytotoxicity assays provide important information about
cellular health and viability following exposure to a toxic substance and are useful for
investigating the correlation between protein aggregation and cytotoxicity, which may
provide

information

important

for

understanding

the

pathogenesis

of

protein

conformational diseases.
In vitro cytotoxicity assays are used to determine the viability of a cell following
exposure to a toxic substance, such as a misfolded protein conformer or mature
amyloid. The in vitro assays rely on the markers of cell death, whether that is the
compromised integrity of the cell membrane, the release of enzymes into the
extracellular space that are normally compartmentalized, etc., as direct and indirect
measurements of cell viability. However, assays to monitor long-term cytotoxicity are
lacking. Colorimetric in vitro assays are widely used pharmacology and ecotoxicology
studies to determine cell death following exposure to a toxicant or a suspected toxic
species [86]. Often several cytotoxicity assays are employed to accurately determine cell
fitness and survival. Cytotoxicity assays have also shown the correlation that as the
order of oligomer species increases, the degree of toxicity of the oligomer also increases
providing valuable information about the identity of most toxic soluble oligomer species,
which has implications for drug target research [87].
Below are examples of commonly used and robust assays for measuring the
number of living cells (cell viability) and determining the number of dead cells
(cytotoxicity). The LDH assay and MTT assay are spectrophotometry-based assays for
measuring cytotoxicity in vitro. Despite the ease of use of these inexpensive assays and
their ability to be used in high-throughput screening, there are several limitations
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associated with their use. Notably, spectrophometric assays that indirectly measure
plasma membrane breakdown do not distinguish among different cell death modalities
[88]. Vital dye assays represent another method for measuring cell viability in response
to cytotoxic agents in vitro. However, vital dyes are also limited by their inability to
distinguish different modes of cell death [89].
4.1 LDH Leakage Assay for Compromised Membrane Integrity
Lactate dehydrogenase (LDH) is a cytosolic enzyme that can be used as a
biomarker of cell death and cell lysis

[90]. The lactate dehydrogenase assay is an

example of an intracellular protein release assay. After cell death, the cell membrane
loses its structural integrity, which results in the release of normally intracellular enzymes
into the cell culture medium [91]. Colorimetric and fluorometric detection of LDH using
commercially available kits allows researchers to monitor cytotoxicity in vitro [88] . LDH
is catalyzes the oxidization of lactate to pyruvate and generates NADH; NADH strongly
absorbs 340 nm light. Monitoring absorbance values using a 96-well plate provides an
estimation of cytotoxicity [90]. The LDH assay is widely used to investigate cytotoxic
affects and was recently applied to detect cytotoxicity of amyloids in rat embryonic
neuronal cell culture [92,93]. However, disadvantages of the LDH assay include low
sensitivity and a high degree of variability [86]. Moreover, LDH enzymatic activity can be
affected by cell culture medium, such as pH and components within the medium, leading
to an underestimation of cell death [88] .
4.2 MTT Assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction
inhibition assay, commonly referred to as the MTT assay, is a robust colorimetric assay
for assessing cell viability in a variety of cultured cell types [90]. The MTT assay of cell
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viability was first described by Mosmann [94]. MTT is a water-soluble tetrazolium salt
that converts toformazan, which is purple and water insoluble, by reduction of the
tetrazolium ring mediated by mitochondrial dehydrogenase enzymatic activity [95]. Only
viable, metabolically active cells will convert MTT to formazan. Thus, formazen will
accumulate as as a precipitate in viable, healthy cells. Spectrophotometric quantification
of relative levels of formazan

allows researchers to measure MTT conversion and

overall cell viability [90]. The MTT assay is versatile and linear over a broad range of
densities. However, the MTT assay may be more useful in cells with high metabolic
activity [86].
4.3 Vital Dyes
Besides the LDH and MTT assay, vital dyes are frequently used by researchers
to distinguish between living and dead cells in vitro. Vital dyes are fluorescent or colored
molecules that can be used in membrane permeability assays to measure cell death [89]
. Exclusion dyes, such as Trypan blue, cannot cross plasma membranes of healthy cells,
and can be used to measure cell viability. Other commonly used exclusion dyes include
propidium iodide and 4’,6-diamidino-2-phenylindole, which label dead cells that no
longer have intact plasma membranes [96]. Researchers determine the percentage of
viable cells in response to a cytotoxic agent by staining the cells with an exclusion dye
and counting the number of viable cells using a light microscope and a cell counting
instrument, such as a hemocytometer. The percentage of viable cells is the ratio of
viable cells to the total number of cells [89] .
Dyes can also be used to label living cells, such as calcein acetoxymethyl ester
(calcein-AM). The vital dye calcein-AM has been used effectively in cytotoxicity assays
[97,98]). Calcein-AM is lipid soluble and easily crosses cell membranes. Inside the cell,
is hydrolyzed by cytosolic esterases to yield calcein, a fluorescent and membrane
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impermeable product [89] . Cells with intact plasma membranes will retain fluorescent
calcein. Dying or dead cells with damaged plasma membranes release calcein, which
has a strong green fluorescence signal at 530 nm [99]. Therefore, cytotoxicity can be
determined by measuring the release of calcein from lysed cells using a fluorimeter. A
drawback of calcein-AM is that esterase enzymatic activity may be affected by events
not related to cell death, which may lead the researcher to underestimate levels of
cytotoxicity [89].
5. Pharmacological Agents and Drug Therapies for Protein Misfolding Diseases
Aggregation can be promoted by intrinsic and extrinsic factors, including the
amino acid sequence of a polypeptide, pH, temperature, chaperone protein levels, and
protein concentration [38]. Aggregation can be inhibited in vitro by different classes of
compounds, notably anthracycline, anionic sulphonates, Congo red, and rifampicin,
which prevent the formation of oligomers, as well as by other proteins. Prefibrillar
oligomers are the most toxic protein conformation, not the mature amyloid fibril [100],
therefore many pharmacological studies have explored different avenues for abrogating
protein aggregation and its associated toxicity. Strategies explored so far include
increasing the activity of the protein quality control network, stabilizing the soluble
disease-associated protein, destabilizing the insoluble misfolded protein, preventing
aggregation at the early stages of amyloid formation, and changing the protein folding
landscape to favor native protein folding.
5.1 Metals
It has been shown that metals may have a role in inducing protein aggregation.
Specifically, divalent Cd2+, but not Mn2+ impairs proteosomal activity in mouse neuronal
cells expressing prion protein. This impaired proteasome system lead to an
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accumulation of high molecular weight ubiquitinated proteins in the cell, and ultimately
cell toxicity and death [101]. These observations were also replicated in yeast [102].
Arsenite, As (III) was also found to interfere with chaperone activity and with the folding
of peptides in yeast. As (III) exposure was shown to induce the formation of over 140
protein aggregates, which can further induce misfolding and aggregation of other
proteins [102]. A number of other metals have also been identified as promoting protein
aggregation, and inhibiting of protein refolding both in vivo and in vitro, including Hg2+
and Pb2+ [103,104].
5.2 Therapeutic Intervention Methods Targeting Aggregates
A number of therapeutic strategies have been implemented as a means to target
amyloid and aggregate formation due to the inherent toxicity of both the fibrils and
aggregates [105,106]. Some techniques include inhibiting the formation of the β-sheet
secondary structure by using short peptides, or small inhibitory molecules. Others
include bolstering the natural defense towards aggregates, such as heat shock proteins,
or agents that induce chaperone activity, to enhance clearance mechanisms.
5.2.1 β-sheet Breakers
β-sheet breakers are short peptides that recognize and inhibit the amyloid
conformation. Specifically, this is commonly done using short peptides, that recognize
the hydrophobic or “central core” of the beta amyloid (Aβ) peptide [100]. This class of
peptides can bind to oligomers and fibrils to destabilize the β-sheet structure that is a
common trait of amyloids. The unique property of these peptides is their specificity for
abnormally folded proteins; they destabilize only non-native protein conformers without
affecting the soluble protein conformer [100]. Thus, this class of drugs can deter amyloid
fibrillogenesis and downstream aggregation [107].Two β-sheet breaker peptides, KLVFF
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and LPFFD , have been shown to prevent the oligomerization of oligomers into amyloid
fibrils, thus preventing the formation of amyloid plaques [108,109]. Research shows that
the LPFFD peptide can better halt amyloid fibrillogenesis than KLVFF due to its lower
hydrophobicity [110].
5.2.2 Antibodies
Several monoclonal antibodies have been developed that specifically target
amyloid-beta monomers and oligomers, as well as some polyglutamine aggregates
[105]. Two antibodies have been specifically examined for their role in mitigating Aβ
pathology: bapineuzumab and solanezumab. Bapineuzumab targets the N-terminus of
amyloid-beta whereas solanezumab binds to the central region. Both monoclonal
antibodies have been tested in clinical trials in patients diagnosed with mild to moderate
AD. However, despite success in the laboratory, monoclonal antibodies have not yet
shown significant clinical changes or altered disease endpoints in patients [111].
A conformation specific peptide, which mimics a pathological conformation of
amyloids, was developed using polymerized British amyloidosis (pABri) peptide.
Although the peptide does not have sequence homology to amyloid-beta or any other
human protein, pABri is synthesized in the beta-sheet form and elicits an immune
response against the pABri peptide, as well as other amyloids. This technique been
used successfully in APP transgenic mice to direct the immune system against amyloid
formation, which led to a reduction in amyloid plaque burden and improved cognition
[112].
5.2.3 Natural Products as Putative Therapeutic Agents
Pharmacological studies have identified many diverse compounds associated
with increasing molecular chaperone expression, restoring proper protein folding,
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decreasing the levels of pathologic misfolded proteins and inhibiting amyloid formation.
For example, polyphenols have strong anti-amyloidogenic activity and act by promoting
clearance of amyloid from the system. Most polyphenols have been shown to disrupt
aggregation of α-synuclein [106]. A polyphenol that is commonly found in green tea, (−)epigallocatechin-gallate has been shown to inhibit Huntington aggregation [113]. Other
polyphenols such as curcumin have also been shown to aid in reducing protein
aggregation through the induction of heat shock proteins [114]. Other examples include
natural products that may interrupt or modulate the processing of amyloid in the brain,
specifically pomegranate extract has been shown to disrupt Aβ in transgenic mice
favoring the Aβ40 species over Aβ42 [115].
Drugs that inhibit amyloid fibrillization are also under investigation as potential
therapies for protein conformational disorders. For example, cyclohexanehexol
stereoisomers exhibit anti Aβ aggregation activity and are naturally occurring
compounds with high absorption levels and no reported adverse side effects [100].
Additional research is focused on applications of chemical chaperones, ligands that bind
to native proteins and osmolytes to stabilize the native protein state and destabilize the
non-native, aberrantly folded state [38].
5.2.4 Molecular Chaperones
Molecular chaperone proteins, also referred to as heat shock proteins, are
activated during cellular stress, and recognize and bind to surfaces of non-native or
misfolded proteins to prevent or alleviate protein aggregation [116]. Biochemical assays
have shown that several classes of molecular chaperones can modulate amyloid levels
and inhibit amyloid fibrillization. Hsp70 and the co-chaperone Hsp40 were reported to
block the self-assembly of polyglutamine [117]. Therefore, heat shock proteins represent
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a potential therapeutic avenue for future development of drugs to alleviate amyloid
burden.
Another class of possible therapeutic agents that may be effective against
neurodegeneration includes small molecules that target the heat shock response or
selectively alter the activity of chaperone proteins. Hsp90 has emerged as a possible
target for neurodegeneration and cancer therapy because of its role as a robust protein
chaperone that assists in stabilizing and activating several disease-related proteins.
Geldanamycin is a potent inhibitor of the chaperone protein [118]. . Inhibiting Hsp90
activates the heat shock response of the cell by de-repressing expression of the global
chaperone transcription factor HSF-1 [119] Preclinical studies for geldanamycin showed
that the small molecule causes hepatotoxicity [120]. The quinone 19-position of
geldanamycin is reactive with biological nucleophiles, such as glutathione [121].
Geldanamycin analogues with substitutions at the C19 position block nucleophilic
substitution,

thereby

reducing

unwanted

reactions

with

biological

molecules.

Isomerization change from trans to cis-amide conformation of these geldanamycin
analogues allowed for strong protein binding. Importantly, the analogues had reduced
toxicity in epithelial and endothelial cells. The study provided strong evidence that these
C19 substituents of geldanamycin did inhibit Hsp90 in dopaminergic neural cells and
human cancer cells without incurring toxicity in cell lines, suggesting that these
substituents may be promising agents for modulating protein folding in protein
conformational disorders [121]. Inhibition of Hsp90 also activates Hsp70. Both
chaperones recognize different sets of client proteins, and a reduction in Hsp90 function
could promote Hsp70 function, leading to enhanced protein stabilization, degradation, or
refolding [121]. Geldanamycin has also been shown to decrease cellular levels of
hyperphosphorylated tau, which is stabilized by Hsp90 [122].
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Chaperones, including the Hsp70/Hsp40 system of co-chaperones increase the
degradation of protein aggregates and clearance of misfolded polyQ proteins by
targeting the abnormal proteins to the proteasome, as observed by decreased half-life of
the misfolded polyQ protein [123]. Therefore, overexpression of Hsp70/40 proteins is a
therapeutic option to enhance clearance of aggregates; overexpression of Hsp70/40 can
prevent amyloid formation, as well as rescue cells with amyloid accumulation [100]. It is
known that molecular chaperones can bind unfolded polypeptides and prevent protein
aggregation in vitro by solublizing and reactivating protein aggregates. The Hsp100
family of chaperones are composed of ATP-dependent disaggregases which unfold and
reactivate proteins. Studies by Schirmer et al. showed that Hsp100 chaperones can
work in synergy with Hsp70 to reactivate protein aggregate [124]. Yeast protein Hsp104
works with Hsp70/40 system to disassemble and rescue aggregated proteins has also
been shown to disassemble amyloid fibers in vitro [125] . Overexpression of Hsp70 in a
Drosophila model of Huntington’s Disease mitigated neurodegeneration and increased
the lifespan of the fly [126].
5.2.5 Chemical chaperones
Chemical chaperones are a unique class of drugs that can alter the balance of
folded and misfolded proteins within the cell. Chemical chaperones are low molecular
mass and can stabilize proteins against misfolding and aggregation, caused by thermal
and chemical denaturing events. Some promising groups of compounds that target prion
diseases include the anthracyclines, porphyrins, and diazo dyes. Chemical chaperones
can alter protein conformation by blocking the conversion of soluble, biologically active
prion protein to the insoluble, transmissible prion conformer [127,128]. The clinically
approved anti-malarial compound quinacrine, binds specifically to the C-terminal helix of
the normal isoform of the prion protein and stabilizes the normal protein conformation
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[129]. By stabilizing the normal, cellular non-prion protein, whose function is not known,
conversion to the misfolded, transmissible prion isoform is blocked. However, quinacrine
cannot pass through the blood-brain barrier so it has limited therapeutic applications in
animal models [49]. Therapeutic research for prion diseases now includes an array of
compounds such as the polycationic compounds (i.e., dendritic polyamines),
polysulphate polyanions/glycosaminoglycans, tetracyclic compounds, and tetrapyrrolic
compounds that have anti-prion activities [130].
6. Conclusion
Much progress has been made in characterizing and understanding the structure
and assembly of amyloid. The most toxic species in amyloid disorders are widely
considered to be the oligomers preceding the formation of mature amyloid fibrils and
plaque deposits. In addition, the conformational conversion process itself may cause
downstream events that contribute to neurodegeneration. There are many pressing
questions left to address in the field of amyloid proteins and neurodegenerative disease.
It has been challenging to determine the structural identity and associated toxicity of
various oligomers. However, the heterogeneous nature of oligomers and amyloids could
explain the diverse phenotypes and clinical symptoms associated with different
neurodegenerative diseases. Additionally, it is unknown when the soluble oligomers
cause toxicity during the course of a disease and what molecular events trigger an initial
misfolding event, which leads to amyloid generation. Is the initiating molecular event
gradual, stochastic, spontaneous, or cumulative? Moreover, what is the time course of
protein aggregation, and how does the cellular protein quality control system contribute
to the development of plaques and the onset disease? Early intervention will most likely
provide the best therapeutic advantage to mitigating these diseases. Research that
examines the molecular mechanisms of amyloid assembly and accumulation and
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investigates the conformations of cytotoxic pre-amyloid oligomers will provide valuable
information that could be applied to the development of disease-modifying therapies.
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Figure 1. A.) Amyloid assembly cascade. Natively folded proteins that are
amyloidogenic may misfold into a non-native conformation, which can then selfassociate and undergo nucleation to form fibrils. Additional elongation and
condensation events enable further accumulation into amyloid containing
aggregates. In vitro seeding and amplification assays such as PMCA, ASA, and
RT-QuiCK can detect and quantitate pre-amyloid intermediates. Amyloid specific
dyes ThioflavinT and Congo Red bind to amyloid-containing aggregates and can
be used to monitor amyloid assembly kinetics in vitro.
B.) Protein aggregates of Alzheimer's Disease. Alzheimer's disease (AD) is
characterized by the histopathological hallmarks of extracellular amyloid plaques
and intracellular neurofibrillary tangles (NFT's). Amyloid plaques are largely
composed of amyloid-beta peptide, which is a product of cleavage of amyloid
precursor protein (APP). Phosphorylated tau (p-Tau) is a microtubule-associated
protein associated with AD that accumulates intracellularly to form neurofibrillary
tangles.
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Abstract
Molecular

chaperone

proteins

are

required

for

maintaining

protein

homeostasis by facilitating proper folding of nascent polypeptides, misfolded proteins
and unfolded proteins. Hsp104 belongs to the AAA+ (ATPases associated with
diverse cellular activities) superfamily of ATPases that share similar domain
organization. In Saccharomyces cerevisiae, heat shock protein 104 (Hsp104)
regulates prion inheritance and coordinates with Hsp70 and Hsp40 to disassemble
aggregated proteins, including amyloids. In the yeast prion model system of [PSI+],
overexpression of Hsp104 cures yeast cells of the [PSI+] prion. Previous research
showed that [PSI+] prion curing mediated by Hsp104 overexpression requires the Ndomain of Hsp104 (1). To further investigate the biochemical mechanism of amyloid
recognition and prion curing by Hsp104 overexpression, we constructed an hsp104
gene library containing mutations in the N-terminal domain and screened clonal
isolates in Saccharomyces cerevisiae using the [PSI+] colorimetric assay. Using a
novel, quantitative fluorescence-based assay we identified several specific sites in the
N-domain of Hsp104 that are essential for [PSI+] curing by Hsp104 overexpression.
This study provides novel insight into chaperone-mediated recognition and
disassembly of amyloids, which are expressed in yeast as prions and are pervasive in
human neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s
disease, and Huntington’s disease.
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Introduction
Prions are amyloidogenic protein conformations that propagate from cell to
cell in either a functional or pathogenic capacity (2, 3, 4). Prions are non-genetic
elements that self-template and are inherited in a non-Mendelian manner; reversion of
the prion fold to the native fold, also referred to as prion curing, is reversible (5).
Budding yeast have been shown to contain as many as eight propagating prions (4).
One of the most extensively studied prions in yeast is Sup35, which confers the
phenotype [PSI+].
Sup35 is a translation termination protein that exists in at least two
conformations: the native conformation and the prion conformation (6). The [psi-]
phenotype in S. cerevisiae is characterized by the presence of soluble, natively folded
Sup35 protein (Sup35p), which recognizes stop codons and subsequently releases
polypeptides from the ribosome (7). In yeast, Sup35 can adopt the prion conformation
and subsequently aggregate into insoluble amyloid fibrils, thus decreasing the pool of
soluble Sup35 protein (8). The [PSI+] phenotype is characterized by low levels of
soluble Sup35p and high levels of insoluble Sup35, which results in translation
termination errors from read-through of nonsense codons (9). Therefore, the
presence or absence of [PSI+] in yeast can be determined by monitoring translation
efficiency of a nonsense codon present in the adenine biosynthesis gene ade2. This
mutation, ade2-1 ochre, leads to accumulation of aminoimidazole ribotide (AIR), a
red-colored intermediate produced during in the formation of purine bases, in cells
with functional Sup35 (10, 11). The [PSI+] red/white colorimetric assay is reliably used
to monitor translation fidelity as a marker of prion phenotype in yeast. The
accumulation of amyloid aggregates (prions) alleviates the accumulation of the redpigmented metabolite in strains carrying mutations in the adenine biosynthesis
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pathway (11). The prion conformation of Sup35 protein, referred to as the [PSI+]
phenotype, thus suppresses nonsense mutations and colonies appear white on solid
media (12). This traditional [PSI+] assay is both qualitative and binary; the phenotype
[psi-] can be identified by red colonies and the phenotype [PSI+] is associated with
white colonies.

Strong [PSI+] and weak [PSI+] phenotypes in yeast have been

observed in research studies that impaired Hsp70 binding to prion in yeast (13). A
strong [PSI+] phenotype refers to strong lack of red pigmentation and mitotic stability
(13). Mutations in the middle domain of Hsp104 also affect prion propagation in yeast
and yield differential [PSI+] phenotypes that range in color from pink to red yeast
colonies (14).
Hsp104 is an ATP-dependent molecular chaperone protein that functions to
remodel the Sup35 amyloid and segregate it into daughter cells during division.
Hsp104 is a ring-shaped hexameric protein that belongs to the AAA+ (ATPases
associated with diverse cellular activities) ATPase protein superfamily (15, 16).
Common to all AAA+ proteins are highly conserved nucleotide binding domains that
contain Walker motifs (17). Several proteins in the AAA+ superfamily use mechanical
force to remodel substrate proteins by hydrolyzing ATP (18). Hsp104 contains two
nucleotide-binding domains per subunit that function cooperatively (19, 20). The
flexible pore loops of Hsp100 proteins are critical for substrate translocation and
protein remodeling. Mutations targeting the pore loops of Hsp100 proteins, such as
HslU and ClpX, impair substrate engagement and translocation of polypeptides
through the axial channel (21, 22). The mechanism for Hsp104-mediated
disaggregation is thought to rely on the threading of polypeptides through an axial
channel. Cryoelectron microscopy maps of Hsp104 hexamers bound to different
nucleotides suggests that the two nucleotide binding domains of Hsp104 form stacked
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rings and a central cavity (23). Research suggests that substrates are disaggregated
by Hsp104 by threading and translocation of substrate through the axial channel into
the central cavity of Hsp104 due to substrate binding of the NBD1 and NBD2 rings
coupled to sequential ATP hydrolysis (23). Conserved tyrosine residues (pore-loop)
located in the central channel of Hsp104 bind to and grip polypeptides (24 – 28). The
mechanism of disaggregation by substrate threading and translocation is conserved
in ClpB, the bacterial homolog of Hsp104 (26, 28, 29, 30). ATP hydrolysis cycles
cause changes in the conformation of Hsp104, thus providing the mechanical force
required to unfold and translocate polypeptides through the axial pore of Hsp104 (23,
26).
Hsp104 remodels heterogenous aggregates, including amorphous as well as
highly ordered amyloid aggregates (31 – 33). Hsp104 reactivates misfolded proteins
and is necessary for prion inheritance in Saccharomyces cerevisiae (34, 35). It is
thought that Hsp104 fragments prions and generates seeds for prion assembly, which
catalyzes the propagation of prions in yeast (36). All yeast prions with the exception of
[PSI+] require Hsp104 for prion propagation (37 – 42). Deletion of the hsp104 gene
results in the loss of the prions [PSI+], [URE3], [PIN+]/[RNQ+], [SWI+], and [MOT3] (35,
41). Hsp104 fragments prion fibrils and generates amyloid seeds, which function as
propagation units that accelerate the self-assembly of prions; deletion of hsp104 is
thought to inhibit the fragmentation of prions, resulting in large aggregates that cannot
be efficiently transmitted from mother to daughter yeast cells (41). Moreover,
overexpression of the Hsp40 yeast protein Ydj1p cures the [URE3] prion, possibly by
an Hsp70/Hsp40 mechanism (42). The overexpression of Hsp104 cures yeast of the
[PSI+] and [MCA] prions (41, 43).
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The N-terminal domain of Hsp104 (amino acid residues 1 – 147) is
dispensable for thermotolerance, protein disaggregation of select substrates, and
[PSI+] prion propagation, but is required for [PSI+] loss (prion curing) when Hsp104 is
overexpressed in vivo (1). Hsp104 cooperates with the Hsp70/40 chaperone system
to disaggregate proteins in vivo (44, 45). Hsp70 acts upstream of Hsp104 and
regulates Hsp104 binding to protein aggregates (46). Hsp70 is required for speciesspecific targeting of client proteins to ClpB and Hsp104, suggesting a conserved
mechanism of substrate binding and disaggregation by the Hsp70-Hsp100 chaperone
system at the surface of protein aggregates (32). Hsp70 binds to the middle domain
of Hsp104, which may facilitate threading of protein substrates through the Hsp104
axial channel (47, 48).
Analysis of the crystallized structure of the N-terminal domain of Hsp104 in S.
cerevisiae suggests that misfolded proteins may bind to the N-domain (49). The
unstructured linker of ClpB is thought to regulate the position of the N-domain and
affect substrate binding to aggregates (50). Currently, it is unknown where amyloids
(prions) bind to Hsp104. Given that the N-domain is implicated in recognizing amyloid,
further investigation into the N-domain of Hsp104 is warranted to better characterize
substrate binding to Hsp104. Therefore, we randomly mutagenized the N-domain of
Hsp104 and screened clonal isolates in S. cerevisiae using the [PSI+] colorimetric
assay to monitor changes in prion phenotype and possible impairments of Hsp104
binding to prion substrate. We found several mutations in the Hsp104 N-domain that
are impaired for prion curing, thermotolerance, and disaggregation, suggesting an
important role of the N-domain in the direct recognition and/or clearance of the Sup35
amyloid.
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Results
Curing of [PSI+] by Hsp104 overexpression detected by fluorescence
Although the [PSI+] colorimetric conversion assay has been widely used to
qualitatively assess amyloid abundance and prion inheritance, it does not allow for
quantitative detection of intermediate phenotypes. Therefore, we developed a novel
fluorometric assay to quantitatively characterize different [PSI+] phenotypes in yeast,
which are associated with differential translation termination efficiency and [PSI+]
prion propagation. Yeast carrying the ade2-1 nonsense mutation in the adenine
biosynthesis pathways accumulate red pigment due to the polymerization of
aminoimidazole ribotide (10). The polymerization and oxidation of 4-aminoimidazole
ribotide in the yeast vacuole results in the accumulation of an endogenously
fluorescent red pigment (51). The red pigment stably persists in the vacuole and
fluorescence has been previously observed by excitation at 450 – 490 nm and
visualization of emitted light at 520-nm (51). The [PSI+] prion phenotype in yeast can
be detected in ade2-1 mutants by screening yeast cells for white colony color; red
colonies of yeast carrying the ade2-1 mutation are [psi-] and contain mostly soluble,
functional Sup35 protein (11).
To determine if red pigment accumulation is quantifiable in cell lysates by
fluorescence, we cultured [psi-] and [PSI+] yeast on agar plates for five days until red
colonies were visible for the [psi-] strain (Figure 1A). We harvested cells from solid
media, lysed the cells with glass beads and measured protein concentrations of the
soluble lysate. We monitored fluorescence emission spectra of soluble cell extracts,
normalized to total protein, following excitation at 488 nm. Fluorescence has also
previously been used to separate mixed populations of red and white yeast cells by
fluorescence-activated cell sorting (FACS) with an excitation at 488 nm (52). We
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observed that [psi-] cell lysates produce a large, broad emission peak at 565 nm;
however, a much lower emission peak was detected for [PSI+] cell lysates (Figure
1B).
To determine if the amplitude of the emission peak is dependent on the protein
concentration in [psi-] cell lysate, we compared emission spectra over a range of
concentrations (0.05 to 0.8 mg ml-1) (Figure 1C). We observed that as protein
concentration increased, the amplitude of the emission peak at 565 nm also
increased, indicating that the emission detected is concentration-dependent, tracking
with soluble protein. This also provided evidence that our novel fluorometric assay
was linearized and within the working range of detecting differences in fluorescence
signal based on the presence or absence of the [PSI+] prion in adenine biosynthesis
yeast mutants.
The adenine biosynthesis pathway metabolite AIR accumulates over time in
colonies of [psi-] during incubation at 30 °C. It is detectable as pink colony color at day
3 and continues to develop into a darker red as the colonies age. To confirm that
fluorescence associated with AIR-containing [psi-] colonies also accumulates with
time, we streaked [psi-] yeast cells onto rich yeast extract/peptone/dextrose (YPD)
solid media and incubated the plates for 3, 5 and 7 days at 30°C. At each time point,
we harvested the cells, collected soluble cell lysates and measured the peak emission
amplitude. We observed that the differences in fluorescence emission intensity of [psi] and [PSI+] S. cerevisiae lysates was highly significant on day 5 (p-value = 0.0007)
and day 7 (p-value = 0.006) of growth (Figure 1D). [PSI+] cells do not develop dark
red colony color or soluble fluorescence over time. To visualize the fluorescence
associated with red pigment accumulation in [psi-] cells, we performed confocal
fluorescence microscopy using similar excitation/emission conditions. We compared
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the basal fluorescence of [psi-] and [PSI+] yeast cells by confocal microscopy. As
expected, we observed a strong fluorescence signal in [psi-] cells at the excitation 488
nm (Figure 1E). However, under the same visualization conditions, we did not
observe endogenous fluorescence in [PSI+] cells (Figure 1E).
To determine if red pigment accumulation associated with Hsp104 overexpression
in [PSI+] yeast is endogenously fluorescent similar to the wild-type [psi-] phenotype in
yeast, we transformed the vector pYS104 (53) into [PSI+] cells containing
chromosomal hsp104. We observed that curing of [PSI+] prion by Hsp104
overexpression results in a conversion of white colony phenotype to red colony
phenotype (Figure 2A). Moreover, the red pigment in [PSI+] yeast overexpressing
Hsp104 has a similar endogenous fluorescence signal as [psi-] cells containing the
empty pYES2 vector (Figures 2A and 2B). Thus, the fluorometric assay that we
developed to quantify [PSI+] phenotype can be used to classify parental [PSI+] and
[psi-] yeast strains as well as yeast strains carrying plasmids that modify [PSI+]
phenotype.
The Walker B motif in AAA+ proteins is responsible for ATP hydrolysis (54). To
determine if a mutation known to impair ATP hydrolysis in Hsp104 also affects [PSI+]
phenotype, we constructed the Walker B NBD1 mutation E285Q in hsp104. The S.
cerevisiae containing the Hsp104(E285Q) mutation in the NBD1 domain had a pink
colony color on SD-URA solid media, which is associated with a weakly [PSI+]
phenotype (Figure 2A). We compared the development of fluorescence signal over
time in yeast strains containing the ade2-1 mutation transformed with pYS104,
pYES2, and the Hsp104(E285Q) Walker B mutation. Yeast cells were harvested on
days 3, 5, and 7 of growth and analyzed protein lysates using our novel fluorometric
assay. Significant differences in emission fluorescence intensities among the different
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S. cerevisiae strains occurred on day 5 of growth (p-value = 0.0008) and day 7 of
growth (p-value = 0.004). We found that the greatest differences in fluorescence
signal among [PSI+] yeast containing empty pYES2 vector, pYS104, and
Hsp104(E285Q) occurred at the emission wavelength 565 nm (Figure 2C). The
fluorescence intensity of yeast lysates at 565 nm is significantly different between
[PSI+] yeast and [psi-] yeast containing empty vector (p-value = 0.0084). Moreover, we
found a significant difference in fluorescence intensity at the emission wavelength 565
nm of [PSI+] yeast overexpressing Hsp104 and [PSI+] containing the Walker B
mutation Hsp104(E285Q), p-value = 0.0359 (Figure 2C). Confocal microscopy of
yeast expressing pYES2, pYS104, and Hsp104(E285Q) showed that the weakly
[PSI+] phenotype associated with Hsp104(E285Q) had endogenous fluorescence,
which appeared much weaker in intensity than the fluorescence associated with S.
cerevisiae overexpressing Hsp104 (Figure 2D).

Identification of Hsp104 N-domain residues important for [PSI+] curing in
Saccharomyces cerevisiae
To identify which amino acids in the Hsp104 N-domain are important for
amyloid recognition and curing of the [PSI+] prion phenotype, we performed random
mutagenesis and phenotypic screening to monitor S. cerevisiae cells for colony color
conversion in cells expressing Hsp104 mutant proteins in the plasmid pYS104 (Figure
3A). Using error-prone PCR amplification, we generated random mutations in hsp104
in the region spanning the N-domain (amino acid residues 1 – 307). Next, the
mutagenized fragments were used as primers to amplify a plasmid containing fulllength hsp104, and DpnI-digested PCR products were subsequently transformed into
E. coli. Mutagenized pYS104 plasmids were isolated from clonal isolates that grew on
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ampicillin selection plates. In total, 127 plasmids extracted from E. coli were
transformed into [PSI+] S. cerevisiae and screened for conferring a color change from
white to red. Clonal isolates that had an intermediate or weak [PSI+] phenotype (pink),
or loss of Hsp104 function (white) were sequenced and mapped to the Hsp104 Ndomain structure (Figure 3B). Mutations identified in the screen included seven
frameshift mutations, five single and two double substitution mutations. High-level
expression of plasmid-encoded Hsp104 wild type and mutant proteins was confirmed
by Western blot using antibodies directed against Hsp104 (Figure 3C).
We found five mutations in the N-domain of Hsp104 that are associated with
intermediate [PSI+], or weakly [PSI+], phenotype in yeast: A133D, L54P, H34D/E138V,
L36V, and P81L (Figure 4A). Moreover, we observed that cells cured of [PSI+]
reverted to a strongly [PSI+] phenotype in cells carrying the mutation V69F in hsp104
(Figure 4A). The double mutation A99T/V74A in hsp104 resulted in the phenotypic
appearance of dark red colonies, which had more red pigmentation than yeast cells
overexpressing hsp104, on SD-URA solid media. We further investigated double
mutations of interest by generating single substitution mutations in the yeast
expression plasmid pYS104 using site-directed mutagenesis. We observed that
Hsp104 A99T is responsible for the red pigmentation of yeast colonies on SD-URA.
Interestingly, the variant Hsp104 V74A was associated with a weakly [PSI+]
phenotype. Furthermore, the yeast variant Hsp104 H34D was weakly [PSI+] and the
variant Hsp104 E138V was strongly [PSI+] (Figure 4A).
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Functional analyses of Hsp104 N-domain mutants in vivo
The phenotypic [PSI+] colorimetric differences that we observed among the
hsp104 N-domain variants could have been caused by variable expression of Hsp104
among yeast strains. To determine if variable Hsp104 expression was responsible for
the phenotypic differences among our strains, we performed immunoblots using an
antibody against Hsp104. S. cerevisiae strains containing H34D, L36V, L54P, V69F,
V74A, P81L, A99T, A133D, and E138V all expressed Hsp104 protein. Mapping the Ndomain mutations to the crystal structure of the Hsp104 N-domain of S. cerevisiae
(55) containing mutations shows that the following mutations are near the surface:
L54P, V74A, P81L, A133D, and E138V (Figure 4B). Thus, it is possible that these
residues may contact amyloid substrate and participate in substrate binding.
Yeast strains carrying mutations in hsp104 show maximal differences in
fluorescence intensity at 565 nm when excited at 488 nm. One-way ANOVA of the
fluorescence intensities was used to determine that the means of the fluorescence
intensity for each strain at the emission wavelength 565 nm is significantly different (p
< 0.0001) (Figure 4C). Confocal microscopy was used to visualize the endogenous
fluorescence of S. cerevisiae carrying the Hsp104(V69F) mutation, which is
associated with loss of prion curing (Figure 4D). We observed reduced endogenous
fluorescence in this yeast strain (Figure 4D), as expected from the conversion of
colony color from red to white on SD-URA solid media.

Characterization of Hsp104 N-domain variants by thermotolerance assays
Hsp104 is required for thermotolerance in yeast. To determine if the mutations
that we identified in the N-domain are impaired for thermotolerance, we carried out
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thermotolerance assays with different strains of yeast containing mutations in hsp104.
Yeast strains were grown to mid-logarithmic phase of growth and Hsp104 expression
was induced by mild heat shock at 37°C for 30 minutes. Yeast cells were exposed to
extreme heat shock at 52°C at 0, 5, and 10 minutes and serially diluted fivefold on
SD-URA solid media. Heat shock at 52°C for 15 minutes and 30 minutes resulted in
no colony growth on SD-URA plates (data not shown). We assessed the cell viability
of the yeast strains carrying mutations in the Hsp104 N-domain after five days of
growth at 30°C and found that cells expressing Hsp104(H34D), Hsp104(V69F),
Hsp104(A133D), and Hsp104(E138V) had reduced viability and thus impaired
thermotolerance (Figure 5B) compared to yeast strains that were not subjected to
heat shock at 52°C (Figure 5A). It should also be noted that all cells have
endogenous expression of Hsp104 from the chromosome and loss of function
phenotypes likely emerge from dominant-negative mutations.
To determine if the Hsp104 variants H34D, L36V, L54P, V69F, V74A, P81L,
A99T, A133D, and E138V have impaired disaggregation and/or reactivation of
aggregated proteins, we grew yeast strains containing Hsp104 mutations to early midlogarithmic growth, incubated the liquid cultures in 37°C for 30 minutes, heat shocked
the cells at 52°C for 15 minutes, recovered the yeast cells at 30°C for 20 minutes and
extracted soluble and insoluble protein fractions using mechanical lysis with glass
beads. We monitored protein aggregate load in insoluble yeast protein fractions by
SDS-PAGE and Coomassie stain (Figure S1). We observed that yeast containing the
mutation Hsp104(L54P) had a 1.8-fold increase in thermal aggregate accumulation
compared to yeast cells overexpressing wild-type Hsp104 (Figure 6). The mutation
Hsp104(V74A) was associated with a1.8-fold increase in thermal aggregates and
yeast containing Hsp104(P81L) had a 1.9-fold increase in thermal aggregate load
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compared to wild-type Hsp104 (Figure 6). Therefore, the hsp104 mutations L54P,
V74A, and P81L are associated with impaired reactivation of protein aggregates.

Discussion
The amino acid residues 1 – 163 in the N-domain of ClpB are thought to be
important for early recognition of polypeptide substrates targeted for disaggregation
(56 – 58). Research does not support that the entire N-domain is essential for
thermotolerance or prion propagation (1). However, the inversion of Hsp104 residues
110 – 121 (inversion of nucleotides 330 – 363) in the N-domain results in loss of both
thermotolerance and prion propagation (59). Hsp104 overexpression has been shown
to convert [PSI+] yeast to a [psi-] phenotype, thus “curing” yeast of the Sup35 amyloid
(35, 54). By contrast, Hsp104 lacking the N-domain (Hsp104ΔNTD) does not cure
[PSI+] yeast of Sup35 amyloid (1). It has been suggested that the N-domain of
Hsp104 may fine-tune substrate recognition to prevent the nonspecific disaggregation
of polypeptides and directly bind to amyloid substrates (60). Here, we provide
evidence that specific residues in the N-domain of Hsp104 are necessary for
substrate recognition of Sup35 amyloid.
Hsp104 and its bacterial homolog ClpB are highly conserved and are found
throughout bacteria, fungi, plants, and lower eukaryotes. Hsp104 disaggregates
thermal aggregates and remodels stable, ordered aggregates, such as fibrillar Sup35
and Ure2 (61 – 63). Previous studies have provided evidence that the N-domain of
ClpB is important for recognition of substrate proteins and remodeling of aggregates;
a hydrophobic substrate-binding site in the N-terminal domain of ClpB was identified
by Rosenzweig and coworkers. Specifically, the residues W6A, L14A, L91A, L111A
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were found to be important for ClpB binding to aggregates (64). A separate study
found that the ClpB N-domain residues T7A, D103A, E109A are involved in substrate
binding based on luciferase reactivation assays and the observation that the Ndomain supports the casein-induced activation of ClpB ATPase activity (58). Mapping
these residues to the E. coli ClpB structure modeled on the crystal structure of T.
thermophilus ClpB shows that the following residues are surface-exposed and are
likely involved in direct substrate recognition of aggregated proteins: T7, L91, L14,
D103, and E109 (Figure 7A).
Pairwise alignments of the Hsp104 N-domain and the ClpB N-domain were
conducted using the EMBOSS Needle tool from EMBL-EBI (65, 66). The alignment of
the Hsp104 N-domain (amino acid residues 1 – 165) to the ClpB N-domain (amino
acid residues 1 – 149) using EMBOSS Needle results in a similarity score of 45.2%.
The amino acid residue H34 is a highly conserved residue; the residue is conserved
in the S. cerevisiae Hsp104 and E. coli ClpB N-domain sequences (Figure 7B). The
mutation H34D identified during phenotypic screening is associated with an
intermediate [PSI+] phenotype, which suggests that prion curing mediated by
overexpression of Hsp104 is impaired. Notably, the biochemical change from
histidine, a positively charged residue, to aspartic acid, a negatively charged residue
may result in major functional changes of Hsp104. An additional mutation, A133D,
occurs at a highly conserved site between the S. cerevisiae Hsp104 and E. coli ClpB
sequences. The substitution of alanine, a nonpolar amino acid, with aspartic acid, a
negatively charged amino acid, may change the binding properties and functional
interactions of Hsp104. Notably, the mutations at H34D and A133D are associated
with impaired thermotolerance and prion curing by Hsp104 overexpression.
Furthermore, the hsp104 mutations L36V and V69F are conserved residues and are
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associated with weakly [PSI+] and strongly [PSI+] phenotypes in S. cerevisiae,
respectively. The hsp104 mutations L54P, V74A, P81L, A99T, and E138V are semiconserved residues. Therefore, it is possible that the sites H34 and A133 in ClpB and
Hsp104 are evolutionary conserved and are important for direct binding to aggregated
proteins.
Thermotolerance assays conducted in this study suggest that hsp104
mutations H34D, V69F, and A133D are associated with impaired cell viability after
exposure to extreme thermal stress. Thus, these amino acid residues in Hsp104 may
be important for thermotolerance. Based on our results, we propose a model of
Hsp104-mediated disassembly of amyloid protein that involves initial substrate
recognition by the Hsp70/40 co-chaperone system, binding of Hsp70 to the middle
domain of Hsp104 to deliver substrate to Hsp104, and binding of amyloid substrate to
the N-domain of Hsp104 before substrate translocation through the axial channel of
Hsp104 into the central cavity for disaggregation (Figure 7C). Our results suggest that
surface-exposed Hsp104 residues, including A133D, bind to Sup35 amyloid. The
Hsp104 residues P81L, V74A, and L54P are associated with increased thermal
aggregate load after extreme heat shock, suggesting a role for these residues in
protein disaggregation. Thus, these residues may be involved in the recognition of
amyloid fibrils. Our results suggest that conserved residues H34 and A133 in the Ndomain may engage amyloid substrate and enable Hsp104 to translocate Sup35, or
other aggregated substrates through the axial channel for unfolding and reactivation
in collaboration with Hsp70/40.
The mutations in the Hsp104 N-domain identified by [PSI+] colorimetric
screening in S.cerevisiae V69F and E138V are associated with complete loss of
Hsp104-mediated curing of Sup35 prion as evidence by the reversion of colony color
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from red, a [psi-] phenotype, to white, a strongly [PSI+] phenotype. Furthermore, the
mutations

Hsp104(H34D),

Hsp104(L36V),

Hsp104(L54P),

Hsp104(V74A),

Hsp104(P81L), and Hsp104(A133D) caused a conversion from the [psi-] phenotype to
a weakly [PSI+] phenotype as evidenced by the colorimetric change in yeast colonies
from red to pink or pale orange-pink. It is possible that these point mutations in
hsp104 impair the oligomerization of Hsp104, thereby rendering wild-type Hsp104
protein non-functional. Future research should address this hypothesis to determine if
oligomerization of Hsp104 is affected by the point mutations H34D, L36V, L54P,
V69F, V74A, P81L, and A133D described here. Moreover, in vitro disaggregation
assays, ATP activity assays, and binding assays of Hsp104 containing the mutations
H34D, L36V, L54P, V69F, V74A, P81L, A99T, and A133D would provide more
mechanistic information about the point mutations in Hsp104 that are associated with
complete or partial loss of Hsp104-mediated curing of Sup35 prion. Here, we provide
evidence that the N-domain of Hsp104 recognizes amyloid fibrils and is essential for
substrate recognition of Sup35 prion.

Materials and Methods
The [PSI+] yeast strain used in this study is strain PSI+ [BSC783/4a], ATCC® MYA536™. The genotype of this strain is: MATa SUQ5 ade2-1 ura3-1 his3-11 his3-15
leu2-3 leu2-112 [PSI+]. The [psi-] yeast strain used in this study is a prion-deficient
mutant derived from the BSC783/4a strain and is designated 783/4a psi-, ATCC®
MYA-537™. The [psi-] strain has the genotype MATa SUQ5 ade2-1 ura3-1 his3-11
his3-15 leu2-3 leu2-112 [psi-]. Both yeast strains are haploid and have previously
been used in prion studies (67). Yeast strains were grown at 30°C in synthetic
dextrose media minus uracil solid media (SD-URA; 1.7 g yeast nitrogen base, 5 g
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ammonium sulfate, 20 g dextrose per liter, and 17 g agar per liter) and yeast
extract/peptone/dextrose

media

(YPD;

containing

1%

yeast

extract,

2%

bactopeptone, 2% glucose, and 40 mg of adenine sulfate per liter).

Mutagenesis
The Megawhop cloning method has been used to construct mutant libraries of
specific protein domains (66). First, mutations in the N-domain of Hsp104 were
introduced into the gene hsp104 using an error-prone DNA polymerase (Agilent
Genemorph II Random Mutagenesis kit). The DNA fragment generated from the
random mutagenesis polymerase chain reaction, or the “megaprimer”, was used to
amplify the template pYS104 vector, resulting in nicked plasmid DNA (68). Parental
plasmid DNA was removed by DpnI digestion and the digestion reaction products
were transformed into Escherichia coli. Transformants were grown on LB Lennox
media containing ampicillin. Plasmids recovered from E. coli were then purified and
screened in Saccharomyces cerevisiae using a fluorescence-based [PSI+] assay.
Site-directed mutagenesis of hsp104 on the vectorpYS104 (54) was carried out using
the QuikChange Mutagenesis kit (Agilent Genomics). Primers were designed to
introduce the following substitutions into hsp104: A99T, V74A, H34D, and E138V
(Table 3). Yeast transformants were grown on synthetic dextrose plates lacking uracil
and were replica plated.
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Yeast Whole Cell Extraction and Western Blot
Yeast whole cell lysates were extracted under non-denaturing conditions as
previously described. Yeast cells were grown on synthetic dextrose solid media
lacking uracil and supplemented with 2 % galactose at 30°C. After five days of
growth, yeast cells were scraped off the solid media and pelleted at 3,000 x g for 5
minutes at 4°C. Cells were washed twice with ice-cold phosphate buffered saline and
resuspended in yeast lysis buffer (50 mM Tris pH 8.0, 5 mM EDTA, 0.5 mM NaCl, 5%
glycerol, 1% Triton X-100) containing protease inhibitors. Yeast cells were lysed by
vortexing cells resuspended in lysis buffer with 0.5 mm glass beads (Scientific
Industries, Inc.) eight times with two-minute cooling periods on ice between each
vortex. The protein concentration of lysates was quantified using the bicinchoninic
acid assay (Pierce BCA Protein Assay kit) and protein concentrations were
subsequently normalized. Hsp104 antibody (Thermo Fisher Scientific) was diluted
1:1,000 in Tris buffer containing 0.1% Tween-20 and 0.05% nonfat milk. All Western
blot bands were normalized to beta-actin (Abcam) or GAPDH (Thermo Fisher
Scientific).

Fluorescence [PSI+] Assay
Yeast whole cell lysates were normalized to a final protein concentration of 0.5
mg/mL. Using a quartz cuvette, 80 μL of lysate was excited at 488 nm at PMT 750 V.
Emission wavelengths were captured between 500 and 800 nm. The excitation slit
width was 10 nm and the emission wavelength was 20 nm.
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Thermotolerance Assay
Thermotolerance experiments were conducted with yeast strains as previously
described (69, 70). Briefly, yeast cells were grown in SD-URA media to midlogarithmic phase (OD600 of 0.400 – 0.600) in SD-URA media. The synchronized
liquid cultures of yeast were incubated for 30 minutes at 37°C with vigorous aeration
to induce the expression of Hsp104. Subsequently, yeast cultures were moved to a
52°C water bath and 1 mL aliquots of cultures were removed, transferred to ice
briefly, and serial diluted five-fold in SD-URA media before spot plating onto SD-URA
+ 2% galactose solid media 0 minutes and 5 minutes after heat shock at 52°C to
determine cell viability.
To measure thermal aggregate accumulation in [PSI+] yeast containing
mutations in hsp104, yeast cultures were grown in 30°C to mid-logarithmic phase in 5
mL of SD-URA media and pretreated at 37°C for 30 minutes with vigorous aeration.
Cultures were then transferred to a 52°C water bath for 15 minutes. Subsequent to
the extreme heat shock, yeast cultures were incubated at 30°C with vigorous aeration
to allow cells to recover from the thermal stress. Yeast cells were harvested by
centrifugation and protein was extracted by glass bead lysis in lysis buffer. Equal
volumes (5 µL) of insoluble yeast protein were boiled in LDS sample buffer; the final
sodium dodecyl sulfate (SDS) concentration of the protein samples was 2%. The
insoluble protein samples were loaded in a 3 – 8% Tris-acetate gel and
electrophoresed at 150V in Tris-acetate running buffer containing SDS. Gels were
incubated in Coomassie stain to observe total protein levels across lanes. Intensity of
each full lane was analyzed using ImageJ software (National Institute of Health
ImageJ).
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Statistical analyses
Differences in mean fluorescence intensities were measured using an unpaired, onetailed t-test with alpha level equal to 0.05. Analysis of variance tests and post-hoc
Tukey’s multiple comparison tests were conducted to determine differences in
fluorescence intensities across more than two yeast strains. Statistical analyses were
carried out using Graphpad Prism version 6.0, GraphPad Software, La Jolla,
California, USA (www.graphpad.com).

Pairwise protein alignment
Protein sequences were globally aligned using the EMBOSS Needle tool (66) from
the European Bioinformatics Institute (EMBL-EBI) (65). The default settings in
EMBOSS Needle were used for protein alignment.
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Table 1. Yeast strains used in the study.

Strain

783/4a PSI+
[BSC783/4a]

Genotype

MATa SUQ5 ade2-

Ploidy

Source

Haploid

ATCC MYA-536

Haploid

ATCC MYA-537

1 ura3-1 his3-11
his3-15 leu2-3 leu2112 [PSI+]

783/4a psi-

MATa SUQ5 ade21 ura3-1 his3-11
his3-15 leu2-3 leu2112 [psi-]
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Table 2. Mutations of interest in Hsp104 N-domain identified by [PSI+] assay.
Random Mutation in

Colony

Hsp104

Phenotype

V69F

Function

Phenotype

White

-

Strongly [PSI+]

L54P

Orange-pink

+/-

Weakly [PSI+]

A133D

Dark orange-pink

+/-

Weakly [PSI+]

H34D and E138V

Light orange-pink

+/-

Weakly [PSI+]

H34D

Orange-pink

+/-

Weakly [PSI+]

E138V

Light pink

+/-

Weakly [PSI+]

V74A and A99T

Dark red

+

[psi-]

V74A

Light pink

+/-

Weakly [PSI+]

A99T

Dark red

+

[psi-]

P81L

Light pink

-

Strongly [PSI+]

Q113A

Light orange-pink

+/-

Weakly [PSI+]

L36V

Orange-pink

+/-

Weakly [PSI+]
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Table 3. Primers used for site-directed mutagenesis.

Primer

DNA Sequence (5’ to 3’)

Hsp104 H34D
CAATGAAGGCAGCTAGAATATCTATAGGTTGTAATTGTGGATG
Forward
Hsp104 H34D
CATCCACAATTACAACCTATAGATATTCTAGCTGCCTTCATTG
Reverse
Hsp104 A99T

TTGTTTTTGAATCTTAGCAGTGTCTTGAAGGACTTTCCC

Forward
Hsp104 A99T
GGGGAAAGTCCTTCAAGACACTGCTAAGATTCAAAAACAA
Reverse
Hsp104 V74A
CAGGTTGCTGTTGAGGAATTCTTGCTAGATTTCTATTAACCACTTTC
Forward
Hsp104 V74A
GAAAGTGGTTAATAGAAATCTAGCAAGAATTCCTCAACAGCAACCTG
Reverse
Hsp104
E138V

GTTGCTTGATGGCCACAATATCTACTTGAGCTTCC

Forward
Hsp104
E138V

GGAAGCTCAAGTAGATATTGTGGCCATCAAGCAAC

Reverse
Hsp104
E285Q

CTTACCATTACCCATTAACATGTGAATCTGATCAATGAATAACACAATTAGAGTCTT

Forward
Hsp104
E285Q

AAGACTCTAATTGTGTTATTCATTGATCAGATTCACATGTTAATGGGTAATGGTAAG

Reverse
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Figure 1. Red pigment in S. cerevisiae ade2-1 mutants is intrinsically
fluorescent.
A.) Red pigment accumulates in the [psi-] yeast strain that contains the ade2-1
mutation. Yeast with soluble Sup35 accumulates red pigmentation.
B.) The [psi-] and [PSI+] yeast strains have intrinsic fluorescence at 488 nm.
C.) The fluorescence signal associated with red pigment accumulation is
dependent on the protein concentration of [psi-] lysates; fluorescence signal
increases with increasing protein concentration.
D.) The fluorescence signal is time-dependent; the maximal colorimetric
differences between [PSI+] and [psi-] strains occurs on day 5 of growth at
30°C. The greatest difference between fluorescence signal of [PSI+] and [psi-]
yeast occurs on day 5 (p-value = 0.0006) and day 7 (p-value = 0.006).
E.) S. cerevisiae carrying the ade2-1 mutation and the [psi-] phenotype
accumulate red pigment, which has intrinsic fluorescence. Yeast cells with the
[PSI+] phenotype grow into white colonies on solid SD-URA plates + 2 %
galactose and do not have endogenous fluorescence. Wavelength excitation
488 nm; Wavelength emission 520 nm. Scale bar indicates 5 μm.
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[psi-]

Figure 2. Red pigment accumulation and endogenous fluorescence in yeast
[PSI+] and [psi-] strains.
A.) Streaks of [PSI+] yeast strains containing Hsp104, empty vector (pYES2), and
Hsp104 E285Q. The Walker B mutation in the NBD1 domain of Hsp104 (E285Q)
is weakly [PSI+], as evidenced by the pink colony phenotype on SD-URA solid
media. B.) Overexpression of Hsp104 in [PSI+] yeast results in red pigment
accumulation, which has intrinsic fluorescence at 488 nm comparable to [psi-]
yeast. Red pigmentation develops over time in yeast strains containing
overexpressed Hsp104 in the vector pYS104. The maximal differences in
fluorescence between [PSI+] yeast containing empty vector and [PSI+] yeast cured
by Hsp104 occurs on day 5 of growth (p-value = 0.0008) and day 7 of growth (pvalue = 0.0035). Unpaired, one-tailed t-tests.
C.) The differences in fluorescence signal between [PSI+] yeast containing empty
vector pYES2 and pYS104 vector overexpressing Hsp104 is significant (p =
0.0255) Fluorescence intensity at 565 nm is highly significantly different between
[PSI+] yeast and [psi-] yeast containing empty vector (p-value = 0.0084). Yeast
containing the Hsp104 Walker B mutant E285Q shows significantly less
fluorescence than [PSI+] yeast overexpressing Hsp104 (p-value = 0.0359).
Unpaired, one-tailed t-tests.
D.) The intermediate [PSI+] phenotype has a similar emission profile as [PSI+].
Wavelength excitation 488 nm, wavelength emission 520 nm. Scale bar shown
indicates 5 μm.
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Figure 3. Selection of mutations in the N-terminal domain of Hsp104.
A.) Random mutagenesis of the N-terminal domain of Hsp104 was carried out using
an error-prone DNA polymerase and primers that targeted the N-domain of Hsp104.
The products of the random mutagenesis PCR were used as primers in a subsequent
PCR to amplify the plasmid pYS104. The PCR products were transformed into
chemically competent E. coli. Plasmids were isolated from E. coli and transformed into
electrically competent S. cerevisiae for [PSI+] colorimetric screening.
-

B.) The colorimetric [PSI+] assay screens for [psi ] and [PSI+] phenotypes. Yeast
strains that carried mutations in Hsp104 associated with loss of prion curing appear
white on SD-URA solid media and were sequenced and further analyzed. Here, a red
box marks yeast strains that have loss-of-function Hsp104.
C.) Protein expression levels of Hsp104 in yeast strains. Mutants of interest were
further screened for analysis by determining protein expression levels of induced
lysates. Western blot Hsp104 protein is made in all [PSI+] S. cerevisiae strains
containing mutations in Hsp104.

80

A
N-domain

1. Error-prone
PCR

3.
Amplification
of pYS104

2. Mutagenized
gene fragments
are primers

B

5.

4

3.

2.

6.

4. Transformation
of library into E. coli

C

104 kDa

81

5. Clonal
isolation
of vector

6. Transformation
of S. cerevisiae
for screening

Figure 4. Functional analyses of hsp104 mutations of interest.
A.) Yeast strains carrying point mutations in hsp104 on day 3 of growth at 30 °C.
B.) Model of Hsp104 N-terminal domain in S. cerevisiae (PDB 6AMN; Lee, J. et al.,
2017) containing mutations H34D (cyan), L36V (yellow), L54P (light blue), V69F
(green), V74A (orange), P81L (violet), A99T (magenta), A133D (light pink), and
E138V (wheat).
C.) Yeast strains carrying mutations in hsp104 show maximal differences in
fluorescence intensity at 565 nm when excited at 488 nm. One-way ANOVA of the
fluorescence intensities was used to determine that the means of the fluorescence
intensity of each strain at 565 nm is significantly different (p < 0.0001).
D.) Confocal fluorescence microscopy of yeast cells grown on day 5 of growth.
[PSI+] yeast carrying empty vector pYES2 (white colonies on SD-URA solid media)
has decreased endogenous fluorescence compared to [PSI+] yeast overexpressing
Hsp104 and [psi-] yeast containing pYES2. The loss-of-function V69F mutation in
Hsp104 is associated with reduced endogenous fluorescence (pale pink colonies on
SD-URA solid media). Wavelength excitation 488 nm; wavelength emission 520 nm.
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Figure 5. Impaired thermotolerance of [PSI+] yeast containing mutations in
the N-domain of Hsp104. Hsp104 NTD mutants were incubated at 37°C for 30
minutes and subsequently transferred to 52°C for A.) 0 minutes of heat shock
and B.) 5 minutes and yeast cultures were fivefold serially diluted onto SD-URA +
2% galactose solid media. Plates were grown at 30°C for 5 days.
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Figure 6. Thermal aggregates accumulate in S. cerevisiae containing mutations
in the Hsp104 N-domain. Yeast cells carrying mutations in hsp104 were grown in
SD-URA + 2% galactose liquid media until early logarithmic growth. Cultures were
incubated at 37°C for 30 minutes before heat shock at 52°C for 15 minutes. Cells
recovered at 30°C for 20 minutes after heat shock. Insoluble protein fractions were
electrophoresed on a 3-8% Tris-acetate gel and Coomassie stained. Cells with the
mutation Hsp104(L54P) had a 1.8-fold increase in thermal aggregate accumulation
compared to cells overexpressing wild-type Hsp104. Furthermore, mutations
Hsp104(V74A) and Hsp104(P81L) were associated with a 1.8-fold and 1.9-fold
increase in thermal aggregate load compared to wild-type Hsp104.
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Figure 7. The role of the N-domain of Hsp104 in substrate binding of amyloid
fibrils.
A.) E. coli ClpB N-domain modeled on T. thermophilus ClpB crystal structure; PDB
1QVR (Lee S, et al., 2003). The ClpB mutations T7 (yellow), L91 (orange), L14
(pink), D103 (red), and E109 (green) are surface-exposed.
B.) Protein alignment of S.cerevisiae Hsp104 N-domain (a.a. 1 – 165) and E.coli
ClpB N-domain (a.a. 1 – 149). Residues highlighted in yellow are Hsp104 N-domain
mutations. Residues highlighted in gray are identical. Red arrows denote highly
conservative mutations. EMBOSS Needle (EMBL-EBI) pairwise protein alignment.
C.) Model of Amyloid Binding to Hsp104. (I) Hsp70, bound to nucleotide exchange
factor (NEF) and Hsp40, binds to amyloid protein substrate. Hsp104 is a hexameric
protein with an axial channel and tyrosine pore loops. (II) Hsp70 binds to the middle
domain of Hsp104 and a segment of the amyloid binds to the N-domain of Hsp104.
Hsp104 pore loops translocate polypeptides through the axial channel. (III) Amyloid
protein is threaded through the axial channel of Hsp104, driven by the movement of
the pore loops coupled to rounds of ATP hydrolysis. (III) Amyloid protein is
reactivated by Hsp104 into natively folded proteins.
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Figure S1. Thermal aggregates in S. cerevisiae strains containing
mutations in the N-domain of Hsp104. Yeast lysates were loaded on a
3 – 8% Tris-acetate gel and electrophoresed at 150V. The gel was
subsequently Coomassie stained. Yeast containing L54P, V74A, and
P81L mutations in Hsp104 show increased thermal aggregates in
response to heat shock at 52°C.
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Abstract
ClpX is a member of the Clp/Hsp100 family of ATP-dependent chaperones
and partners with ClpP, a compartmentalized protease, to degrade protein substrates
bearing specific recognition signals. ClpX targets specific proteins for degradation
directly or with substrate-specific adaptor proteins. Native substrates of ClpXP include
proteins that form large oligomeric assemblies, such as MuA, FtsZ and Dps in
Escherichia coli. To remodel large oligomeric substrates, ClpX utilizes multivalent
targeting strategies and discriminates between assembled and unassembled
substrate conformations. Although ClpX and ClpP are known to associate with protein
aggregates in E. coli, a potential role for ClpXP in disaggregation remains poorly
characterized. Here, we discuss strategies utilized by ClpX to recognize native and
non-native protein aggregates and the mechanisms by which ClpX alone, and with
ClpP, remodels the conformations of various aggregates. We show that ClpX
promotes the disassembly and reactivation of aggregated Gfp-ssrA through specific
substrate remodeling. In the presence of ClpP, ClpX promotes disassembly and
degradation of aggregated substrates bearing specific ClpX recognition signals,
including heat-aggregated Gfp-ssrA, as well as polymeric and heat-aggregated FtsZ,
which is a native ClpXP substrate in E. coli. Finally, we show that ClpX is present in
insoluble aggregates and prevents the accumulation of thermal FtsZ aggregates in
vivo, suggesting that ClpXP participates in the management of aggregates bearing
ClpX recognition signals.
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Introduction
Maintaining cellular proteostasis relies on chaperone pathways that promote
native protein folding. Typical strategies include targeting misfolded, unfolded, and
aggregated polypeptides for reactivation or degradation (Bukau and Horwich,
1998;Wickner et al., 1999;Stoecklin and Bukau, 2013). Misfolded proteins are
generated during polypeptide elongation and as a complication of environmental
stress (Powers and Balch, 2013). The challenges imposed on chaperone systems by
proteotoxic stress are especially relevant in pathogenic organisms like E. coli, which
experience extreme fluctuations in environmental conditions leading to accumulation
of protein aggregates and subsequent proteotoxicity (Mogk et al., 2011). Protein
quality control systems reactivate, degrade and remove damaged and aggregated
proteins. Under thermal stress in E. coli, the heat shock response provides a cellular
defense mechanism and upregulates heat shock protein and chaperone levels to
restore proteostasis (Mogk et al., 2011).
In addition to preventing protein aggregation, chaperone proteins mediate
aggregate clearance through proteolysis of non-native proteins and aggregation
reversal (Hartl et al., 2011;Mogk et al., 2011). Clearance of misfolded proteins in E.
coli is carried out by AAA+ (ATPases Associated with diverse cellular Activities)
proteins, which initiate substrate recognition, unfolding, and translocation into a
proteolytic chamber (ClpP, HslV) (Snider and Houry, 2008;Sauer and Baker, 2011).
Several AAA+ proteins, such as Lon and FtsH, contain both AAA+ chaperone and
proteolytic domains within a single protomer (Sauer and Baker, 2011). The
chaperone-protease Lon recognizes exposed aromatic and hydrophobic residues,
which may contribute to less stringent substrate selectivity and favor degradation of
unfolded or misfolded proteins (Gur and Sauer, 2008).
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The Clp ATPases of the AAA+ superfamily can be separated into two
functional

categories:

degradation

or

disaggregation

machines.

Degradation

machines, including ClpX, ClpA, and HslU form complexes with peptidases ClpP or
HslV to remove misfolded proteins or specific substrates (Zolkiewski, 2006).
Disaggregation machines, including Hsp104 and its bacterial homolog ClpB,
disaggregate and reactivate aggregated proteins by an ATP-dependent mechanism
and can function in cooperation with the Hsp70/DnaK system independent of protein
degradation (Zolkiewski, 1999;Dougan et al., 2002;Doyle et al., 2007;Sweeny and
Shorter, 2016). Through a collaborative mechanism, Hsp70, with Hsp40, binds first to
a polypeptide segment of an aggregated protein and then the substrate is remodeled
by Hsp104/ClpB (Zietkiewicz et al., 2004;Zietkiewicz et al., 2006;Acebron et al.,
2009).
E. coli substrates that are degraded by ClpXP include a variety of cellular
proteins, metabolic enzymes and several proteins capable of forming large
conformational assemblies, including FtsZ, Dps and MinD (Flynn et al., 2003;Stephani
et al., 2003;Neher et al., 2006;Camberg et al., 2009;Camberg et al., 2014;Conti et al.,
2015). ClpXP can associate with cellular aggregates in E. coli and can promote
removal of cellular inclusions, but direct protein disaggregation in vitro is not well
characterized for ClpX (Vera et al., 2005;Winkler et al., 2010). An early study
suggested that ClpX, in the absence of ClpP, could protect the lambda O phage
protein from aggregation and resolubilize lambda O aggregates (Wawrzynow et al.,
1995). In Bacillus subtilis, ClpX also localizes to protein aggregates, suggesting that it
may be involved in protein disaggregation (Kruger
et al., 2000;Kain et al.,
76
2008;Kirstein et al., 2008)Simmons et al., 2008). ClpX and ClpX substrates are
present in polar protein aggregates in E. coli under stress in vivo, suggesting that
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ClpX associates with aggregated proteins and participates in their removal (Kain et
al., 2008;Maisonneuve et al., 2008;Simmons et al., 2008).
ClpXP comprises an asymmetric, hexameric ring of ClpX docked to two
stacked heptameric rings of the ClpP serine protease (Wang et al., 1997;Glynn et al.,
2009). Although ClpX has been shown to independently remodel substrates, such as
MuA, in the presence of ClpP, hydrophobic ‘IGF’ loops on the bottom surface of the
ClpX hexamer contact hydrophobic pockets on the ClpP tetradecamer, allowing
unfolded substrates to access the ClpP proteolytic chamber (Kim et al.,
2001;Abdelhakim et al., 2010;Baker and Sauer, 2012). Nucleotide binding by ClpX
protomers, in the cleft between the large and small AAA+ subdomains, regulate the
position of the subdomains relative to each other; these conformational changes
enable ClpX to couple substrate translocation to ATP hydrolysis (Glynn et al.,
2009;Baker and Sauer, 2012). Substrates are then translocated into the ClpP
chamber for degradation (Baker and Sauer, 2012).
Substrates bind to the ClpX N-domain and to residues in the ClpX central
channel (pore-loops) (Bolon et al., 2004;Park et al., 2007;Martin et al., 2008;Baker
and Sauer, 2012). The N-domain of ClpX is separated from the AAA+ domain by a
flexible linker and can dimerize independently. The N-domain is important for direct
recognition of some substrates, including FtsZ and MuA, as well as adaptor proteins,
but is not required for direct recognition of the ssrA-tag (Abdelhakim et al.,
2008;Martin et al., 2008;Camberg et al., 2009;Baker and Sauer, 2012). Adaptor
proteins, such as RssB or SspB, promote the interaction and engagement of specific
substrates, such as RpoS or ssrA-tagged substrates, respectively (Sauer and Baker,
2011). The ssrA tag is an 11-residue degron appended to a nascent polypeptide
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when the ribosome stalls during protein synthesis, targeting the misfolded protein for
subsequent degradation (Gottesman et al., 1998;Levchenko et al., 2000).
ClpXP is implicated in the degradation of diverse cellular substrates and more
than 100 substrates have been reported (Flynn et al., 2003;Neher et al., 2006). Native
substrates of ClpX contain recognition motifs at the N- or C-termini (Flynn et al.,
2003). Notably, the essential cell division protein FtsZ in E. coli has two distinct ClpX
motifs: one in the flexible linker region and one near the C-terminus (Camberg et al.,
2014). FtsZ is a tubulin homolog that assembles into linear polymers in vitro and
forms the septal ring critical for division in vivo, called the Z-ring (Erickson et al.,
2010). ClpXP degrades approximately 15% of FtsZ proteins during the cell cycle in E.
coli and is capable of degrading both monomers and polymers in vitro (Camberg et
al., 2009). ClpXP degrades polymers more efficiently, which is consistent with a
common strategy of multivalent recognition of substrates by AAA+ ATPases (Davis et
al., 2009;Camberg et al., 2014;Ling et al., 2015). In addition to FtsZ, several other
ClpXP substrates form large oligomeric structures, including the tetrameric phage
protein MuA, the dodecameric bacterial protein Dps, and the bacterial cell division
ATPase MinD (Stephani et al., 2003;Neher et al., 2006;Abdelhakim et al., 2010;Conti
et al., 2015). Like FtsZ, alternate monomeric and oligomeric conformations of MuA
are also differentially recognized by ClpX (Abdelhakim et al., 2008;Abdelhakim et al.,
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2010;Ling et al., 2015).

In this study, we use engineered and native substrates to investigate the role
of ClpX and ClpXP in the disassembly and degradation of protein aggregates that
bear specific ClpX recognition signals. We observed that ClpX, with and without ClpP,
destabilizes Gfp-ssrA aggregates in vitro. The native ClpXP substrate FtsZ forms
several discrete conformations, including linear ordered polymers and also heat97

induced aggregates. Our results show that ClpXP disassembles both heat-induced
and linear polymers containing FtsZ. Finally, we also demonstrate that thermal stress
promotes aggregation of FtsZ, which is exacerbated in cells deleted for clpX or clpP.
Together, these results show bona fide chaperone activity for ClpX in vitro and
suggest that ClpX, with or without ClpP, may play a broader role in rescue and
disassembly of protein aggregates.

Materials and Methods
Bacterial strains and plasmids
E. coli strains and plasmids used in this study are described in Table 1. An
expression plasmid encoding FtsZ(ΔC67) was constructed by introducing a TAA stop
codon (at residue 317 of FtsZ) into pET-FtsZ by site-directed mutagenesis (Camberg
et al., 2009).

Expression and purification of proteins
Gfp-ssrA was purified as previously described (Yakhnin et al., 1998). ClpX,
ClpP, FtsZ, and FtsZ(ΔC67) were each overexpressed in E. coli BL21 (λDE3) and
purified as described (Maurizi et al., 1994;Grimaud et al., 1998;Camberg et al.,
2009;Camberg et al., 2014). ClpX(E185Q) was purified as described for wild type
ClpX, except the expression strain, E. coli MG1655 ΔclpX carrying plasmid
pClpX(E185Q), was induced with 1% arabinose (Table 1) (Camberg et al., 2011).
Gfp(uv) containing an N-terminal histidine tag was overexpressed in E. coli BL21
(λDE3) and grown to an OD600 of 1.0 and induced for 3 hours at 30 ºC. Cells were
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lysed by French press in purification lysis buffer (20 mM HEPES, pH 7.5, 5 mM
MgCl2, 50 mM KCl, and 10% glycerol). Soluble extracts were bound to TALON metal
affinity resin (GE Healthcare), eluted with an imidazole gradient, and imidazole was
removed by buffer exchange. Protein concentrations are reported as FtsZ monomers,
ClpX hexamers, ClpP tetradecamers, and Gfp or Gfp-tagged monomers. For
polymerization assays, FtsZ was labeled with Alexa Fluor 488 and active protein (FLFtsZ) was collected after cycles of polymerization and depolymerization as described
(Gonzalez et al., 2003;Camberg et al., 2014).
Dynamic light scattering
Dynamic light scattering (DLS) measurements were made using a Zetasizer
Nano ZS (Malvern Instruments). To determine size distribution, FtsZ (5 μM), aggFtsZ
(5 μM), Gfp-ssrA (1.5 μM) and aggGfp-ssrA (1.5 μM) in reaction buffer (50 mM
HEPES, pH 7.5, 100 mM KCl and 10 mM MgCl2) were added to polystyrene cuvettes
and scanned at 23 °C with a detector angle of 173° and a 4 mW, 633 nm He–Ne
laser. The reported intensity-weighted hydrodynamic diameters are based on 15
scans.
Heat denaturation, aggregation, disassembly and reactivation of aggregated
substrates
To heat-inactivate Gfp substrates, Gfp-ssrA (1.5 μM) or Gfp(uv) (1.5 μM) was
added, where indicated, to buffer containing HEPES (50 mM, pH 7.5), KCl (100 mM),
MgCl2 (10 mM), glycerol (10%) and dithiothreitol (DTT) (2 mM) in a volume of 800 μl
and incubated at 85 °C for 15 minutes. Immediately following heat-treatment, the
denatured substrate was placed on ice for 2 minutes and added to a reaction (50 μl)
containing ClpX, (0.3 μM), ClpX (E185Q) (0.3 μM), ClpP (0.3 μM), ATP (4 mM),
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ATPγS (1 mM), or ADP (2 mM), where indicated. Samples containing ATP were
supplemented with an ATP-regenerating system containing phosphocreatine (5 mg
ml-1) and creatine kinase (CK) (60 μg ml-1). Fluorescence recovery was monitored by
measuring fluorescence in a Cary Eclipse fluorometer with excitation and emission
wavelengths set at 395 nm and 510 nm, respectively. Readings were corrected for
background signal by subtracting the fluorescence of buffer. Rates were calculated by
fitting to a one-phase association model in GraphPad Prism (version 6.0b).
Disaggregation was monitored by 90º-angle light scatter with excitation and emission
wavelengths set to 550 nm. Readings were corrected for background signal by
subtracting the scatter of the buffer and then plotted as percent of the initial turbidity.
Heat-induced aggregation of Gfp-ssrA with time was monitored by 90º-angle light
scatter with the temperature of the cuvette holder set to 80 ºC using a circulating
water bath.
To inactivate native FtsZ substrates, FtsZ and FtsZ(ΔC67) (5 µM) were heated
for 15 minutes in reaction buffer (20 mM HEPES, pH 7.5, 100 mM KCl, 10 mM MgCl2)
in a volume of 120 μl at 65 ºC, then cooled on ice for 40 seconds, and held at 23 °C
until addition to reactions (60 μl volume) containing ClpX (0.5 µM or 1 µM),
ClpX(E185Q) (0.5 µM), ClpP (1 µM), ATP (4 mM) and an ATP-regenerating system
(phosphocreatine at 5 mg ml-1 and creatine kinase at 60 μg ml-1), where indicated.
Disaggregation was monitored by 90º-angle light scatter with excitation and emission
wavelengths set to 450 nm. Readings were corrected for background signal by
subtracting the scatter of the buffer and then plotted as percent of the initial turbidity.
Heat-induced aggregation of FtsZ with time was monitored by 90º-angle light scatter
with the temperature of the cuvette holder set to 65 ºC using a circulating water bath.
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Polymerization and GTP hydrolysis assays
FL-FtsZ was incubated with the GTP analog GMPCPP (0.5 mM) in the
presence of increasing concentrations of ClpX and ClpP (0, 0.25, 0.5 or 1 µM) as
indicated and in the presence of phosphocreatine at 5 mg ml-1 and creatine kinase at
60 μg ml-1. Samples were incubated for 3 minutes in buffer containing MES (50 mM,
pH 6.5), KCl (100 mM) and MgCl2 (10 mM) at 23 ºC, then centrifuged at 129,000 x g
in a Beckman TLA 120.1 rotor for 30 minutes. Pellets were resuspended in 0.2 M
NaCl with 0.01% Triton X-100 (100 μl) and the fluorescence associated with FL-FtsZ
for supernatants and pellets was measured using a Cary Eclipse spectrophotometer.
GTP hydrolysis rates for FtsZ and FtsZ(ΔC67) were measured before and after
aggregation using the Biomol Green (Enzo Life Sciences) detection reagent as
described (Camberg et al., 2014).

Heat shock of wild type and deletion strains
E. coli wild type and deletion strains were grown overnight, diluted 1:100 in
fresh Lennox broth the next day and grown at 30 °C to an OD of 0.4. All strains were
incubated in a water bath at 50 °C for 1 hour, followed by recovery at 30 °C for 35
minutes. Cells were harvested by centrifugation and lysed with Bacterial Protein
Extraction Reagent (B-PER) (ThermoFisher Scientific) (2 ml) and lysozyme (25 μg ml1

). Insoluble fractions were collected by centrifugation at 15,000 x g for 5 minutes at 4

°C, resuspended in lithium dodecyl sulfate sample buffer and analyzed by reducing
SDS-PAGE. Total proteins were transferred to a nitrocellulose membrane and
visualized

by

Ponceau

(Fisher

Scientific)

staining

and

membranes

were

immunoblotted using antibodies to ClpX and FtsZ (Camberg et al., 2009;2011). Band
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intensities were analyzed by densitometry (NIH ImageJ), normalized to the intensity of
the average of the ‘no heat’ sample, and evaluated for significance by the MannWhitney test. Where indicated, to test a mild heat shock condition, cells were
incubated in a water bath at 42 °C for 30 minutes, followed by recovery at 30 °C for
35 minutes, and analyzed as described.

Results
ClpXP degrades aggregates in vitro
To determine if ClpX can remodel protein substrates from the aggregated
state, we used the fusion protein, Gfp-ssrA, which forms aggregates upon heat
treatment (Zietkiewicz et al., 2004;Zietkiewicz et al., 2006). Gfp-ssrA is rapidly
degraded by ClpXP and has been extensively studied to understand substrate
targeting by ClpXP. The Gfp moiety is widely used in protein disaggregation assays
because it forms non-fluorescent aggregates when heated, but is disaggregated and
reactivated by several chaperone systems (Zietkiewicz et al., 2004;Zietkiewicz et al.,
2006). Therefore, we heated Gfp-ssrA at 85 °C for 15 minutes to induce aggregation
(aggGfp-ssrA), resulting in an 86% loss of fluorescence emitted (Figure 1A). Next, to
measure the distribution of aggregates by size after heating, we performed dynamic
light scattering (DLS) of untreated and heat-denatured Gfp-ssrA. We observed that
without heating, the particle sizes are uniform with an average hydrodynamic
diameter of 8-10 nm (Figure 1B). After heating, aggregates are approximately 500600 nm, and there is a narrow distribution of particle sizes and no small particles (i.e.,
less than 100 nm) (Figure 1C). Upon heat-treatment, aggregation of Gfp-ssrA (1.5
μM) occurs rapidly and plateaus by 10 minutes by 90°-angle light scattering (Figure
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1D). The heat inactivation is irreversible since incubation of aggregated Gfp-ssrA
(aggGfp-ssrA) alone does not lead to appreciable fluorescence reactivation, which is
consistent with previous reports using Gfp (Figure S1) (Zietkiewicz et al., 2004). To
determine if ClpXP can bind to aggregates and degrade them, we incubated aggGfpssrA with ClpXP and monitored turbidity by 90°-angle light scattering. Incubation of
aggGfp-ssrA with ClpXP led to a 35% loss of turbidity in 2 hours (Figure 1E).
However, when ClpXP was omitted from the reaction, there was very little change in
turbidity over time (5% loss in 2 hours) (Figure 1E). This suggests that ClpXP targets
aggregated substrates for degradation. To determine if degradation is required to
reduce turbidity, we omitted ClpP and observed that ClpX is capable of reducing
sample turbidity by 15% in 2 hours (Figure 1E). Finally, when ATP was omitted from
the reaction containing ClpXP, we observed a less than 10% reduction in the turbidity
of the reaction (Figure 1E). To confirm that ClpXP degrades aggGfp-ssrA, we
incubated aggGfp-ssrA with combinations of ClpX, ClpP and ATP, and sampled
degradation reactions after 2 hours. We observed that in the presence of ClpXP,
aggGfp-ssrA is degraded, but not when ClpP or ATP was omitted (Figure 1F).
Together, these results demonstrate that ClpXP targets aggregates for ATPdependent degradation and that ClpX is also capable of promoting disassembly in the
absence of ClpP.
FtsZ is a well-characterized ClpXP substrate that is essential for cell division
and forms linear polymers in vitro in the presence of GTP (Erickson et al., 2010). We
previously showed that ClpXP binds to GTP-stimulated FtsZ polymers and promotes
FtsZ degradation (Camberg et al., 2009). ClpXP also recognizes and degrades nonpolymerized FtsZ, but less efficiently than polymerized FtsZ (Camberg et al., 2009). In
vitro, FtsZ rapidly aggregates when heated at 65 °C and this aggregation is
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associated with an increase in overall light scatter and a 97% loss of GTPase activity
(Figure 2A and 2B). FtsZ, which purifies as a mixture of monomers (40.4 kDa) and
dimers (80.8 kDa), has an average hydrodynamic diameter of 10-15 nm by DLS
(Figure 2C). Heat treatment of FtsZ (5 μM) at 65 °C produces several particle sizes,
including small (30-40 nm) and large aggregates (>300 nm) (Figure 2D). To
determine if ClpXP reduces the turbidity associated with aggregated FtsZ (aggFtsZ),
we incubated aggFtsZ with ClpXP and ATP and observed a 40% loss of turbidity after
incubation with ClpXP for 2 hours (Figure 2E). However, in the absence of ClpXP, the
light scatter signal remained stable for aggFtsZ (Figure 2E). Incubation of ClpX with
aggFtsZ also resulted in a 25% loss in light scatter, suggesting that ClpX also
promotes disassembly of aggregates similar to what we observed for aggGfp-ssrA
(Figure 2E and 1E).
Next, to confirm that aggFtsZ is degraded by ClpXP, we assembled reactions
containing combinations of aggFtsZ, ClpX, ClpP and ATP and sampled these
reactions at 0 and 120 minutes for analysis by SDS-PAGE. We observed that in the
presence of ClpXP and ATP, 50% of the total aggFtsZ in the reaction is lost to
degradation after 120 minutes (Figure 2F). Omission of either ClpP or ATP from the
reaction prevents loss of aggFtsZ (Figure 2F). These results indicate that ClpXP
degrades aggFtsZ. Furthermore, the amount of aggFtsZ after incubation with ClpX is
unchanged despite the decrease in light scatter detected, suggesting that ClpX can
disaggregate aggFtsZ (Figure 2E and 2F).
In addition to forming aggregates upon heating, FtsZ also assembles into a
linear head-to-tail polymer, which is a native, ordered aggregate, and distinct from the
disordered aggregates which are induced by heating (aggFtsZ). We compared the
loss of aggFtsZ by ClpXP to a similar reaction monitoring loss of native polymerized
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FtsZ, which is a known substrate of ClpXP. Like aggFtsZ, we also observed a ~50%
loss of polymeric FtsZ, stabilized by the GTP analog GMPCPP, after 120 minutes in
reactions containing ClpXP and ATP (Figure 2F). GMPCPP promotes the assembly of
stable polymers that are far less dynamic than polymers assembled with GTP (Lu et
al., 2000). To test if ClpXP disassembles GMPCPP-stabilized FtsZ polymers, we
incubated pre-assembled polymers with ClpXP and ATP. Then, we collected
polymers by high-speed centrifugation. In these assays, we used active fluorescent
FtsZ, labeled with Alexa fluor 488 (FL-FtsZ), to quantify the amount of polymerized
FtsZ in the pellet fraction and soluble FtsZ in the supernatant. We observed that after
incubation of GMPCPP-stabilized FtsZ polymers with increasing concentrations of
ClpXP (0 μM to 1 μM), few FtsZ polymers were recovered in the pellet fractions
containing ClpXP (26% of the total FtsZ was recovered in the reaction containing 1
μM ClpXP), indicating that ClpXP is highly effective at promoting the disassembly of
GMPCPP-stabilized FtsZ polymers (Figure 2G).

ClpX reactivates heat-aggregated Gfp-ssrA
Incubation of ClpX with aggGfp-ssrA resulted in loss of turbidity, suggesting
that ClpX may function independently of ClpP to reactivate substrates (Figure 1E).
Reactivation of misfolded proteins may occur through binding and stabilization of
intermediates enabling proteins to adopt the native folded conformation, or through
ATP-dependent chaperone-assisted unfolding. To determine if ClpX, which
recognizes the ssrA amino acid sequence, is able to reactivate aggGfp-ssrA, we
monitored fluorescence of aggGfp-ssrA in the presence and absence of ClpX and
ATP. AggGfp-ssrA regains very little fluorescence alone, approximately 20 units,
which is 8% of the initial fluorescence lost upon heating; however, in the presence of
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ClpX, fluorescence recovers rapidly in the first 10 minutes of the reaction and then
plateaus, regaining approximately 85 units, which is 27% of the initial fluorescence
lost upon heating (Figure 3A).
ClpX catalyzes ATP-dependent unfolding of substrates (Kim et al., 2000;Singh
et al., 2000). To determine if ATP is essential for reactivation, we incubated aggGfpssrA with ClpX under various nucleotide conditions including with ATP, the ATP
analog ATPɣS, ADP and omission of nucleotide. We observed an 82% slower rate of
fluorescence reactivation when ClpX and aggGfp-ssrA were incubated with ATPɣS
than with ATP (0.02 AU min-1 and 0.11 AU min-1, respectively), and no recovery over
background with ADP or without nucleotide (Figure 3B). Reactivation by ClpX and
ATP is prevented in the presence of ClpP, and the residual fluorescence after heat
treatment is lost upon degradation (Figure S2). Together, these results indicate that
ClpX requires ATP to reactivate Gfp-ssrA and, surprisingly, that ATPɣS is also
capable of promoting reactivation, although at a much slower rate than ATP (Figure
3B).

Reactivation and disaggregation by ClpX requires a specific recognition
sequence
Next, we determined if a ClpX recognition motif is important for efficient
recognition of aggregated substrates by ClpX. We compared reactivation of aggGfpssrA with heat-aggregated Gfp (aggGfp) without an ssrA tag. We observed that after
incubation with ClpX and ATP for 60 minutes, approximately 30 units of fluorescence
were recovered, which is 8% of the initial pre-heat fluorescence, indicating that
aggGfp is a poor substrate for reactivation by ClpX (Figure 4A). In contrast, aggGfp-
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ssrA recovered 33% (>100 units) of the initial pre-heat fluorescence after incubation
with ClpX (Figure 4A).
Two regions of FtsZ are important for promoting degradation of E. coli FtsZ by
ClpXP, one in the unstructured linker region (amino acids 352-358) and one near the
C-terminus (residues 379 through 383) (Camberg et al., 2014). Using a truncated
FtsZ mutant protein, FtsZ(ΔC67), which is deleted for 67 C-terminal amino acid
residues, including both regions involved in ClpX recognition, we tested if ClpXP
reduces the light scatter in reactions containing heat-aggregated FtsZ(ΔC67)
[aggFtsZ(ΔC67)]. We heated FtsZ(ΔC67) at 65 °C for 15 minutes, the condition that
promotes aggregation of full length FtsZ, and confirmed that heat treatment resulted
in an 84% loss of GTP hydrolysis activity and an increase in light scatter, which is
stable over time (Figure 4B and 4C). In the presence of ClpXP, we observed no
decrease in light scatter for aggFtsZ(ΔC67) after incubation for 120 minutes (Figure
4C), which is expected since FtsZ(ΔC67) is a poor substrate for ClpXP degradation
(Figure S3). Together, these results demonstrate that for ClpX to recognize
aggregates and promote disaggregation, disassembly and/or reactivation, a ClpX
recognition motif is required.

Impaired reactivation by ClpX(E185Q)
ATP is required for reactivation of aggGfp-ssrA, however, it is unknown if this
event requires ATP-hydrolysis and substrate unfolding. Therefore, we used the ClpX
mutant protein ClpX(E185Q), which has a mutation in the Walker B motif and is
defective for ATP-hydrolysis, but interacts with substrates (Hersch et al.,
2005;Camberg et al., 2014). We observed that ClpX(E185Q) is defective for
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disaggregation of aggGfp-ssrA by monitoring turbidity by 90°-angle light scatter of
reactions containing aggGfp-ssrA, ClpX(E185Q) and ATP (Figure 5A). We also tested
if aggFtsZ is disassembled by ClpX(E185Q), and observed no reduction in light
scatter in reactions containing aggFtsZ, ClpX(E185Q) and ATP after 120 minutes
compared to ClpX (Figure 5B). Finally, we tested if reactivation of aggGfp-ssrA
requires ATP hydrolysis using ClpX(E185Q) instead of ClpX. We observed that
ClpX(E185Q) promotes a small amount of reactivation of aggGfp-ssrA and restores
fluorescence, but to a much lesser extent than the level observed for wild type ClpX
(Figure 5C). These results suggest that ATP hydrolysis by ClpX is required to
promote efficient reactivation of aggGfp-ssrA and disassembly of large complexes
containing aggFtsZ or aggGfp-ssrA (Figure 5A, 5B and 5C).

ClpXP prevents accumulation of FtsZ aggregates in vivo under extreme thermal
stress
ClpX and ClpP were previously reported to localize to protein aggregates in E.
coli, suggesting that ClpXP may target aggregates in vivo for direct degradation
(Winkler et al., 2010). We used the native ClpXP substrate FtsZ, which aggregates
upon heat treatment, to determine if ClpX and/or ClpXP modulates FtsZ aggregate
accumulation after thermal stress by comparing the levels of FtsZ present in insoluble
cell fractions (Figure 2A and 6A). Wild type cells and cells deleted for clpX, clpP, clpB,
clpA, dnaK, lon, hslU and hslV were exposed to heat shock and insoluble protein
fractions were collected and analyzed by immunoblot. We observed that FtsZ was
present in the insoluble fraction of wild type cells (BW25113), and this amount was
42% higher in cells exposed to heat shock at 50 °C (Figure 6A and S4A). However,
FtsZ levels were even higher in the insoluble fractions of ΔclpX and ΔclpP strains
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compared to the parental strain (2.4-fold and 2.3-fold, respectively), although the
amount of total protein was similar to the wild type strain exposed to heat shock
(Figure S4B). We detected less protein overall in the ΔdnaK strain after recovery, but
this strain also had poor viability after heat shock and recovery (Figure S4C). In
addition, we also detected ClpX in the insoluble fraction in all strains except the clpX
deletion strain (Figure S4A). Next, we conducted a mild heat shock, 42 °C for 30
minutes, followed by recovery, and observed that deletion of clpB had a larger effect
on the accumulation of insoluble FtsZ than deletion of clpX (Figure S4D).

To

determine the relative contributions of either clpB or clpX during a 40 minute recovery
period after incubation at 50 °C, we analyzed insoluble FtsZ levels at 20 minute time
intervals during recovery (Fig. 6B). Notably, we observed that in cells deleted for clpX,
insoluble FtsZ was present immediately after heat treatment and continued to
accumulate throughout the recovery period to a greater extent than in wild type or
clpB deletion cells. These results suggest that ClpXP prevents accumulation of FtsZ
aggregates in cells exposed to extreme thermal stress. Since we observed that
insoluble FtsZ levels were elevated in ΔclpB strains exposed to mild heat shock
(Figure S4D), we repeated the recovery time course in clpX and clpB deletion strains
after mild heat shock, 42 °C for 30 minutes, to monitor insoluble FtsZ levels (Figure
S4E). We observed that insoluble FtsZ accumulates during the recovery period in
clpB deletion strains after mild heat shock (Figure S4E).
Finally, if ClpXP is active in cells after severe heat shock, then it should not be
a thermolabile protein. To determine if ClpXP remains active after exposure to 50 °C
in vitro, we incubated ClpXP in buffer at 50 °C for one hour, and then measured
activity after addition of Gfp-ssrA by monitoring the loss of Gfp-ssrA fluorescence. We
observed that ClpXP remained active for unfolding and degradation of Gfp-ssrA after
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incubation at 50 °C for one hour (Figure S4F). As a control, ClpXP was also incubated
in buffer at 30 °C for one hour and then assayed for activity. We observed that ClpXP
incubated at 30 °C was more active than ClpXP incubated at 50 °C, suggesting that a
partial loss of activity had occurred at high temperature (Figure S4F). However, this
assay was performed in the complete absence of other cellular chaperones or
substrates and suggests that some ClpXP likely continues to retain activity after
exposure to heat stress, while some may become inactivated.

Discussion
Here, using both a native and an engineered aggregated substrate, we
demonstrate that ClpXP has the operational capacity to disassemble and degrade
large aggregates that have ClpX degrons. In this study, FtsZ, a native substrate of
ClpXP in E. coli, was aggregated in vitro by thermal stress, and we further show that
FtsZ also aggregates in vivo when cells are exposed to high temperature (Figure 2A
and 6A). The observation that FtsZ is aggregation prone is in agreement with a prior
study reporting the presence of FtsZ in intracellular aggregates of ΔrpoH cells
incubated at 42 °C by mass spectrometry (Tomoyasu et al., 2001). FtsZ aggregates
are cleared in vitro and in vivo by ClpXP, and ClpXP does not require the assistance
of additional chaperones (Figure 2E, 2F and 6A). Moreover, in the absence of ClpP,
ClpX also promotes disassembly of FtsZ and Gfp-ssrA aggregates indicating that
disassembly can also occur by a proteolysis-independent mechanism, although
disaggregation is more efficient in the presence of ClpP. ClpXP-mediated
disassembly of Gfp-ssrA aggregates requires ATP in experiments monitoring turbidity
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(Figure 1E). In addition, the Walker B mutation in ClpX, E185Q, which impairs ATP
hydrolysis, also impairs disaggregation of aggGfp-ssrA and, to a lesser extent,
aggFtsZ. Aggregate disassembly and resolubilization by ClpX was previously
described using the substrate lambda O protein, and here we show disassembly of
aggregates and kinetic monitoring using two additional substrates, as well as
reactivation of Gfp-ssrA fluorescence (Wawrzynow et al., 1995). Reactivation of GfpssrA is largely dependent on ATP hydrolysis (Figure 3B), since ClpX(E185Q) only
weakly promotes reactivation of aggregated Gfp-ssrA (Figure 5C), yet ClpX(E185Q) is
capable of stable interactions with substrates in the presence of ATP, although they
are not unfolded (Hersch et al., 2005;Camberg et al., 2014). It is unlikely that there
are soluble, unfolded Gfp-ssrA monomers in solution after heating, since we did not
detect them by DLS and it has been demonstrated that soluble, unfolded Gfp rapidly
refolds, in 20 to 30 seconds, by a spontaneous reaction that does not require
chaperones (Figure 1C) (Makino et al., 1997;Tsien, 1998;Zietkiewicz et al., 2004).
Therefore, it is likely that large aggregates contain loosely associated unfolded
proteins, which can be removed and reactivated by ClpX and, in the case of Gfp-ssrA,
allowed to spontaneously refold. As expected, recognition by ClpX is highly specific,
as Gfp without an ssrA-tag is not reactivated (Figure 4A).
We also detected partial disaggregation of aggFtsZ by ClpX, but not by
ClpX(E185Q) (Figure 5B). Aggregation of FtsZ is induced at 65 °C, but the
aggregates formed by FtsZ are smaller than those formed by Gfp-ssrA (30 nm and
600 nm, respectively) (Figure 1C and 2D). FtsZ aggregates likely contain 8-10
monomers, based on the average size of a folded FtsZ monomer, which is
approximately 40 Å in diameter (Figure 2D) (Oliva et al., 2004). In contrast, Gfp
aggregates in this study likely contain more than 120 subunits, based on an average
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size of a folded Gfp monomer, which is approximately 50 Å across the long axis (van
Thor et al., 2005). The small size of the FtsZ aggregate may allow it to be more
susceptible to disassembly by ClpX than a larger aggregate.
In the model for disassembly of aggregates by ClpXP, ClpX binds to exposed
recognition tags on the surface of the aggregate and promotes removal, unfolding and
degradation of protomers from within the aggregate (Figure 7A). Removal of
protomers eventually leads to destabilization and fragmentation of the aggregate as
well as degradation (Figure 1F and 2F). Although this process does not require ClpP,
it occurs more robustly when ClpP is present than when ClpP is omitted (Figure 1E
and 2E).

For aggregated substrate reactivation, ClpX likely engages unfolded

protomers from the aggregate, which may be internal or loosely bound to the exterior
of the aggregate, unfolds and release them. For small aggregates, this activity may be
sufficient to lead to fragmentation and capable of promoting reactivation of substrates
such as Gfp-ssrA (Figure 7B).
Finally, we observed large increases in insoluble FtsZ when cells were
exposed to two different temperatures, 50 °C, which represents extreme heat shock,
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and 42 °C, which represents a mild heat shock (Figure 6A, 6B and S4D). At 42 °C,
deletion of clpB was associated with a large accumulation of insoluble FtsZ,
suggesting that under mild heat stress, ClpB is the major factor that ensures FtsZ
solubility (Figure S4D and S4E). However, we observed a remarkably different result
after heat shock at 50 °C and throughout the recovery period. Specifically, in a clpX
deletion strain, large amounts of insoluble FtsZ accumulate during the recovery period
to a greater extent than in a clpB deletion strain (Figure 6A and 6B). It is unknown if
ClpXP and ClpB are processing FtsZ aggregates directly in vivo, because we did not
observe a reduction of aggregated FtsZ during the recovery period for any strain. FtsZ
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is typically present at very high levels (5,000 to 20,000 copies per cell) and is
essential for cell division in E. coli (Bramhill, 1997). Interestingly, FtsZ also forms
linear polymers as part of its normal biological function to promote cell division, and
polymers are efficiently recognized, disassembled and degraded by ClpXP (Figure 2F
and 2G) (Camberg et al., 2009;Camberg et al., 2014;Viola et al., 2017). Given the
diverse conformational plasticity of FtsZ, its use as a model disaggregation and
remodeling substrate will be informative for studies of targeting and processing of
multisubunit substrates by AAA+ proteins. As with FtsZ, many other ClpXP substrates
are detectable in protein aggregates in cells (Flynn et al., 2003;Maisonneuve et al.,
2008). Moreover, a previous study showed that ClpXP is important for cell viability
under thermal stress conditions in cells depleted of DnaK (Tomoyasu et al., 2001).
Given that it is estimated that 2-3% of E. coli proteins are ClpXP substrates, ClpXP
likely serves as an additional mechanism to manage accumulation of aggregationprone proteins in vivo, particularly under extreme stress conditions (Flynn et al.,
2003;Maisonneuve et al., 2008).
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Strain or

Genotype

Plasmid

Source, reference,
or construction

Strains
BW25113

JW0429

F-, DE(araD-araB)567, lacZ4787(del)(::rrnB-3), LAM-,

Datsenko and

rph-1, DE(rhaD-rhaB)568, hsdR514

Wanner, 2000

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), Δlon-

Baba et al., 2006

725::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514
JW0428

F-, Δ(araD-araB)56, ΔlacZ4787(::rrnB-3),

Baba et al., 2006

ΔclpX724::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514
JW0427

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3),

Baba et al., 2006

ΔclpP723::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514
JW2573

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3),

Baba et al., 2006

ΔclpB757::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514
JW0866

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3),

Baba et al., 2006

ΔclpA783::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514
JW3902

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3),

Baba et al., 2006

ΔhslU790::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514
JW3903

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3),

Baba et al., 2006

ΔhslV720::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514
JW0013

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3),

Baba et al., 2006

ΔdnaK734::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514
JW0462

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-

Baba et al., 2006

3),ΔhtpG757::kan, λ-, rph-1, Δ(rhaD-rhaB)568,
hsdR514
JC0259

MG1655 ΔclpX::kan

Camberg et al.,
2011
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Plasmids
pET-ClpX

kan

Camberg et al. 2009

pET-ClpP

kan

Maurizi et al. 1994

pET-FtsZ

kan

Camberg et al. 2009

pET-

kan

This study

kan

This study

amp

Singh et al., 2000

amp

Camberg et al.,

FtsZ(ΔC67)
pET-H6Gfp(uv)
pBad-GfpssrA
pClpX(E185Q)

2011

Figure 1. Disaggregation and degradation of aggregated Gfp-ssrA by ClpXP.
(A) The fluorescence emission spectra (450-600 nm) of Gfp-ssrA (1.0 μM) (green)
123
and heat-treated Gfp-ssrA (1.0 μM) (black) (85 °C for 15 minutes) were measured
using an excitation wavelength of 395 nm. Plotted curves are representative of three
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Figure 2. Aggregation and disaggregation of native ClpXP substrate FtsZ.
(A) Aggregation by 90°–angle light scatter was measured for FtsZ (5 µM) (black circles)
in a cuvette attached to a circulating water bath at 65 °C for 30 minutes as described in
Materials and Methods. The curve shown is representative of at least three replicates.
(B) Rates of GTP hydrolysis were measured for FtsZ (5 µM) (gray) and aggFtsZ (5 µM)
(black) with GTP (1 mM) for 15 minutes at 30 °C, as described in Materials and Methods.
The average rate was determined from at least four replicates. (C) DLS was performed
for FtsZ (5 µM) (gray) as described to determine particle size (nm) distribution. (D) DLS
was performed for aggFtsZ (5 µM) (black) as described to determine particle size (nm)
distribution. (E) Disaggregation of aggFtsZ (5 µM) was monitored by 90°-angle light
scatter as described in Materials and Methods. Disaggregation reactions contained
aggFtsZ (5 µM) (black circles) or aggFtsZ (5 µM) and ClpX (1 µM) (blue circles), or
aggFtsZ (5 µM), ClpX (1 µM), and ClpP (1 µM) (red circles), with ATP (4 mM) and a
regenerating system. Light scattering was monitored for 120 minutes. The curves shown
are representative of at least three replicates. (F) Degradation was monitored for FtsZ
and aggFtsZ as described in Materials and Methods in reactions containing FtsZ (6 µM),
aggFtsZ (6 µM), ClpX (0.5 µM), ClpP (0.5 µM), ATP (4 mM) and a regenerating system,
where indicated. For degradation of FtsZ, GMPCPP (0.5 mM) was included to promote
the assembly of stable polymers. Degradation reactions were incubated at 23 °C for 120
minutes. To detect protein loss due to degradation, samples from 0 and 120 minutes
were analyzed by SDS-PAGE to solubilize any remaining aggregates.
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Figure 3. Reactivation of aggregated Gfp-ssrA in the presence of ClpX.
(A) Reactivation of aggGfp-ssrA (1.0 μM) was monitored as described in
Materials and Methods in the absence (black circles) and presence (blue circles)
of ClpX (0.3 μM), ATP (4 mM), and a regenerating system. Fluorescence
emission (AU) was monitored for 30 minutes. The curves shown are
representative of at least three replicates.
(B) Reactivation of aggGfp-ssrA (1.0 μM) was monitored in the absence (black
circles) or presence of ClpX (0.3 μM), ATP (4 mM) and a regenerating system
(blue circles), ATPγS (2 mM) (orange circles), ADP (2 mM) (green circles), or no
nucleotide (gray circles), where indicated. Fluorescence emission (AU) was
monitored for 60 minutes. The curves shown are representative of at least three
replicates.

128

Figure 4. Aggregation and disaggregation of ClpXP substrates with and
without recognition motifs.
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(A) Reactivation of aggGfp-ssrA (1.0 μM) alone (dark gray circles) or in the
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aggFtsZ(ΔC67)
aggFtsZ(ΔC67) + ClpXP

aggFtsZ + ClpXP
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Figure 5. Disaggregation and reactivation of ClpX substrates in the
presence of ClpX(E185Q).
(A) Disaggregation was monitored by 90°-angle light scatter, as described in
Materials and Methods for aggGfp-ssrA (1.0 µM) alone (black circles) or in
the presence of ClpX (0.5 μM) (blue circles) or ClpX (E185Q) (0.5 μM) (open
circles), where indicated, with ATP (4 mM), and a regenerating system. Light
scattering was monitored for 120 minutes. The curves shown are
representative of at least three replicates.
(B) Disaggregation was monitored by 90°-angle light scatter for aggFtsZ (5
µM), ClpX (0.5 µM) or ClpX(E185Q) (0.5 µM) where indicated, ATP (4 mM),
and a regenerating system for 120 minutes as described in Materials and
Methods. The curves shown are representative of at least three replicates.
(C) Reactivation was monitored as described in Materials and Methods for
aggGfp-ssrA (1.0 μM) alone (black circles) or in the presence of ClpX (0.3
μM) (blue circles) or ClpX (E185Q) (0.3 μM) (open circles), with ATP (4 mM)
and a regenerating system, where indicated. Fluorescence emission (AU)
was monitored for 90 minutes. The curves shown are representative of at
least three replicates.
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Figure 6. FtsZ aggregation in deletion strains after heat shock.
(A) FtsZ levels were compared in insoluble cell extracts prepared from single
gene deletion strains (Table 1) after heat shock at 50°C for 1 hour and
recovery (30°C) as described in Materials and Methods. Cells were collected
and insoluble protein extracts were analyzed by immunoblotting using antiFtsZ antibodies. Relative FtsZ levels were quantified by densitometry from
four independent experiments. Where indicated, ‘*’ represents a p-value of
0.03.
(B) Insoluble FtsZ levels were monitored during the 30°C recovery period (0,
20 and 40 minutes) after heat shock at 50°C for 60 minutes in wild type, ΔclpB
and ΔclpX deletion strains.
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Figure 7. Model of aggregate disassembly.
(A) ClpXP binds to aggregated substrates bearing a ClpX-recognition motif.
ClpXP unfolds and degrades protomers from within the aggregate, leading
to fragmentation and disassembly in an ATP-dependent manner.
(B) ClpX binds to aggregates that contain unfolded proteins bearing a ClpXrecognition motif. Unfolded proteins loosely associated with the aggregate
surface are reactivated by ClpX through a direct protein interaction that
requires ATP-dependent unfolding.
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Supplemental Figure S1. Heat-aggregation of Gfp-ssrA.
The fluorescence emission of aggGfp-ssrA (1.0 μM) (black
circles) was monitored as described in Materials and Methods
for 90 minutes.
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Supplemental Figure S2. Unfolding and degradation of aggregated
Gfp-ssrA by ClpXP. Unfolding and degradation were monitored for
aggGfp-ssrA (1.0 μM) alone (black circles) or in the presence of ClpP (0.3
μM) (gold circles), ClpX (0.3 μM) and ClpP (0. μM) (red circles) with ATP (4
mM), where indicated. Fluorescence emission (AU) was monitored as
described in Materials and Methods.
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Supplemental Figure S3. Degradation of FtsZ and FtsZ(∆C67)
by ClpXP. Degradation was monitored for FtsZ (6 µM) and
FtsZ(∆C67), ClpXP (0.5 µM), ATP (4 mM), GMPCPP (0.5 mM),
and a regenerating system where indicated at 23°C for 120
minutes as described in Materials and Methods, and samples were
analyzed by SDS-PAGE and Coomassie stain.
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Supplemental Figure S4. Insoluble FtsZ in deletion strains after heattreatment.
(A) Single gene deletion strains (Table 1) were incubated at 50 °C for 1 hour and
recovered as described in Materials and Methods. Cells from deletion strains were
collected and insoluble protein extracts were collected as described and analyzed by
reducing SDS-PAGE. Immunoblots were performed with antibodies to FtsZ or ClpX as
described.
(B) Total protein present in insoluble cell extracts shown in (A) after heat shock at 50 °C
and recovery was detected by transferring proteins to a nitrocellulose membrane and
staining with Ponceau.
(C) Cell viability for all strains in (A) was determined by measuring colony forming units
-1

(CFU ml ) of cultures before heating (‘pre-HS’), after heat treatment at 50 °C for 1 hour
(‘post-HS’), and after 35 minutes of recovery at 30 °C (‘post-rec’).
(D) FtsZ levels were compared in single gene deletion strains after heat shock at 42 °C
for 30 minutes and recovery (30 °C) as described in Materials and Methods. Cells were
collected and insoluble protein extracts were analyzed by immunoblotting with
antibodies to FtsZ as described.
(E) Insoluble FtsZ levels were monitored in wild type, ΔclpX and ΔclpB deletion strains
before heat shock (50 °C for one hour or 42 °C for 30 minutes, where indicated) and
during the 30 °C recovery period (0, 20 and 40 minutes). At the indicated times, cells
were collected from cultures and insoluble protein extracts were analyzed by
immunoblotting with antibodies to FtsZ as described.
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Supplemental Figure S4. Insoluble FtsZ in deletion strains after heattreatment.
(F) Thermal stability of ClpXP was assayed by incubation of ClpX (0.5 μM) and
ClpP (0.7 μM) in phosphate buffered saline supplemented with ATP (4 mM)
MgCl2 (10 mM), glycerol (15%), Triton X-100 (0.005%), and TCEP (1 mM).
Reactions containing ClpXP were added to a preheated quartz cuvette attached to
a circulating water bath set to 50 °C or 30 °C, where indicated, and incubated for
one hour. The circulating water bath was rapidly cooled to 30 °C, the reactions
were supplemented with ATP and regenerating system, Gfp-ssrA (0.2 μM) was
added, and fluorescence was monitored with time in the absence (black) or
presence of ClpXP, treated at 50 °C (red) or 30 °C (aqua).
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Abstract
Alzheimer’s

disease

is

characterized

by

the

hyperphosphorylation,

mislocalization, and aggregation of tau into neurofibrillary tangles (Noble et al., 2013).
Tau is an intrinsically disordered protein that lacks secondary structure, which
provides the protein with flexibility (Mandelkow et al., 2012). In Alzheimer’s disease,
tau changes conformation and becomes filamentous, forming ordered aggregates and
is abnormally hyperphosphorylated. The extent of neurofibrillary tangle accumulation
within the brain tissue of patients with Alzheimer’s disease highly correlates to
disease severity and progression (Braak and Braak, 1991). It is thought that tau
hyperphosphorylation

causes

deficits

in

neuronal

functioning

by

whereby

pathologically phosphorylated tau protein triggers the conformational change of tau
into fibrils and highly ordered, fibrillar aggregates (Alonso et al., 2001). Here, we
model tau hyperphosphorylation in vitro by treating human neuroblastoma SH-SY5Y
cells with the protein phosphatase 2 (PP2A) inhibitor okadaic acid (Zhang and
Simpkins, 2010). We find that chaperone protein levels change in response to
different exposures of okadaic acid, indicating that chaperone proteins may be
involved in Alzheimer’s disease pathogenesis.
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Introduction
Alzheimer’s disease is characterized by the accumulation of filamentous
amyloid-beta and tau protein into extracellular amyloid-beta plaques and intracellular
neurofibrillary tangles (Crews and Masliah, 2010). The pathology of Alzheimer’s
disease is thought to arise from alternative processing of the amyloid precursor
protein by beta-secretase and gamma-secretase, which results in the formation and
accumulation of amyloid-beta (Aβ) peptides that are 40 residues (Aβ40) and 42
residues (Aβ42). The accumulation of Aβ42 peptide triggers amyloid fibril formation
and deposition of amyloid plaques, which are thought to be cytotoxic and responsible
for the neurodegeneration observed in Alzheimer’s disease (Kametani and
Hasegawa, 2018). However, studies have reported that amyloid plaques in transgenic
mouse brain tissue are not closely correlated with neurodegeneration or changes in
cognitive functioning (Kim et al., 2007; Kim et al., 2013). Moreover, brain imaging
studies have shown that amyloid plaques are distributed in brains of cognitively
normal aged patients and are not specific to patients with Alzheimer’s disease
(Edison et al., 2007; Li et al., 2008; Davis et al., 1999; Fagan et al., 2009; Price et al.,
2009; Chetelat et al., 2013). Thus, it is possible that amyloid plaques are not a
defining pathological hallmark of Alzheimer’s disease, but instead accumulate as a
result of aging.
Deficits in amyloid precursor protein metabolic activity are thought to
contribute to the formation of a pathological environment that triggers tau pathology
(Tanzi and Bertram, 2005). Research from a double transgenic mouse model of
Alzheimer’s disease that expressed both mutant amyloid precursors protein and wildtype human tau showed that amyloid-beta oligomers accelerate the formation of
neurofibrillary tangles and neurodegeneration (Hurtado et al., 2010). Neurofibrillary
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tangles are intracellular deposits of paired helical filaments that accumulate in regions
of the brain associated with cognitive functioning (Binder et al., 2005) and are
associated with cognitive impairments (Santacruz et al., 2005; Di et al., 2016). Both
neurofibrillary tangles and amyloid-beta plaques are filamentous aggregates that have
a cross-beta structure, similar to the human prion protein structure (Iqbal et al., 2005).
The main constituent of the paired helical filaments is abnormally phosphorylated tau
protein, referred to as hyperphosphorylated tau (Grundke-Iqbal et al., 1986; Kosik et
al., 1986; Ihara et al., 1986).
Microtubule-associated tau protein is transcribed from the MAPT gene on
chromosome 17 and alternative splicing of exon2, exon3, and exon10 results in six
different tau isoforms in the adult human brain (Goedert et al., 2010). The six isoforms
of tau range from 37 to 46 kDa and differ based on the number of N-terminal inserts
and C-terminal microtubule-binding regions (Guo et al., 2017). In the MAPT gene,
exons 2 and 3 encode for 29 amino acid residue regions that are located in the Nterminal domain of tau protein. Exons 9 – 12 encode for the microtubule-binding
repeats in the C-terminal domain of tau (Guo et al., 2017). The longest tau isoform
contains 2 N-terminal domain inserts and 4 microtubule-binding repeats (Mandelkow
et al., 2012). The domain architecture of tau is divided into an acidic N-terminal
projection domain (residues 1 – 150), a proline-rich domain (residues 151 – 243), a
microtubule-binding domain, and the C-terminal domain (Mandelkow et al., 2012).
Microtubule-associated tau protein functions to stabilize microtubules and
support long-distance, microtubule-mediated axonal transport Drubin and Kirschner,
1986; Johnson and Stoothoff, 2004). In a Drosophila melanogaster model of
Alzheimer’s disease, overexpression of amyloid precursor protein caused axonal
transport defects and deficits in short-term synaptic plasticity (Rusu et al., 2007).
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Impaired axonal transport may therefore cause cognitive dysfunction in Alzheimer’s
disease. Furthermore, the phosphorylated tau has greater binding affinity for the light
chain of kinesin-1, a motor protein involved in axonal transport, whereas
dephosphorylated tau shows decreased binding to kinesin-1 in rat cortical neurons
(Cuchillo-Ibanez et al., 2008). Although soluble tau protein is primarily localized to the
axons

of

healthy

neurons,

early

in

Alzheimer’s

disease

pathology

hyperphosphorylated tau dissociates from microtubules and mislocalizes to the
somatodendritic compartment (Morris et al., 2011; Braak et al., 2011). Without
biologically functional, soluble tau protein, neuronal processes become disrupted.
Microtubules become destabilized, axonal transport decreases, and synapses retract
(Dubey et al., 2015).
In Alzheimer’s disease, tau hyperphosphorylation is thought to result in a toxic
gain of function and loss of normal tau function. Tau protein contains more than 45
possible sites for phosphorylation (Hanger et al., 2007). Normally, tau contains 2 – 3
mol phosphate/mol of protein; phosphorylation levels greater than this impair the
ability of tau to bind microtubules and regulate microtubule assembly (Kӧpke et al.,
1993; Lindwall et al., 1984; Alonso et al., 1994). Furthermore, hyperphosphorylation
of tau is thought to promote misfolding and aggregation of tau protein into paired
helical filaments (Alonso et al., 1996). During Alzheimer’s disease pathogenesis, tau
hyperphosphorylation at various sites occurs before the aggregation of tau fibrils into
intracellular neurofibrillary tangles (Figure 1A). Thus, aberrant phosphorylation of tau
may cause the aggregation (Kӧpke et al., 1993). Previous research has shown that
treating transgenic mice with kinase inhibitors changes the phosphorylation state of
tau, decreases the number of tau-positive aggregates, reduces neurodegeneration,
and improves motor function (Noble et al., 2005; LeCorre et al., 2006; Sundaram et
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al., 2013). Evidence that hyperphosphorylation of tau at Thr212 induces the selfassembly of tau into fibrils and aggregates in vitro further support the hypothesis that
tau hyperphosphorylation induces self-assembly of tau (Alonso et al., 2010).
Phosphorylation of the tau phosphorylation sites Thr212, Thr231, and Ser262 results
in caspase-3 activation in 85% of transfected PC12 and CHO cells, suggesting that
these residues may be important in Alzheimer’s disease neurodegeneration (Alonso
et al., 2010). However, there is not a consensus in the field that tau
hyperphosphorylation causes tau self-assembly into aggregates. Previous research
showed that in vitro phosphorylation of tau at the KXGS motifs in the microtubule
binding repeat domain does not facilitate tau aggregation into paired helical filaments
(Schneider et al., 1999). Analysis of the expression of tau phospho-epitopes in postmortem brains of patients with different severities of Alzheimer’s disease pathology
showed differential expression of specific phospho-tau epitopes during neurofibrillary
tangle formation and deposition (Augustinack et al., 2002). Therefore, it is possible
that specific sites of tau phosphorylation drive the aggregation of tau into paired
helical filaments whereas other sites of tau phosphorylation, though important in
dissociating tau from microtubules, do not contribute to tau assembly into aggregates.
Protein quality control and Alzheimer’s Disease
Neurofibrillary tangles sequester tau protein, preventing tau protein from
associating with and stabilizing microtubules (Gendron and Pretrucelli, 2009).
Furthermore, protein degradation pathways are dysfunctional in Alzheimer’s disease.
Paired helical filaments from the brains of patients with Alzheimer’s disease and
synthetic paired helical filaments both impair the proteasome, which prevents the
clearance of pathological protein aggregates (Keck et al., 2003). Protein aggregates
are a threat to cell viability because they disrupt membranes and promote misfolding
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in the rest of the proteome (Taylor and Dillin, 2011; Gidalevitz et al., 2006). Within the
cell, the protein quality control network safeguards against protein aggregation (Balch
et al., 2008). When there is cellular stress, such as heat stress, proteins can become
structurally damaged and misfold (Powers and Balch, 2013). Heat shock proteins, or
molecular chaperone proteins, are upregulated in response to cell stress to manage
protein misfolding (Morimoto, 2008). The transcription factor HSF-1 induces heat
shock proteins in response to stress. Overexpression of HSF-1 prolongs lifespan in
the model organisms D. melanogaster and C. elegans (Taylor and Dillin, 2011).
During aging, the ability to mount a heat shock response to environmental stresses
decreases (Ben-Zvi et al., 2009). Irreversibly misfolded proteins are normally removed
from cell via two main degradation pathways: the ubiquitin-proteasome system and
autophagy (Taylor and Dillin, 2011). With age, autophagy function decreases (Terman
et al., 1995). Postmortem brains of patients with AD show extensive autophagosome
accumulation within neurites, which may be due to impairment in the clearance of
proteins by macroautophagy (Nixon et al., 2005). Thus, the cell’s ability to remove
pathological protein aggregates declines with age, which makes aged neurons more
susceptible to proteotoxic stressors. Additionally, the expression of ATP-dependent
chaperone proteins, specifically Hsp90 and Hsp70, declines with age and even more
so in Alzheimer’s disease (Brehme M et al., 2014).
The role of ATP-dependent chaperones such as Hsp70 and Hsp90 in
Alzheimer’s disease pathology is not well understood (Figure 1B). Inhibition of Hsp90
decreases the aggregation of tau into neurofibrillary tangles (Salminen et al., 2011)
and promotes the elimination of aggregated, hyperphosphorylated tau (Luo et al.,
2007). Thus, Hsp90 may be involved in a pathological pathway that promotes the
aggregation of tau into paired helical filaments. By contrast, overexpression of Hsp70
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increases the association of tau with microtubules, which is necessary for normal
axonal transport and cytoskeletal integrity (Duo et al., 2003). Both Hsp70 and Hsp90
bind to tau, suggesting a role for these chaperone proteins in modulating the folding
of tau (Miyata et al., 2011; Thompson et al., 2012).
In eukaryotes, Hsp90 is a critical regulator of protein folding, protein trafficking,
and cell signaling; Hsp90 has 400 putative substrate proteins that it regulates (Pearl
et al., 2006; Barrott and Haystead, 2013). Due to the diverse set of client proteins that
Hsp90 interacts with, the conformation and nucleotide occupancy of Hsp90 is tightly
regulated by a network of co-chaperone proteins and post-translational modifications,
including phosphorylation, methylation, and acetylation (Pearl et al., 2006). It is known
that Hsp90 binds more tightly, and thus has greater affinity for Tau P30L, a mutant of
tau that is associated with tau aggregation, compared to wild-type tau protein (Luo et
al., 2007). Furthermore, inhibiting Hsp90 in cell culture and in human tau transgenic
mice mitigates tau aggregation and pathology (Luo et al., 2007). It is thought that
Hsp90 stabilizes phosphorylated, pathological tau and prevents its degradation
(Tortosa et al., 2009; Jinwal et al., 2010; Dickey et al., 2007). Moreover, the Hsp90
co-chaperone protein ATPase homolog 1 (Aha1) has been shown to increase tau
fibrillization into aggregates in vitro and in a mouse model (Shelton et al., 2017). The
co-chaperone proteins FKBP51 and FKBP52 also form a complex with Hsp90 and
have been shown to accelerate tau aggregation (Blair et al., 2013). In contrast, the
co-chaperone protein carboxy terminus of Hsp70-interacting protein (CHIP), an E3
ubiquitin ligase, forms a complex with Hsp90 and targets client proteins to the
proteasome for clearance. Previous work has shown that CHIP in complex with
Hsp90 targets hyperphosphorylated tau protein for proteasomal degradation (Dickey
et al., 2007).
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There is strong evidence in the literature for neuroprotective effects of Hsp70
in Alzheimer’s disease pathology caused by tau and amyloid-beta aggregation.
Research shows that Hsp70 promotes the degradation of hyperphosphorylated tau
protein and has been shown to inhibit the aggregation of all six human tau isoforms
with greater affinity for tau isoforms containing three microtubule-binding repeats
(Voss et al., 2012). In vitro, the addition of Hsp70 to preformed aggregates of
oligomeric and prefibrillar tau decreases tau aggregation and rescues fast axonal
transport from tau-mediated pathology (Patterson et al., 2011). Furthermore, the
overexpression of Hsp70 in transgenic mice resulted in decreased synaptic loss,
amyloid-beta plaque load, and cognitive deficits (Hoshino et al., 2011). In vitro, the
Overexpression of Hsp70 protected against toxicity associated with amyloid-beta 42
(Magrané et al., 2004).
The proline-directed kinases glycogen synthase kinase-3 and cyclin
dependent kinases regulate tau phosphorylation at epitopes associated with
Alzheimer’s disease pathology (Drewes et al., 1992; Ledesma et al., 1992; Hanger et
al., 1992; Arioka et al., 1993). Dysregulation of phosphorylation is thought to be a
contributing factor in Alzheimer’s disease pathology. Alzheimer’s disease is
characterized by a decrease in the activity and expression of protein phosphatases
(Braithwaite et al., 2012). Specifically, the downregulation of protein phosphatase 2A
(PP2A) has been implicated in contributing to the hyperphosphorylation of tau in AD
(Braithwaite et al., 2012; Gong et al., 2005). Furthermore, protein phosphatase 2A
inhibitor 2 is mislocalized from the nucleus to the cytoplasm in the brains of patients
with Alzheimer’s disease, which may trigger the hyperphosphorylation of tau (Arif et
al., 2014).
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In vitro tau phosphorylation by okadaic acid
Okadaic acid is a lipophilic polyether toxin produced by marine dinoflagellates
of the Prorocentrum and Dinophysis genera that accumulates in filter-feeding
shellfish; consumption of mollusks containing okadaic acid causes diarrheic shellfish
poisoning in humans, which causes damage to the gastrointestinal tract and can be
fatal (Dickey et al., 1990; Cembella et al., 1990; Ito et al., 1994; Edebo et al., 1988).
Moreover, in vitro analysis of okadaic acid demonstrated that the toxin is absorbed by
human digestive cells and can be readily transported into the bloodstream (Ehlers et
al., 2011). In addition to enterotoxic effects, okadaic acid has carcinogenic properties.
Research has shown that okadaic acid potently promote tumor formation, affecting
the liver, skin, and stomach (Suganama et al., 1988; Sontag and Sontag, 2006; Fujiki
and Suganama, 2009). Okadaic acid inhibits protein phosphatases, most notably
protein phosphatase 2A (PP2A). The IC50 value of okadaic acid required to inhibit
50% of PP2A activity is 0.1 – 0.3 nM and 15 – 50 nM of okadaic acid inhibits 50% of
PP1 activity (Swingle et al., 2007). Additionally, okadaic acid inhibits protein
phosphatase 4, protein phosphatase 5, and protein phosphatase 2B as well as PP2A
under certain conditions (Louzauo et al., 2005).
Pharmacologic inhibition of PP2A by okadaic acid has been shown to induce
tau hyperphosphorylation and increase the accumulation of paired helical filaments in
several models of Alzheimer’s disease. Increased tau phosphorylation was observed
in human brain slices of the temporal lobe treated with okadaic acid (Harris et al.,
1993). In a cell culture model of Alzheimer’s disease, undifferentiated SH-SY5Y
neuroblastoma cells treated with 0, 15, and 30 nM okadaic acid for 24 hours showed
dose-dependent hyperphosphorylation and accumulation of neurofilament proteins
localized to the cell body (Wang et al., 2001). Primary hippocampal cultures isolated
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from rats at gestational day 18 develop strong SMI-3I immunoreactivity in the soma
and dystrophic neurites, indicating neurofilament phosphorylation, when treated with
10 nM okadaic acid for 36 hours (Kim et al., 1999). Treatment of human neuronal
NT2N cells differentiated with retinoic acid and subsequently treated with PP2A
inhibitors, including okadaic acid, showed increased tau phosphorylation, decreased
binding of tau to microtubules, depolymerization of Glu-microtubules, and
degeneration of axons (Merrick et al., 1997). Furthermore, cultured neurons showed
an increase in paired helical filament 1 (PHF-1) expression in response to 10 nM
okadaic acid for 6 hours, 12 hours, and 24 hours compared to cells not treated with
okadaic acid, weakly induced expression of the AT8 epitope of tau, and cleaved tau
protein into a 45 kDa fragment after 24 hours (Kim et al., 1999). Okadaic acid
treatment has been reported to specifically enhance phosphorylation at the following
tau phosphorylation epitopes: Ser396/404, Ser202/205, Ser262, and Thr205 (Ekinici
and Shea, 1999; Alvarez-de-la-Rosa et al., 2005; Zhang and Simpkins, 2008). Thus,
treatment of cells with okadaic acid is a useful in vitro model of tau
hyperphosphorylation and paired helical filament assembly and accumulation in
Alzheimer’s disease.

Methods
Cell Culture Growth and Differentiation
Human neuroblastoma SH-SY5Y cells were grown as monolayer cultures in
T75 (Thermo Fisher Scientific) flasks in Dulbecco’s Modified Eagle Medium
(DMEM)/F12 (Gibco) supplemented with 10% fetal bovine serum, 100 U/ml penicillin,
100 µg/ml streptomycin, and 2 mM L-glutamine at 37°C incubator in a humid
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environment (95% air, 5% CO2) as previously described (Bihaqi et al., 2017). Viable
cells were stained with the exclusion dye Trypan blue solution, 0.4% (Thermo Fisher
Scientific) and counted with a hemocytometer before seeding the cells into 6-well and
96-well plates at cell densities of 1.0 x 105 cells/well and respectively. Twenty-four
hours after subculturing the cells, the cells were differentiated with 10 µM all-transretinoic acid (Sigma-Aldrich) for six days as previously described (Bihaqi et al., 2017).
Briefly, lyophilized retinoic acid (50 mg) was dissolved in 1.67 ml of dimethyl sulfoxide
(DMSO) and aliquoted. Retinoic acid stock solution was diluted in 100% ethanol and
subsequently added to complete DMEM culture medium to a final concentration of 10
µM. Retinoic acid causes morphological changes such as neurite outgrowth and
activates expression of neuronal markers such as NeuN, NSE, and synaptophysin in
SH-SY5Y cells (Cheung et al., 2009).

Okadaic Acid Treatment
Lyophilized okadaic acid sodium salt (Enzo Life Sciences) was reconstituted in
100% ethanol to yield a stock solution of 1 mM okadaic acid, which was diluted in
100% ethanol to a final working concentration of 0.1 mM okadaic acid. Okadaic acid
solution was added to DMEM media to yield final concentrations of 10, 25, 50, and
100 nM okadaic acid.

Protein Extraction and Western Blotting
Cells were collected by centrifugation at 1000 xg for 5 minutes at 4°C. Cell
pellets were washed twice with ice-cold phosphate-buffered saline solution and
subsequently resuspended in Radio-Immunoprecipitation Assay (RIPA) Buffer
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containing phosphatase inhibitors and protease inhibitors. The composition of RIPA
buffer was: 50 mM Tris-Cl, pH 7.4, 1% Nonidet-P40, 0.25% sodium deoxycholate,
150 mM sodium chloride, 1 mM ethylene glycol tetraacetic acid, 1 mM
phenylmethylsulfonyl fluoride, 1 mM sodium orthovanate, 1mM sodium fluoride, and 1
tablet of cOmplete™, mini protease inhibitor cocktail (Roche). For every 106 cells, 100
µL of RIPA buffer was used to lyse cells. Lysates were vortexed for 5-minute intervals
for a total of 30 minutes. Lysates were then centrifuged at 10,000 xg for 20 minutes at
4°C. The BCA protein assay kit (Peirce) was used to determine total protein
concentration in lysates. Samples were normalized and boiled in lithium dodecylsulfate (LDS) sample buffer (Thermo Fisher Scientific) for 5 minutes at 95°C. Proteins
were separated by SDS-PAGE and transferred to nitrocellulose membranes.
Nonspecific protein binding was blocked by incubating the blots in 2% nonfat milk in
TBS-T buffer (Tris-Cl buffer saline pH 7.6 containing 0.5% Tween-20) for 2 hours at
room temperature. Membranes were incubated in primary antibody solutions
overnight at 4°C. Chaperone protein expression levels were determined using
antibodies against Hsp90 (Thermo Fisher Scientific), Hsp110 (Enzo Life Sciences),
Hsp90 (Thermo Fisher Scientific), and Hsp70 (Rockland Inc.). Total tau protein levels
were found with anti-tau antibody against the human 46 kDa tau isoform (SigmaAldrich). Phosphorylated tau epitopes were detected using antibodies against Thr212
(Sigma-Aldrich), AT8 (Thermo Fisher Scientific), and Ser396 (Cell Signaling
Technology). Blots were stripped with mild stripping buffer (15 g glycine, 1 g SDS,
0.1% SDS, 10 ml Tween-20; pH 2.2) for 10 minutes at room temperature and probed
for housekeeping protein beta-actin (Abcam) or GAPDH (Thermo Fisher Scientific).
Membranes were incubated in HRP-conjugated secondary antibody dilutions for 1
hour at room temperature before developing the blots with chemiluminescent West
Pico Plus reagent (Thermo Fisher Scientific).
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Cell Death and Cell Viability Assay
To determine the effects of okadaic acid on differentiated cell morphology,
cells in 6-well plates were visualized with phase-contrast microscopy using EVOS FL
Auto Cell Imaging System.

Cell viability was determined using the CellTiter 96®

Aqueous One Solution Cell Proliferation Assay (Promega). Briefly, CellTiter 96® Aqueous
One Solution Cell Proliferation Reagent was thawed in a 37°C water bath and 20 μl of
MTS reagent was added to each well of the 96-well containing 100 μl DMEM culture
medium not containing serum. After incubation of the 96-well plates at 37°C for 3
hours, plates were gently shaken and the absorbance was read at 490 nm in a
microplate reader. Absorbance values were background-corrected for DMEM culture
medium containing MTS reagent alone in wells that did not contain cells. Cell viability
is expressed as percentages of the control group, which was treated with 0.1%
ethanol.

Statistical Analyses
Statistical analyses were conducted with Graphpad Prism version 6.0, GraphPad
Software, La Jolla, California, USA (www.graphpad.com). Error bars represent mean
+/- standard error mean (SEM). One-way analysis of variance (ANOVA) followed by
Tukey’s post hoc multiple comparisons test was used to analyze data sets containing
more than two groups. P-values less than 0.05 were considered significant.

Results
Phosphatase inhibition by okadaic acid in undifferentiated neuronal cells
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To monitor the effects of increased phosphorylation of tau on the physiology
and chaperone protein expression of neuroblastoma cells, we first treated
undifferentiated SH-SY5Y cells with okadaic acid, which inhibits PP2A phosphatase
leading to tau hyperphosphorylation (schematic in Figure 1C) (Bialojan and Takai,
1988). As shown in Figure 2A, undifferentiated cells do not develop neurite
extensions and are not post-mitotic, in contrast to differentiated neuroblastoma cells
(Figure 2B). Undifferentiated SH-SY5Y cells were cultured at a density of 1.6 x 106
cells/ml and treated with 0 nM, 50 nM, and 100 nM of okadaic acid for 24 hours,
doses

of

okadaic

acid

that

have

previously

been

used

to

study

tau

hyperphosphorylation in a cell culture model of Alzheimer’s disease (Zhang and
Simpkins, 2010; Choi et al., 2015). We probed cell lysates of undifferentiated cells
treated with okadaic acid for Hsp70, Hsp90 and Hsp110 and observed that while
levels of Hsp90 and Hsp110 do not change, Hsp70 appeared to be induced upon
okadaic acid treatment. Previous reports of protein phosphatase 2A inhibition by
okadaic acid treatment showed that in vitro levels of the tau phosphorylation epitope
Thr212 increased in response to okadaic acid (Wu et al., 2017). Thus, we probed for
phosphorylated tau using the phosphorylated Thr212 epitope to determine if
undifferentiated SH-SY5Y treated with 50 nM and 100 nM okadaic acid have
increased phosphorylated Tau levels compared to control cells that were not treated
with okadaic acid. We observed a modest migration shift in phosphorylated tau (pTau)
at Thr212 suggesting that in response to okadaic acid treatment, tau may accumulate
additional modifications. However, phosphorylation intensity at Thr212 appears to be
similar (Figure 2C). Together, undifferentiated SH-SY5Y cells appear to have only
modest changes resulting from incubation with okadaic acid, although the increase in
Hsp70 levels is consistent with an enhanced stress response.
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Phosphatase PP2A inhibition by okadaic acid leads to reduced chaperone
function and tau phosphorylation in differentiated neuronal cells
Next, we differentiated SH-SY5Y cells with retinoic acid to generate cells with
neurite extensions and produce physiology that is more relevant to neurons (Figure
2B). Then we treated differentiated cells with okadaic acid to investigate cell viability,
tau hyperphosphorylation and levels of chaperone proteins in response to treatment.
After differentiation with retinoic acid, cells were treated with 0 nM, 25 nM, 50 nM, and
100 nM of okadaic acid (n = 4 per treatment group) for 3 hours (Figure 3A) and 8
hours (Figure 3B) and overall cell morphology was monitored by phase-contrast
microscopy. After 3 hours of okadaic acid exposure, SH-SY5Y cells in the 0 nM and
25 nM okadaic acid treatment groups had apparent normal morphology defined as
cells that had phase-bright soma and neuritic processes, as established by previous
reports of SH-SY5Y healthy phenotype (Kim et al., 1999) (Figure 3A). However,
treatment of cells with either 50 nM or 100 nM okadaic acid for 3 hours caused
widespread cell death as evidenced by loss of neurite extensions, cell rounding, and
cell detachment from the plate (Figure 3A). We observed similar results when cells
were incubated with okadaic acid for 8 hours with high doses associated with cell
detachment and death but normal physiology observed at the lower dose (Figure 3B).
These results suggest that cytoxicity associated with okadaic acid is enhanced in
differentiated cells compared to undifferentiated cells.
Next, we measured cell viability of differentiated SH-SY5Y cells after exposure
to okadaic acid using the MTT colorimetric assay to detect metabolic activity. SHSY5Y cells were seeded at a cell density of 5.0 x 104 cells/ml in a 96-well plate.
Twenty-four hours post-seeding, cells were differentiated with retinoic acid and then
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treated with 0 nM, 10 nM, and 25 nM for 3 hours, 6 hours, and 24 hours. The MTT
assay conducted at the 3-hour and 6-hour exposures to 0 nM, 10 nM, and 25 nM
okadaic acid did not show any significant differences in cell viability compared to cells
treated with only vehicle (0.1% ethanol) (Figure 3C and 3D). However, the 10 nM and
25 nM doses of okadaic acid were associated with reduced metabolic function in the
cells at the 24-hour time point suggesting reduced cell viability (Figure 3E and 3F).
Consistent with this, we also observed that after 24 h exposure to low doses of
okadaic acid cells, cells became rounded and detached (Supplemental Figure S1A).
Viability continued to decrease across a range of okadaic acid concentrations during
prolonged incubations (42 h) (Supplemental Figure S1B and S1C).
Since

differentiated

SH-SY5Y

cells

displayed

phenotypically

normal

morphologies and no significant loss of viability after low-dose (10 nM and 25 nM)
short-term (3 hr) treatment with okadaic acid (Figure 3A, 3C, 3G and S1A), we
harvested cell lysates under these conditions to probe for changes in expression
levels of Hsp70 and Hsp90 and to detect increased levels of phosphorylated tau using
phospho-specific antibodies for the Ser396, Thr212, and Thr181 epitopes. Del Barrio
and colleagues have shown that undifferentiated SH-SY5Y cells treated with 30 nM of
okadaic acid for 16 hours show significant changes in tau phosphorylation at the
Ser396/404 epitope (Del Barrio et al., 2011). After 3 hours of treatment with okadaic
acid, we detected increased levels of Tau phosphorylated at Thr212 and, to a lesser
extent, Ser396, most notably at the 25 nM dose (Figure 4A). However, we observed
no increase in Tau phosphorylated at Thr181, indicating that not all sites are uniformly
affected by okadaic acid. Interestingly, Hsp70 protein levels decrease dramatically
after exposure to 25 nM okadaic acid for 3 h, and we also observed slightly less
Hsp90 after treatment (Figure 4A).
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Next, to determine if changes in protein levels that we detected get more
pronounced with extended incubation with okadaic acid, we harvested cells at 6 h and
probed lysates for Hsp70, Hsp90 and phosphorylated-tau (Thr212) (Figure 4B). We
observed that levels of Hsp70 and Hsp90 continued to decrease over time, indicating
that the reductions in levels were both dose-dependent and time-dependent.
Moreover, we continued to observe elevated levels of tau phosphorylated at Thr212.
Finally, long-term exposure to okadaic acid does not impact overall tau levels as
detected by total tau antibody, which reacts with multiple tau isoforms (Supplemental
Figure S2A and S2B). Together, these results demonstrate that inhibition of protein
phosphatases leads to enhanced phosphorylation of tau and correlates with reduced
function of ATP-dependent chaperones in differentiated SH-SY5Y cells.

Discussion
Protein aggregation is observed throughout several neurodegenerative
diseases, such as Alzheimer’s disease (AD), Parkinson’s disease, and Huntington’s
disease (Pruisner, 2013). Proteins misfold into a biologically nonfunctional, insoluble
state and proceed to form detergent-resistant aggregates that cannot be degraded by
cellular degradation mechanisms, such as the ubiquitin proteasome pathway in
humans (Jucker and Walker, 2013; Vashist et al., 2011). It is hypothesized that
protein aggregates form in diseases as a result of inefficient protein quality control,
possibly due to aging (Saez and Vilchez, 2014). Research provides evidence that
amyloids and amyloid-like fibers interfere with neuronal functions, including cell
communication, which may contribute to neuronal cell death in neurodegenerative
diseases

(Kakkar

et

al.,

2014).

In

Alzheimer’s

disease,

tau

becomes

hyperphosphorylated and both mouse and human hyperphosphorylated tau have
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been shown to aggregate in vitro (Alonso et al., 2001; Chohan et al., 2005). Tau
hyperphosphorylation

is

not

exclusive

to

Alzheimer’s

disease;

aberrant

phosphorylation of tau and formation of tau-positive inclusions occurs in several
human

neurodegenerative

diseases,

including

Pick’s

disease,

progressive

supranuclear palsy, corticobasal degeneration, and frontotemporal dementia and
Parkinsonism linked to chromosome-17 (Goedert et al., 2010).
Cells have robust protein quality control networks that resolubilize misfolded
proteins and degrade aggregated proteins. Within this network, molecular chaperones
function to stabilize properly folded proteins, refold misfolded or partially unfolded
proteins, and degrade misfolded proteins that are unamenable to refolding
mechanisms (Bukau and Horwich, 1998). There is evidence that molecular
chaperones may be involved in the progression of Alzheimer’s disease pathology.
Research shows that expression levels of ATP-dependent molecular chaperones,
Hsp90 and Hsp70, decrease during the course of aging and neurodegenerative
diseases (Salminen et al., 2011; Brehme et al., 2014). Normally, cellular stress
triggers the upregulation of heat shock proteins, which regulate the folding of unfolded
or misfolded proteins and degrade irreversibly misfolded proteins (Morimoto and
Santoro, 1998). Studies have shown that increasing the expression of heat shock
proteins in animal models of neurodegenerative diseases can be neuroprotective. The
overexpression of Hsp70 mitigates pathological phenotypes in transgenic mouse
models of spinal and bulbar muscular atrophy (Adachi et al., 2003; Katsuno et al.,
2005).
In this study we sought to determine if okadaic acid, a known inhibitor of
PP2A, alters chaperone protein levels in differentiated human neuroblastoma SHSY5Y cells. It is thought that inhibition of PP2A may have a role in Alzheimer’s
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disease pathogenesis. In the brains of patients with Alzheimer’s disease there is an
increase in both the levels of mRNA and expression of inhibitor 1 of PP2A (I1PP2A) and
in vitro expression of I1PP2A hyperphosphorylates tau in NIH3T3 cells (Wang et al.,
2015). Here, we found that long-term exposure to okadaic acid significantly impairs
the viability of differentiated SH-SY5Y cells treated with 10 nM, 30 nM, and 50 nM
okadaic acid for 24 and 42 hours. However, cells tolerated short-term exposure to 10
nM and 25 nM okadaic acid (3 h) without significant loss of viability. These
observations suggest that 24-hour exposure of okadaic acid to differentiated SHSY5Y cells is toxic. Future experiments that measure caspase-3 activation in
response to 24-hour exposure of 10 nM and 25 nM okadaic acid to differentiated SHSY5Y cells could investigate this further.
Reduced chaperone function could exacerbate defects in overall cell viability
and neurodegeneration. Notably, both Hsp70 and Hsp90 chaperone protein levels
decreased in response to increasing doses of okadaic acid at the 3-hour and 6-hour
exposures of okadaic acid to SH-SY5Y cells. Although after 24 hours, we did observe
a surprising increase in Hsp70 levels (data not shown), but the cells had become
rounded and detached with widespread cell death. Together, increasing doses of
okadaic acid seemed to correlate with decreased levels of Hsp70 and Hsp90 in
differentiated cells. It is possible that Hsp70 is downregulated or degraded in
response to phosphatase inhibition. Further research that investigates the mRNA
levels, localization and protein turnover of of Hsp70 and Hsp90 are warranted. Hsp70
and Hsp90 are both also known to be phosphorylated, and phosphorylation states
regulate binding to co-chaperones and substrate selection (Muller, et al., Oncogene,
2013).
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Okadaic acid has been widely used to inhibit protein phosphatases and model
tau hyperphosphorylation and dissociation of tau from microtubules in cultured human
neuroblastoma cells (Caillet-Boudin et al., 1996; Shea et al., 1996). Furthermore,
okadaic acid has been shown to inhibit PP2A and PP1 in vivo. Rat brains injected
with okadaic acid have shown decreased expression of PP2A and PP1 (Arendt et al.,
1998). However, the use of okadaic acid and other small molecule inhibitors
commonly used to inhibit protein phosphatases, such as calyculin A, tautomycin,
nodularin, microcystin-LR, and fostriecin, have several limitations (Swingle et al.,
2007). Calyculin A, nodularin, and microcystin-LR are the most potent phosphatase
inhibitors; nanomolar concentrations of these compounds inhibit PP2A, PP1, PP4,
and PP5 (Swingle et al., 2007). A drawback to using small molecule inhibitors to
inhibit phosphatases is their ability to effectively enter the cell and selectively inhibit a
given phosphatase. For example, cell membranes are permeable to calyculin A and
okadaic acid, but the hydrophobicity of calyculin A and, to a lesser extent, okadaic
acid limit their solubility in cell culture media (Swingle et al., 2007). This study
assumed that okadaic acid effectively entered cells and sought to determine which
doses of okadaic acid could alter tau phosphorylation in vitro. However, it is possible
that okadaic acid did not efficiently inhibit PP2A using the doses 10 nM and 25 nM
and exposure times of 6 and 24 hours. Living cells contain concentrations of PP2A
and PP1 between 0.1 – 1.0 μM depending on the cell line (Cohen et al., 1990). For
future experiments, it is possible to inhibit phosphatases more efficiently by adding a
protein phosphatase inhibitor, such as microcystin or nodularin, directly to cell
extracts and immunoblotting lysates to determine possible alterations in the
expression of tau phospho-epitopes and chaperone protein expression (Swingle et
al., 2007).
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Phase-contrast microscopy clearly showed neuronal degeneration in response
to short exposures (3 hours, 8 hours) of 50 nM and 100 nM okadaic acid but it is
difficult to determine the extent of phosphorylation inhibition due to widespread cell
death and low protein yield in cell extracts. Okadaic acid toxicity could be due in part
to impaired cytoskeletal architecture and loss of cell-cell contact (Opsahl et al., 2013).
The toxin has previously been shown to impair cell adhesion and reorganize
filamentous actin, resulting in morphological rearrangement (Vale and Botana, 2008;
Franchini et al., 2010). Previous reports demonstrated that okadaic acid within the
range of 100 – 500 nM alters cytoskeletal structure and induces apoptotic cell death
in human neuroblastoma cells (Kahn et al., 2012, Valdiglesias et al., 2011). Stable
isotope labeling of amino acids in undifferentiated SH-SY5Y cells treated with 400 nM
okadaic acid followed by isolation of lipid rafts and mass spectroscopy analysis
identified 167 phosphoepitopes of 67 proteins associated with the actin cytoskeleton,
mictrotubules, and cell adhesion structures that are affected by okadaic acid (Opsahl
et al., 2013). Thus, okadaic acid may exert cytotoxicity by promoting the breakdown of
the cytoskeleton and inducing cell detachment.
Furthermore, okadaic acid causes oxidative damage, genotoxicity, and
activation of apoptosis in various cell lines. Treatment of leukocytes, HepG-2 cells,
and SH-SY5Y cells with okadaic acid resulted in altered cell morphology in all cell
lines tested and changes in the cell cycle of leukocytes and SH-SY5Y cells with the
greatest impairment observed in SH-SY5Y cells (Valdiglesias et al., 2011). Moreover,
treatment of the cell lines with okadaic acid both increased the rate of apoptosis and
caspase-3 activation in leukocytes, HepG-2 cells, and SH-SY5Y cells (Valdiglesias et
al., 2011). Okadaic acid treatment has also been shown to induce both direct and
indirect oxidative damage to SH-SY5Y cells in culture (Valdiglesias et al., 2011).
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Additionally, DOK cells treated with 10 nM okadaic acid showed evidence of
cytotoxicity based on LDH release and the same dose of okadaic acid induced
caspase-3-dependent apoptosis and DNA damage in HepG-2 hepatic cells (SouidMensi et al., 2008).
The most selective phosphatase inhibitors are tautomycin/tautomycetin,
okadaic acid, and fostriecin (Swingle et al., 2007). Of these, fostriecin, a phosphate
ester, has the most selectivity, inhibiting PP2A/PP4 compared to PP1/PP5 with
selectivity > 104, whereas the selectivity of okadaic acid to inhibit PP2A/PP4
compared to PP1/PP5 is <102 (Swingle et al., 2007). Furthermore, fostricein is water
soluble and readily enters living cells via the reduced folate transporter (Fry et al.,
1984). Therefore, fostriecin has advantages over okadaic acid in models of in vitro
and in vivo phosphorylation. A drawback of using fostriecin is the instability of the
compound due to its lactone ring compared to okadaic acid, which is stable in organic
solvents (Swingle et al., 2007). However, fostriecin can be stored in buffered solution
containing ascorbate with a pH range of 5.5 – 7.5 to prevent oxidation and exposure
to light (Swingle et al., 2007). The use of fostriecin to inhibit PP2A in human
neuroblastoma SH-SY5Y cells is a more selective, and possibly less toxic,
experimental approach compared to okadaic acid. Moreover, it is possible to model
the

phosphorylation

of

tau

by

mutating

Ser/Thr

residues

to

Glu,

or

pseudophosphorylate tau to determine which phosphoepitopes of tau are directly
involved in Alzheimer’s disease pathogenesis (Alonso et al., 2010).
Here, we used okadaic acid as it has previously been reported to alter tau
phosphorylation (Harris et al., 1993). Phase-contrast microscopy clearly showed
neuronal degeneration in response to short exposures (3 hours, 8 hours) of 50 nM
and 100 nM okadaic acid (Figure 3), but it is difficult to determine the extent of
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phosphorylation inhibition due to widespread cell death and low protein yield in cell
extracts. Okadaic acid toxicity could be due in part to impaired cytoskeletal
architecture and loss of cell-cell contact (Opsahl et al., 2013). The toxin has
previously been shown to impair cell adhesion and reorganize filamentous actin,
resulting in morphological rearrangement (Vale and Botana, 2008; Franchini et al.,
2010). Previous reports demonstrated that okadaic acid within the range of 100 – 500
nM alters cytoskeletal structure and induces apoptotic cell death in human
neuroblastoma cells (Kahn et al., 2012, Valdiglesias et al., 2011). Stable isotope
labeling of amino acids in undifferentiated SH-SY5Y cells treated with 400 nM okadaic
acid followed by isolation of lipid rafts and mass spectroscopy analysis identified 167
phosphoepitopes of 67 proteins associated with the actin cytoskeleton, mictrotubules,
and cell adhesion structures that are affected by okadaic acid (Opsahl et al., 2013).
Thus, okadaic acid may exert cytotoxicity by promoting the breakdown of the
cytoskeleton and inducing cell detachment under high exposure conditions.
Furthermore, okadaic acid causes oxidative damage, genotoxicity, and activation of
apoptosis in various cell lines. Treatment of leukocytes, HepG-2 cells, and SH-SY5Y
cells with okadaic acid resulted in altered cell morphology in all cell lines tested and
changes in the cell cycle of leukocytes and SH-SY5Y cells with the greatest
impairment observed in SH-SY5Y cells (Valdiglesias et al., 2011b). Moreover,
treatment of the cell lines with okadaic acid both increased the rate of apoptosis and
caspase-3 activation in leukocytes, HepG-2 cells, and SH-SY5Y cells (Valdiglesias et
al., 2011b). Okadaic acid treatment has also been shown to induce both direct and
indirect oxidative damage to SH-SY5Y cells in culture (Valdiglesias et al., 2011c).
Based on our results, chaperone protein expression of Hsp70 decrease in
response to increasing exposure and dosage of okadaic acid. However, Hsp90
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expression increases in response to increasing exposure and concentration of
okadaic acid. It is possible that Hsp70 destabilize fibrils and aggregates of
hyperphosphorylated tau and the levels of these chaperones may decrease in
correlation to increasing aggregate load (Figure 5). By contrast, Hsp90 may stabilize
aberrantly phosphorylated tau protein and could be involved in the assembly of tau
fibrils into neurofibrillary tangles. Our results show that Hsp70 levels consistently
decrease in response to increasing concentration of okadaic acid over 3 hours and 6
hours of exposure. However, differentiated SH-SY5Y cells treated with okadaic acid
for 24 hours show a two-fold increase in Hsp70 levels compared to vehicle-treated
cells (Supplemental Figure S3). We could not probe for changes in Hsp70 expression
in cells treated with 25 nM okadaic acid for 24 hours due to widespread cell death and
low protein concentration. Thus, further research should be done to investigate longterm effects of okadaic acid on cultured human neuroblastoma cells differentiated with
retinoic acid to investigate changes in chaperone levels over chronic exposure.
Treating differentiated neuroblastoma cells with low doses of okadaic acid, such as 5
nM and 10 nM okadaic acid for 24 hours and 48 hours would provide more
information to compare to the findings discussed here. Moreover, future experiments
should be carried out that expose differentiated SH-SY5Y cells to okadaic acid for 24
hours, remove the cell culture medium containing okadaic acid, replace with growth
medium containing fetal bovine serum, and monitor cells over time for changes in
Hsp90, Hsp70, and Hsp110 chaperone protein levels.
A caveat of the okadaic acid model of hyperphosphorylated tau is that
inhibition of PP2A and to a lesser extent, PP1, could phosphorylate the chaperone
proteins Hsp70 and Hsp90. Phosphorylation of Hsp90 and Hsp70 in eukaryotes may
change the functional activities and interactions of these chaperone proteins with co-
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chaperone proteins. Post-translational modifications that regulate Hsp90 conformation
and binding to co-chaperone proteins include phosphorylation, methylation,
acetylation, ubiquitylation, nitrosylation, and sumoylation (Kargӧz and Rüdiger, 2015;
Wandinger et al., 2008). Therefore, excessive phosphorylation of chaperone proteins
could alter their accessibility for nucleotides and substrate proteins. It is interesting to
note that the proline-directed kinase Gsk3β, which regulates tau phosphorylation, is a
client of Hsp90 (Lochhead et al., 2006; Tortosa et al., 2009; Banz et al., 2009). It is
possible that Hsp90 may contribute to Alzheimer’s disease by facilitating the
phosphorylation activity of the tau kinase Gsk3β. Overall, it is clear that ATPdependent chaperone proteins are involved in Alzheimer’s disease tau pathology and
it remains to be understood how molecular chaperone proteins are affected by the
aggregation and accumulation of hyperphosphorylated tau protein.
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Figure 1. Tau protein hyperphosphorylation and chaperone proteins.
A.) Human tau phosphorylation in Alzheimer’s disease. Exon 2 and 3 are
located near the N-terminus of tau protein.
B.) Chaperone protein structures. Hsp110: crystal structure of Sse1, yeast
Hsp110 as a complex with ATP, PDB 2QXL (Liu Q and Henderson WA, 2007).
Full-length Hsp90 crystal structure of HtpG from E. coli is shown bound to ADP
(PDB 2IOP; Shiau AK, et al., 2006). The crystal structure of human Hsp70
nucleotide binding domain with the mutation R272K is shown bound to ADP
(PDB 5BN9; Narayanan D, et al., to be published).
C.) Experimental setup for okadaic acid treatment of undifferentiated (1) and
differentiated (2) SH-SY5Y cells.
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Figure 2. Undifferentiated SH-SY5Y cell response to okadaic acid
treatment.
A.) Undifferentiated SH-SY5Y morphology. Scale bar indicates 100 μm.
B.) Morphology of SH-SY5Y cells after retinoic acid-induced
differentiation. SH-SY5Y cells were treated with retinoic acid (10μM) for
six days to induce morphological changes such as neurite extension.
Scale bar indicates 100 μm.
C.) Western blots of undifferentiated SH-SY5Y cells. Cells were treated
with 0 nM, 50 nM, and 100 nM okadaic acid for 24 hours in culture media.
Antibodies were used to determine protein levels of Hsp90, Hsp70,
Hsp110, and the phosphorylated tau protein epitope Thr212.
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Figure 3. Differentiated cell response to okadaic acid. A.) Cells treated with
0 nM, 25 nM, 50 nM, and 100 nM okadaic acid for 3 hours. Microscopy of the
cells shows that the 50 nM dose of okadaic acid at 3 hours is lethal to cells
(40x objective). Cells are rounded and floating when treated with 100 nM
okadaic acid for 3 hours (20x objective). The 50 nM dose of okadaic acid at 8
hours causes cells to lose morphology (40x objective). The 100 nM dose of
okadaic acid at 8 hours causes widespread cell death (20x objective). After 3
hours of okadaic acid exposure, cells treated with 10 and 25 nM okadaic acid
do not show changes in morphology or viability compared to vehicle-treated
cells. B.) Cells do not show changes in cell viability after 8 hours of exposure
to 10 nM and 25 nM okadaic acid. C.) Cells treated with 10 nM and 25 nM
okadaic acid for 3 hours do not have significantly different percent cell viability
compared to vehicle-treated cells. D.) Cells exposed to 10 nM and 25 nM
okadaic acid for 6 hours show reduced cell viability compared to vehicletreated cells. E.) Cells treated with 10 nM and 25 nM okadaic acid show a
significant decrease in viability after 24 hours of treatment. F.) Absorbance
values at 490 nm over 3, 6, and 24 hours of okadaic acid treatment of
differentiated SH-SY5Y cells. Cell viability decreases over time and levels off
at 24 hours of okadaic acid treatment. G.) Morphology of differentiated SHSY5Y cells treated with 10 nM okadaic acid for 3 hours. For all microscopy
images, scale bar indicates 100 µm.
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Figure 4. Chaperone protein expression levels in okadaic
acid-treated differentiated SH-SY5Y cells over time.
A.) SH-SY5Y cells were exposed to okadaic acid for 3 hours and
25 µg of cell lysate was run on SDS-PAGE and immunoblotted.
B.) SH-SY5Y cells were exposed to okadaic acid for 6 hours and
15 µg of cell lysate was run on SDS-PAGE and immunoblotted.
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Figure 5. Model of chaperone-mediated tau assembly into
neurofibrillary tangles. Hsp70 and Hsp110 destabilize fibrils and
aggregates of tau. By contrast, Hsp90 stabilizes misfolded tau and
facilitates the assembly of tau into fibrils and ordered aggregates.
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Figure S1. Time-course viability of differentiated SH-SY5Y cells in
response to okadaic acid treatment.
A.) SH-SY5Y cells were treated with retinoic acid (10 μM) for 6 days and
subsequently treated with 0, 10, and 25 nM okadaic acid for 3, 6, and 24 hours.
Phase-contrast microscopy. Scale bar indicated 100 µm.
B.) Percentage of viable cells decreases in response to increasing doses of
okadaic acid after 24 hours of exposure. Cells treated with vehicle only, 0.1%
ethanol, had 100% viability.
C.) Cell viability in response to treatment with 0, 10, and SH-SY5Y cells treated
with 0, 10, 25, 30, and 50 nM okadaic acid for 42 hours.
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Figure S2. Differentiated SH-SY5Y morphology and chaperone protein
expression in response to okadaic acid.
A.) Microscopy of differentiated SH-SY5Y were treated with 0 nM okadaic
acid and 25 nM of okadaic acid for 24 hours and with 50 nM okadaic acid for
3 hours.
B.) Cells were treated with 50 nM okadaic acid for 3 hours and 25 nM
okadaic acid for 24 hours. Tau protein levels after okadaic acid treatment.
Total tau levels do not change, but the phospho-Tau epitope Thr212 is
reactive to okadaic acid-induced tau hyperphosphorylation.
C.) ATP-dependent chaperone protein levels after okadaic acid treatment.
Cells were treated with 50 nM okadaic acid for 3 hours and 25 nM okadaic
acid for 24 hours. Hsp70 levels decrease in response to prolonged OA
exposure. Hsp90 shifted in migration in response okadaic acid induced
PP2A inhibition.
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Figure S3. Expression of Hsp70 in SH-SY5Y cells treated with
okadaic acid for 24 hours. Cells treated with 10 nM okadaic acid
show an increase in Hsp70 levels compared to vehicle-treated cells.
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Table S1. Okadaic acid doses required to observe in vitro changes in tau
phosphorylation levels.

Okadaic
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Phospho-Tau

Acid Dose

Exposure

Epitope

40 nM
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Reference

Ma XH, et al. Brain Res. 2018;
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of Pharmaceutical Sciences.
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Zhang Z and Simpkins JW.
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Brain Res. 2010; 1345: 176 –
181.

50 nM and
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Abstract
Protein aggregates are thought to be the end result of derailed protein quality
control pathways, which are impaired during aging (1). The protein quality control
system involves different pathways that manage and regulate protein folding and
aggregation. Misfolded proteins such as Aβ peptide, tau, alpha-synuclein, and yeast
prion proteins (insoluble Sup35 protein) share the motif of stacked, in-register beta
sheets; thus, these misfolded proteins represent different types of amyloid protein (2).
Amyloid proteins have stable, low-energy conformations that are resistant to protein
degradation (3). Important components of the protein quality control network are
molecular chaperones. Restoring protein homeostasis by modulating chaperone
proteins may provide disease-modifying therapeutic strategies for managing
neurodegenerative diseases (4). We hypothesize that E. coli ClpX and ClpXP
expressed in S.cerevisiae will not recognize Sup35 amyloid fibers. Decreasing the
substrate specificity of the chaperone protein complex ClpXP may result in a novel
chaperone tool with enhanced specificity for amyloid aggregates that can both bind
and degrade amyloids. Thus, we constructed and expressed a novel chimeric protein
in the [PSI+] yeast prion system, an extensively utilized model of amyloid assembly, to
determine if non-native chaperone proteins affect prion propagation and amyloid
assembly.
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In the cell, protein homeostasis is regulated by chaperone proteins that can
remodel and degrade misfolded, unfolded, and aggregate proteins. ClpXP and
Hsp104 are chaperone proteins that belong to the AAA+ superfamily of ATPases (5).
The AAA+ (ATPases associated with diverse cellular activities) superfamily of ATPdependent enzymes have highly conserved domains and function as chaperones
and/or proteases to manage protein folding and multiprotein complexes (5). The
Clp/Hsp100 family of ATP-dependent enzymes within the AAA+ protein superfamily
includes the cytosolic proteins ClpX, ClpA, and Hsp104. Members of the Clp/Hsp100
family refold or degrade protein assemblies, misfolded proteins, and aggregated
proteins (6). Within the Clp/Hsp100 family, ATPases (ClpX) partner with a peptidase
(ClpP) to form stacked, barrel-like structures that functions as chaperone proteases
(6). The chaperone ATPase component of this complex threads polypeptides through
the central axial channel of the chaperone protease complex into the peptidase
chamber for degradation (7).
ClpXP is an ATP-dependent chaperone protease that binds to and degrades
an estimated 50 substrate proteins based on proteomic analysis (8). ClpX forms a
hexameric ring that binds to ClpP, which forms stacked heptameric rings; thus, there
is asymmetrical binding between ClpX and ClpP (9, 10). ClpX contains an N-domain,
a large nucleotide-binding domain (AAA+ domain), and a small AAA+ domain (11).
The N-domain of ClpX forms dimers that are connected to the large AAA+ domain by
a flexible linker region and functions to bind adaptors, client proteins, and stabilize the
hexameric structure of ClpX (12). Substrate recognition by ClpX requires the
presence of short peptide sequences, or degradation tags, on client proteins, on the
C-terminus or N-terminus of client proteins (5, 83). An example of a C-terminal
degradation tag recognized by ClpX is the ssrA tag, an 11-amino acid peptide
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signaling sequence on substrate proteins (8, 13, 14, 15). The ClpX N-domain is
required for recognition of several client proteins, such as the λO protein and the
UmuD subunit of UmuD.D’ DNA polymerase (11).
The chaperone ATPase ClpXP couples ATP binding and hydrolysis to
mechanical force, which is required for translocation of polypeptides through the axial
channel of ClpX into the cavity of ClpP, a serine protease (16). The pore loops
(GYVG) in the axial channel of ClpX grip and processively thread unfolded
polypeptides through the narrow central channel of ClpX into the ClpP barrel (11, 13,
17). ClpX also functions independently of ClpP as a chaperone protein to remodel
misfolded proteins in vitro and in vivo and disassemble protein complexes, notably the
MuA transposase tetramer (19 – 21). Biochemical studies have shown that ClpX
functions at small step sizes to perform mechanical work, which allows the enzyme to
generate substantial force to remodel diverse sets of substrate proteins (21).
Lon is a chaperone protease that belongs to the AAA+ superfamily of
ATPases. Unlike ClpX, Lon can bind to a wider range of substrates and recognizes
surface-exposed hydrophobic residues on misfolded or unfolded proteins (22). Both
ClpXP and Lon bind to proteins via the recognition of degradation signals on the Cterminus or N-terminus of substrate proteins (5, 8). The N-domain of Lon contains
three amino acid residues that bind to the degradation signal of the substrate SulA
(23). ClpX and Lon associate with aggregates in bacteria, but it is currently unknown if
Lon can disassemble aggregates in vivo (24, 25).
The only member of the Clp/Hsp100 proteins within the AAA+ protein
superfamily that can disaggregate proteins is the chaperone protein Hsp104 (26). In
Saccharomyces cerevisiae, deletion and overexpression of Hsp104 modulate prion
propagation and thus alter the [PSI+] prion phenotype in yeast; thus, changes in the
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basal levels of Hsp104 “cures” yeast of the [PSI+] prion phenotype (27, 28). The Ndomain of Hsp104 (amino acid residues 1 – 147) is required for [PSI+] prion curing in
S. cerevisiae, but is not required for thermotolerance or [PSI+] prion propagation
(Hung and Masison, 2006). Overexpression of Hsp104 is neuroprotective in models of
Parkinson’s disease, suggesting that Hsp104 can also bind to human prion proteins,
such as alpha-synuclein (30).
Engineered chimeric AAA+ chaperone proteases can refold aggregates and
degrade misfolded proteins. The ClpB variant referred to as BAP associates with the
ClpP peptidase and functions to both disaggregate and degrade aggregates in
cooperation with the co-chaperone bacterial protein DnaK (31). Moreover, an Hsp104
variant called HAP was engineered to display both disaggregation and proteolytic
activity; HAP consists of Hsp104 in association with ClpP (32). Replacing the helixloop-helix region of Hsp104 and ClpB with the helix-loop-helix from ClpA containing
the IGL/F motif required for ClpP association allows both ClpB and Hsp104 to
translocate segments of polypeptides extracted from misfolded proteins into the ClpP
protease barrel (31, 32). Therefore, we hypothesized that engineering a novel
chaperone protease containing the N-domain of Hsp104 and the ClpXΔNTD
sequence in association with ClpP could bind to and proteolytically degrade amyloid
proteins.
Before testing this hypothesis, we first tested if AAA+ chaperone proteins
could affect prion propagation in the [PSI+] yeast prion model of amyloid assembly.
We utilized two approaches to answering this research question. First, we screened
domain-specific mutations Lon in the S. cerevisiae [PSI+] model of amyloid assembly
to identify variants with enhanced amyloid substrate recognition. Next, we engineered
a novel chaperone protease and expressed the construct in the [PSI+] yeast amyloid
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model to determine if the chimeric protein had enhanced recognition of amyloid. We
hypothesized that the chimeric protein would resolubilize amyloid protein, thereby
abrogating prion propagation.

Results
Random mutations in the N-domain of Lon (amino acid residues 1 – 307) were
generated with an error-prone DNA polymerase with the goal of decreasing substrate
specificity of Lon. Decreasing the substrate specificity of Lon could result in substrate
recognition of fibrillar amyloid proteins. We hypothesized that wild-type Lon would not
recognize Sup35 amyloid fibers in yeast. After cloning wild-type lon into the double
expression vector pYES2 and transforming this construct in [PSI+] yeast, we observed
that the phenotype of the colonies was the same as [PSI+] yeast cells containing the
empty vector pYES2 (Figure S1). This suggests that prion propagation was not
altered by the expression of the E. coli chaperone protease Lon in S. cerevisiae. Next,
we investigated if the expression of E. coli ClpXP affects prion propagation and
amyloid assembly in [PSI+] yeast by transforming the construct pESC-URA + ClpXP
(Marissa Viola) into yeast. We observed expression of ClpXP in [PSI+] yeast did not
change the prion phenotype; yeast colonies were white, which is associated with a
[PSI+] prion phenotype (Figure S2A). We analyzed the phenotype of yeast lysates
containing ClpXP using a novel spectrophotometric liquid assay to detect the red
pigment from ade2-1 yeast mutants that accumulates in [psi-] yeast cells. Extraction of
protein from yeast cells using Y-PER (Thermo Fisher Scientific), normalization of
yeast lysates, and excitation of lysates at 488 nm showed that yeast expressing
ClpXP has a similar emission profile as [PSI+] yeast containing empty pYES2 vector
(Figure SB). Thus, wild-type Lon and ClpXP do not recognize Sup35 prion in the
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[PSI+] amyloid model system in vivo and do not modulate prion propagation or curing
of [PSI+] prion in yeast.
Mutations were randomly generated at a low frequency in the Lon N-domain
and transformed into XL Gold E. coli cells. Clonal isolate plasmid DNA was recovered
and transformed into [PSI+] S. cerevisiae. In total, 116 clonal isolates derived from the
random mutagenesis of the N-domain of Lon were screened in [PSI+] yeast. Of these
mutations, no hits in the [PSI+] colorimetric screen were found. A hit in the screen was
defined as a mutation in lon that was associated with a uniform pink or red phenotype
in [PSI+] S. cerevisiae. Hits in the screen were sequenced to classify the mutation(s)
in lon. Sequencing results showed that a hit in the screen had multiple mutations (> 5
mutations) and a frameshift mutation at nucleotide base pair 157. Therefore, we did
not identify any residues in Lon associated with altered substrate recognition by
domain-specific point mutations. Thus, we did not discover mutant gene copies of lon
that modified the interaction between Lon and Sup35 amyloid to improve amyloid
recognition.
Next, we investigated if engineered chaperone proteases could recognize and
disassemble Sup35 prion fibrils in vivo. The AAA+ protein superfamily consists of a
diverse set of ATP-dependent chaperone proteins that have highly conserved
domains (Figure 1A). Within the AAA+ superfamily, distinct families of chaperone
proteins are grouped together based on their domain architecture (67). We cloned the
N-domain of Hsp104 and the ClpXΔNTD sequence into pESC-URA+ClpXP. First,
clpX was constructed and expressed in the double expression vector pYES2
(Invitrogen). Primers were designed to insert a HindII restriction enzyme site
upstream of the clpX sequence and insert an XhoI restriction enzyme site
downstream of the clpX sequence (Table 1). Site-directed mutagenesis was carried
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out using the QuikChange II XL Site-directed Mutagenesis kit. To express the ClpX
sequence without the N-terminal domain (ClpXΔNTD), both pYES2 and pYES2+ClpX
were double digested using the restriction enzymes SacI and NotI (New England
Biolabs), resulting in linearized DNA that was subsequently ligated overnight at 16°C.
The ligation products were heat inactivated at 65°C and ligation products were
transformed into XL Blue chemically competent Escherichia coli cells (Agilent).
Sanger sequencing of the construct confirmed that the ClpXΔNTD sequence (1092
base pairs) was successfully cloned into the pYES2 vector.
In order to express the Hsp104 N-terminal domain (amino acid residues 1 –
161) in the pYES2+ClpXΔNTD construct, restriction enzyme sites flanking the
Hsp104 N-domain sequence were cloned into the pYS104 vector using the
polymerase chain reaction (PCR). Upstream of the Hsp104 N-domain, a KpnI site, 5’
GGTACC 3’, was inserted and downstream of the Hsp104 N-domain a SacI site was
inserted. The pYS104 construct containing SacI and KpnI sites and the vector pYES2
were double digested with KpnI and SacI. Ligation was carried out with 80 ng of
pYES2 vector. Subsequently, a NotI restriction enzyme site, 5’ GCGGCCGC 3’, was
inserted at the beginning of the N-domain of ClpX and a SacI site was inserted at the
end of the ClpX sequence in the vector pYES2.
Sanger sequencing of the vector pYES2 + Hsp104 N-domain + ClpXΔNTD
showed that a spontaneous mutation arose; a transition substitution occurred at
nucleotide base pair 928 of the ClpXΔNTD sequence. To correct this, primers were
designed to mutate thymine to cytosine at base pair 928 of ClpXΔNTD. In order to
express the Hsp104 N-domain + ClpXΔNTD construct in the vector pESC-ura+ClpP
(constructed by Marissa Viola), the pYES2 + Hsp104 N-domain + ClpXΔNTD
construct and the pESC-URA + ClpP construct were double digested using the
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restriction enzymes NotI and SacI (New England Biolabs). Subsequently, ligation
reactions were carried out with 100 ng of pESC-URA + ClpP vector (9000 base pairs)
per reaction. Ligation products were heat inactivated and transformed into XL Blue
chemically competent E. coli cells.
The chimeric protein Hsp104 + ClpXΔNTD + ClpP has an N-terminal domain
from Hsp104, and ATPase domain from ClpX, and the ClpP full-length sequence
(Figure 1B). The chimeric protein Hsp104 + ClpXΔNTD + ClpP was transformed into
[PSI+] yeast and grown on SD-URA plates for five days at 30°C. The chimeric protein
did not alter [PSI+] phenotype in yeast (Figure 1C). To determine if ClpX and ClpP
protein were expressed in yeast, lysates were extracted, normalized, and
immunoblotted. We found that yeast containing the chimeric protein did express ClpX
and ClpP (Figure 2A). Moreover, spectrophotometric analysis of yeast lysates using a
novel [PSI+] assay that we developed showed that level of red pigmentation, which
accumulates in [psi-] yeast, is reduced in yeast expressing the chimeric proteins
Hsp104 NTD + ClpXΔN and Hsp104

NTD + ClpXΔN + ClpP compared to yeast

overexpressing Hsp104 from the plasmid PYS104 and yeast expressing the Walker B
NBD1 mutation Hsp104(E285Q) (Figure 2B).
Based on our findings, the chimeric protein Hsp104

NTD + ClpXΔN + ClpP

does not cure [PSI+] yeast of Sup35 prion. However, it is possible that the novel
chaperone protease could enhance prion propagation by severing amyloid fibrils and
generating amyloid seeds for nucleated polymerization of Sup35 protein, thereby
facilitating the amyloid assembly of Sup35 (Figure 3). The chimeric protein Hsp104
NTD + ClpXΔN + ClpP hypothetically could recognize all targets of Hsp104. Future
biochemical assays with this protein should be done to determine if the protein has
enhanced binding of amyloid compared to Hsp104 wild-type protein. Degradation
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assays would determine whether the chimeric protein is degrading amyloid fibrils into
small peptides and thereby functioning as a chaperone protease.
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Table 1. Primers Used for Cloning

Primer

DNA Sequence (5’ to 3’)

pYES2 ClpX
GTACATAAGCTTATGACAGATAAACGCAAACGCAAA
HindIII Forward
pYES2 ClpX
TGAAATGAGCTCTTATTCACCAGATGCCTG
XhoI Reverse
Hsp104 NTD
TTCACAGGTACCATGAACGACCAAACGCAATTT
KpnI Forward
Hsp104 NTD
TCGGATGAGCTCTTAAGGTGTGTTCGTATCAGC
SacI Reverse
ClpXΔNTD NotI
GAAGCGCAACAGGCATCTGGTGAATAAGCGGCCGCGAGCTCTTAATTAAC
Forward
ClpXΔNTD
GTCGGTAGCGCACTGAGCTCGCGTTCACGATGC
SacI Reverse
pYES2+Hsp104
+ ClpXΔNTD bp

CGACGTCTTCCATGGACGGCAGATCGTACAT

928 FWD
pYES2+Hsp104
+ ClpXΔNTD bp

ATGTACGATCTGCCGTCCATGGAAGACGTCG

928 FWD
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Figure 1. Domain organization and phenotype of chimeric protein.
A.) Domain architecture of ClpX and Hsp104. ClpX contains an N-domain that
dimerizes, a large nucleotide-binding domain, and a small nucleotide-binding
domain. Hsp104 contains an N-domain, two nucleotide-binding domains, and a
unique coiled-coil middle domain.
B.) Proposed surface structure of chimeric chaperone protease Hsp104 NTD +
ClpXΔNTD + ClpP. Hsp104 N-domain structure (PDB 6AMN; Lee et al., 2017).
ClpXΔNTD structure (PDB 3HWS; Glynn et al., 2009). ClpP structure (PDB
1TYF; Wang et al., 1997).
C.) [PSI+] yeast containing the chimeric protein Hsp104 NTD + ClpXΔN + ClpP
has white colony color and thus carry a [PSI+] phenotype. [PSI+] yeast
containing the plasmid pYS104 overexpress Hsp104, which resolubilizes
insoluble Sup35 protein and is associated with a [psi-] phenotype.
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[PSI+] + pYS104

[PSI+] + pESC-URA

Figure 2. Expression of chimeric protein in S. cerevisiae and
functional analysis.
A.) Western blots shows bands reactive to ClpX and ClpP for lysate
extracted from yeast cells transformed with Hsp104 NTD + ClpXΔN +
ClpP.
B.) Functional analysis of Hsp104 NTD + ClpXΔN + ClpP shows that
the level of red pigmentation, which correlates to soluble Sup35 levels,
is decreased in yeast expressing the chimeric proteins Hsp104 NTD +
ClpXΔN and Hsp104 NTD + ClpXΔN + ClpP compared to yeast
overexpressing Hsp104 and the Hsp104 Walker B mutation E285Q.
Day 5 lysates, induced by galactose on solid SD-URA media.
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Figure 3. Model of Sup35 amyloid fibril severing by Hsp104 NTD +
ClpXΔNTD + ClpP. Polypeptide segments of amyloid aggregate is
threaded through the central channel of Hsp104 and substrate is
translocated into the ClpX central channel where it is threaded into the
ClpP proteolytic barrel. The degradation products, short polypeptide
segments, may serve as amyloid seeds to propagate Sup35 prion in
yeast. Both substrate translocation and degradation of polypeptide
require ATP binding and hydrolysis.
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Supplemental Figure S1. Phenotype of [PSI+] yeast carrying pyes2 +
Lon wild-type construct. Yeast expressing the full-length lon sequence
in the vector pYES2 have [PSI+] phenotype, which is associated with the
presence of insoluble Sup35 fibrils.
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